▁in ▁adults ▁and ▁the ▁el der ly ▁ , ▁the ▁most ▁common ▁side ▁effects ▁( ▁seen ▁in ▁more ▁than ▁1 ▁patient ▁in ▁10 ▁) ▁are ▁decrease d ▁appetit e ▁ , ▁head ach es ▁ , ▁di ar r ho e a ▁ , ▁fe ver ▁( ▁only ▁very ▁common ▁in ▁adults ▁a ged ▁18 ▁to ▁29 ▁years ▁) ▁ , ▁vom i ting ▁( ▁only ▁very ▁common ▁in ▁adults ▁a ged ▁18 ▁to ▁49 ▁years ▁) ▁ , ▁ rash ▁ , ▁reaction s ▁at ▁the ▁site ▁of ▁inject ion ▁ , ▁limitation ▁of ▁arm ▁movement ▁ , ▁ arth ral gia ▁and ▁my al gia ▁( ▁joint ▁and ▁muscle ▁pain ▁) ▁ , ▁chill s ▁and ▁fatigue ▁ .
▁the ▁tablets ▁are ▁taken ▁once ▁a ▁day ▁ , ▁prefer ably ▁before ▁the ▁first ▁meal ▁of ▁the ▁day ▁ .
▁obliga tion ▁to ▁complete ▁post - a ut hor isation ▁measure s
▁these ▁side ▁effects ▁were ▁also ▁the ▁most ▁common ▁side ▁effects ▁when ▁op di vo ▁was ▁used ▁together ▁with ▁i pili mum ab ▁ .
▁cau tion ▁should ▁be ▁exercise d ▁when ▁ad minister ing ▁pe ga sys ▁in ▁combination ▁with ▁other ▁potential ly ▁mye los up press ive ▁agents ▁ .
▁at ▁the ▁beginning ▁of ▁ therapy ▁dop amine rg ic ▁advers e ▁reaction s ▁such ▁as ▁na use a ▁and ▁vom i ting ▁may ▁occur ▁ .
▁tell ▁your ▁doctor ▁or ▁ pharma ci st ▁if ▁you ▁are ▁taking ▁ , ▁have ▁recently ▁taken ▁ , ▁or ▁might ▁take ▁any ▁other ▁medicine s ▁ .
▁there ▁are ▁only ▁limited ▁data ▁available ▁in ▁patients ▁with ▁severe ▁renal ▁im pair ment ▁( ▁see ▁section ▁5.2 ▁) ▁ .
▁of ▁135 ▁patients ▁under go ing ▁retro peri tone al ▁and ▁intra - ab domin al ▁surgery ▁who ▁were ▁included ▁in ▁the ▁control led ▁study ▁of ▁e vice l ▁ , ▁4 ▁patients ▁treated ▁with ▁e vice l ▁were ▁a ged ▁16 ▁years ▁or ▁young er ▁ .
▁how ▁should ▁you ▁take ▁up tra vi ▁?
▁change ▁at ▁week ▁104 ▁b
▁rey ata z ▁given ▁without ▁rito na vir ▁should ▁not ▁be ▁considered ▁in ▁patients ▁treated ▁with ▁a ▁back bone ▁regime n ▁contain ing ▁te no fo vir ▁di so prox il ▁fumar ate ▁and ▁with ▁other ▁con com i tant ▁medication s ▁that ▁reduce ▁ata zana vir ▁bio ava il ability ▁( ▁see ▁section ▁4.5 ▁in ▁case ▁of ▁withdraw al ▁of ▁rito na vir ▁from ▁the ▁recommended ▁ata zana vir ▁boost ed ▁regime n ▁) ▁or ▁in ▁case ▁of ▁perc ei ved ▁challenging ▁compliance ▁ .
▁table ▁6 ▁sustain ed ▁response ▁rates ▁with ▁riba vir in ▁+ ▁pe g inter fer on ▁alfa -2 b ▁( ▁by ▁riba vir in ▁dose ▁[ ▁mg ▁/ ▁kg ▁] ▁ , ▁geno type ▁and ▁viral ▁load ▁)
▁not ▁all ▁pack ▁size s ▁or ▁types ▁may ▁be ▁market ed ▁ .
▁progesteron e ▁is ▁produced ▁by ▁your ▁ova ries ▁during ▁a ▁menstrua l ▁cycle ▁ .
▁post - ho c ▁survival ▁analyse s ▁were ▁under tak en ▁there a fter ▁as ▁described ▁in ▁table ▁7 ▁ .
▁these ▁reaction s ▁are ▁not ▁in ▁themselves ▁an ▁indica tion ▁of ▁sensi t isation ▁ .
▁however ▁ , ▁as ▁for ▁other ▁5- ht 3 ▁anta gon ists ▁ , ▁cau tion ▁should ▁be ▁exercise d ▁in ▁the ▁use ▁of ▁palo nos et ron ▁in ▁patients ▁who ▁have ▁or ▁are ▁likely ▁to ▁develop ▁prolong ation ▁of ▁the ▁q t ▁interval ▁ .
▁pra x bind ▁has ▁been ▁investiga ted ▁in ▁three ▁main ▁studies ▁in vol ving ▁141 ▁healthy ▁adults ▁who ▁previously ▁received ▁da biga tran ▁ .
▁as ▁no ▁clinic al ▁data ▁on ▁exposure ▁to ▁clo pido gre l ▁during ▁pre gna ncy ▁are ▁available ▁ , ▁it ▁is ▁prefer able ▁not ▁to ▁use ▁clo pido gre l ▁during ▁pre gna ncy ▁as ▁a ▁precau tion ary ▁measure ▁ .
▁increasing ▁use ▁of ▁a ▁separate ▁rapid - ac ting ▁bron chod il ator ▁indicate s ▁a ▁worse ning ▁of ▁the ▁under ly ing ▁condition ▁and ▁warrant s ▁a ▁rea sses s ment ▁of ▁the ▁as th ma ▁ therapy ▁ .
▁parent er al ▁products ▁should ▁be ▁inspect ed ▁visual ly ▁for ▁parti cula te ▁matter ▁and ▁disco lou ration ▁( ▁e . g . ▁green ▁or ▁black ▁) ▁prior ▁to ▁administration ▁ .
▁ter fen a dine ▁or ▁a ste mi zole ▁( ▁allergi c ▁problems ▁)
▁in ▁addition ▁ , ▁instructions ▁for ▁hygien e ▁and ▁cleaning ▁of ▁the ▁neb ulis ers ▁provided ▁by ▁the ▁device ▁manufacture rs ▁should ▁be ▁followed ▁carefully ▁ .
▁at ▁month ▁1 ▁ , ▁4 ▁ , ▁and ▁6 ▁post - trans plant ▁ , ▁the ▁mean ▁( ▁range ▁) ▁tro ugh ▁concentration s ▁of ▁bela ta cept ▁were ▁22. 7 ▁( ▁11. 1-4 5.2 ▁) ▁ ,
▁the ▁studies ▁also ▁demonstrat ed ▁sus cept i bility ▁of ▁many ▁solid ▁tum our ▁cell ▁lines ▁to ▁cy tara bine ▁ , ▁particularly ▁after ▁longer ▁period s ▁of ▁exposure ▁to ▁cy tara bine ▁ .
▁if ▁you ▁feel ▁a ▁spin ning ▁sensation ▁or ▁feel ▁tired ▁ , ▁do ▁not ▁drive ▁or ▁use ▁any ▁tools ▁or ▁machines ▁until ▁you ▁are ▁feeling ▁normal ▁again ▁ .
▁ec alta ▁is ▁a ▁powder ▁that ▁is ▁made ▁up ▁into ▁a ▁solution ▁for ▁in fusion ▁( ▁d rip ▁) ▁into ▁a ▁ve in ▁ .
▁after ▁about ▁8 ▁hours ▁ , ▁was h ▁the ▁area ▁where ▁ zyc lara ▁was ▁applied ▁with ▁mild ▁so ap ▁and ▁water ▁ .
▁eg fr ▁has ▁been ▁implica ted ▁in ▁the ▁control ▁of ▁pre na tal ▁development ▁and ▁may ▁be ▁essential ▁for ▁normal ▁organ ogen es is ▁ , ▁prolifera tion ▁ , ▁and ▁differenti ation ▁in ▁the ▁developing ▁em bry o ▁ .
▁infection ▁( ▁g 3 ▁/ ▁4 ▁: ▁2.4 ▁% ▁) ▁; ▁neutro pen ic ▁infection
▁the ▁free ▁ fraction ▁of ▁i bru tin ib ▁also ▁increased ▁with ▁degree ▁of ▁im pair ment ▁ , ▁with ▁3.0 ▁ , ▁ 3.8 ▁and ▁4. 8 ▁% ▁in ▁subject s ▁with ▁mild ▁ , ▁moderat e ▁and ▁severe ▁ liver ▁im pair ment ▁ , ▁respective ly ▁ , ▁compared ▁to ▁3.3 ▁% ▁in ▁plasma ▁from ▁match ed ▁healthy ▁control s ▁within ▁this ▁study ▁ .
▁the ▁con com i tant ▁use ▁of ▁op io ids ▁could ▁enhance ▁the ▁risk ▁of ▁con s tip ation ▁ .
▁administration ▁of ▁zal trap ▁/ ▁fol fir i ▁should ▁be ▁de lay ed ▁until ▁neutro phil ▁count ▁is ▁1.5 ▁x ▁109 ▁/ ▁l ▁or ▁plate let ▁count ▁is
▁if ▁you ▁have ▁a ▁na rro wing ▁of ▁the ▁a or tic ▁heart ▁val ve ▁( ▁a or tic ▁sten osis ▁) ▁if ▁you ▁have ▁heart ▁failure ▁after ▁an ▁a cute ▁heart ▁attack
▁a ▁dose ▁re duction ▁of ▁the ▁gluco cor tico id ▁should ▁be ▁considered ▁with ▁close ▁monitoring ▁of ▁local ▁and ▁system ic ▁effects ▁or ▁a ▁switch ▁to ▁a ▁gluco cor tico id ▁which ▁is ▁not ▁a ▁substrat e ▁for ▁cy p 3 a ▁( ▁e . g . ▁ , ▁be clo met has one ▁) ▁ .
▁§ ▁due ▁to ▁inhibi tion ▁of ▁cy p 3 a ▁by ▁rito na vir ▁ , ▁25- o - des ace tyl - rif abu tin ▁exposure ▁is ▁increased ▁ .
▁ne vira pine ▁teva ▁should ▁not ▁be ▁used ▁as ▁the ▁sole ▁active ▁anti ret rovi ral ▁ , ▁as ▁mono therapy ▁with ▁any ▁anti ret rovi ral ▁has ▁shown ▁to ▁result ▁in ▁viral ▁resist ance ▁ .
▁you ▁should ▁tell ▁your ▁doctor ▁if ▁you ▁have ▁:
▁co - administration ▁of ▁tel zir ▁700 ▁mg ▁twice ▁daily ▁with ▁rito na vir ▁in ▁dos es ▁greater ▁than ▁100 ▁mg ▁twice ▁daily ▁has ▁not ▁been ▁clinic ally ▁evaluat ed ▁ .
▁false ▁positive ▁finding s ▁in ▁patients ▁with ▁cea ▁express ing ▁tu mo urs ▁cannot ▁be ▁exclu ded ▁ .
▁if ▁you ▁are ▁schedule d ▁to ▁inject ▁this ▁medicine ▁every ▁day ▁ , ▁and ▁you ▁accident ally ▁missed ▁a ▁full ▁day ▁' s ▁dose ▁ , ▁continue ▁treatment ▁at ▁the ▁usual ▁dose ▁the ▁following ▁day ▁ .
▁taking ▁a erius ▁oral ▁solution ▁is ▁not ▁recommended ▁if ▁you ▁are ▁pregnant ▁or ▁nur sing ▁a ▁baby ▁ .
▁if ▁you ▁notice ▁any ▁serious ▁effects ▁or ▁other ▁effects ▁not ▁mentioned ▁in ▁this ▁le a flet ▁ , ▁please ▁inform ▁your ▁veterinar y ▁surge on ▁ .
▁no ▁cases ▁of ▁il d - like ▁events ▁have ▁been ▁reported ▁with ▁oni vy de ▁ therapy ▁in ▁clinic al ▁studies ▁ .
▁1 ▁in hal er ▁contain ing ▁30 ▁unit ▁dos es ▁1 ▁in hal er ▁contain ing ▁60 ▁unit ▁dos es
▁clinic al ▁trial ▁data ▁support ▁use ▁up ▁to ▁12 ▁months ▁ , ▁and ▁the ▁maximum ▁benefit ▁was ▁seen ▁at ▁3 ▁months ▁( ▁see ▁section ▁5.1 ▁) ▁ .
▁during ▁a ▁random ised ▁withdraw al ▁period ▁ , ▁significantly ▁more ▁patients ▁re - rando mised ▁to ▁place bo ▁experienced ▁disease ▁re lapse ▁( ▁loss ▁of ▁pasi ▁75 ▁response ▁) ▁compared ▁with ▁patients ▁re - rando mised ▁to ▁en bre l ▁ .
▁summary ▁of ▁product ▁character istic s ▁( ▁sm pc ▁)
▁marketing ▁author isation ▁holder ▁and ▁manufacture r ▁marketing ▁author isation ▁holder
▁ pharma cok ine tics ▁of ▁the ▁combination ▁of ▁om bita s vir ▁25 ▁mg ▁ , ▁par ita pre vir ▁200 ▁mg ▁ , ▁and ▁rito na vir ▁100 ▁mg ▁ , ▁with ▁das abu vir ▁400 ▁mg ▁were ▁evaluat ed ▁in ▁subject s ▁with ▁mild ▁( ▁child - p ugh ▁a ▁) ▁ , ▁moderat e ▁( ▁child - p ugh ▁b ▁) ▁and ▁severe ▁( ▁child - p ugh ▁c ▁) ▁he pati c ▁im pair ment ▁ .
▁there ▁are ▁limited ▁data ▁on ▁patients ▁with ▁he pati c ▁im pair ment ▁in ▁r cc ▁ .
▁ari claim ▁60 ▁mg ▁is ▁available ▁in ▁pack s ▁of ▁28 ▁and ▁98 ▁capsule s ▁ .
▁empty ▁pens ▁must ▁not ▁be ▁re - fill ed ▁and ▁must ▁be ▁properly ▁disc ard ed ▁ .
▁a typ ical ▁fe moral ▁fra c tures ▁have ▁been ▁reported ▁in ▁patients ▁receiving ▁x ge va ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁clinic ally ▁valida ted ▁ phen oty pic ▁interpretation ▁systems ▁may ▁be ▁used ▁in ▁association ▁with ▁the ▁geno ty pic ▁data ▁to ▁estima te ▁the ▁activity ▁of ▁amp rena vir ▁/ ▁rito na vir ▁or ▁fos amp rena vir ▁/ ▁rito na vir ▁in ▁patients ▁with ▁pi - ▁resist ant ▁isola tes ▁ .
▁before ▁every ▁inject ion ▁ , ▁di al ▁1 ▁or ▁2 ▁unit s ▁and ▁press ▁the ▁inject ion ▁mechanism ▁with ▁the ▁pen ▁point ing ▁up ▁until ▁a ▁drop ▁of ▁ huma log ▁mix 25 ▁comes ▁out ▁of ▁the ▁need le ▁ .
▁fira zy r ▁is ▁intended ▁for ▁sub cuta ne ous ▁administration ▁prefer ably ▁in ▁the ▁abdominal ▁area ▁ .
▁move n tig ▁should ▁be ▁taken ▁on ▁an ▁empty ▁stomach ▁at ▁least ▁30 ▁minutes ▁before ▁the ▁first ▁meal ▁of ▁the ▁day ▁or ▁2 ▁hours ▁after ▁the ▁first ▁meal ▁ .
▁red ▁op a que ▁/ ▁white ▁op a que ▁ , ▁size ▁" ▁4 ▁" ▁hard ▁gelatin ▁capsule s ▁ , ▁im print ed ▁with ▁' ▁p g ▁' ▁on ▁cap ▁and ▁' ▁75 ▁' ▁on ▁body ▁ .
▁in ▁assist ed ▁reproduc tive ▁techniques ▁ , ▁there ▁is ▁an ▁increased ▁risk ▁of ▁oh s s ▁with ▁a ▁se rum ▁est radio l ▁> ▁ 3,000 ▁p g ▁/ ▁ml ▁( ▁1 1,000 ▁pm ol ▁/ ▁l ▁) ▁and ▁18 ▁or ▁more ▁fol li cles ▁of ▁11 ▁mm ▁or ▁more ▁in ▁diameter ▁ .
▁con com i tant ▁administration ▁of ▁a ▁p - gp ▁induc er ▁( ▁such ▁as ▁rif ampi cin ▁ , ▁st . ▁joh n ▁' s ▁ wort ▁( ▁hyper icum ▁perfor atum ▁) ▁ , ▁carb amaz e pine ▁ , ▁or ▁ phen y to in ▁) ▁is ▁expected ▁to ▁result ▁in ▁decrease d ▁da biga tran ▁concentration s ▁and ▁should ▁be ▁avoid ed ▁( ▁see ▁section s ▁4.4 ▁and ▁5.2 ▁) ▁ .
▁ara - c ▁75 ▁mg ▁/ ▁m 2 ▁i . v . ▁( ▁1 ▁h ▁) ▁ , ▁days ▁1 -5 ▁;
▁pen ile ▁ha e mor r hage ▁ , ▁pria pis m ▁ , ▁* ▁ha e mato sper mia
▁eleva te ▁the ▁inject ed ▁hand ▁as ▁much ▁as ▁possible ▁until ▁the ▁day ▁after ▁the ▁finger ▁extension ▁procedure ▁ .
▁in activa ted ▁foot - and - mouth ▁disease ▁anti gen ▁ , ▁at ▁least ▁6 ▁ca ttle ▁p d 50 ▁per ▁strain ▁ .
▁for ▁practical ▁information ▁about ▁using ▁clo pido gre l ▁/ ▁a ce tyl sali cy lic ▁acid ▁teva ▁ , ▁patients ▁should ▁read ▁the ▁package ▁le a flet ▁or ▁contact ▁their ▁doctor ▁or ▁ pharma ci st ▁ .
▁health care ▁professionals ▁are ▁asked ▁to ▁report ▁any ▁suspect ed ▁advers e ▁reaction s ▁via ▁the ▁national ▁report ing ▁system ▁listed ▁in ▁appen di x ▁v ▁ .
▁consequent ly ▁ , ▁con com i tant ▁administration ▁with ▁strong ▁cy p 3 a 4 ▁inhibi tors ▁( ▁e . g . ▁ , ▁keto con a zole ▁) ▁should ▁be ▁approach ed ▁with ▁cau tion ▁and ▁con com i tant ▁administration ▁with ▁strong ▁cy p 3 a 4 ▁induc ers ▁( ▁e . g . ▁rif ampi cin ▁) ▁should ▁be ▁avoid ed ▁ .
▁the ▁effective ness ▁of ▁versi can ▁plus ▁pi ▁/ ▁l 4 ▁was ▁investiga ted ▁in ▁a ▁field ▁study ▁in vol ving ▁129 ▁dog s ▁ .
▁the ▁recommended ▁daily ▁dose ▁in ▁adults ▁is ▁4 ▁tablets ▁of ▁sti var ga ▁40 ▁mg ▁( ▁160 ▁mg ▁re gora fen ib ▁) ▁ .
▁ma o - in hib itor s ▁qui no lone ▁antibiotic s ▁pro bene cid ▁mic ona zole
▁the ▁fre que ncy ▁is ▁define d ▁as ▁follow s ▁: ▁very ▁common ▁( ▁1 ▁/ ▁10 ▁)
▁si tag lip tin ▁differ s ▁in ▁chemical ▁structure ▁and ▁ pharma c ological ▁action ▁from ▁gl p -1 ▁analog ues ▁ , ▁insulin ▁ , ▁sul phon yl ure as ▁or ▁meg liti ni des ▁ , ▁bi guan ides ▁ , ▁pero xi some ▁prolifera tor - activa ted ▁receptor ▁gamma ▁( ▁ ppar ▁) ▁ago nist s ▁ , ▁al pha - glu cos idas e ▁inhibi tors ▁ , ▁and ▁a my lin ▁analog ues ▁ .
▁this ▁le a flet ▁was ▁last ▁revi sed ▁in ▁< ▁{ ▁mm ▁/ ▁y y yy ▁} ▁> ▁< ▁{ ▁month ▁y y yy ▁} ▁> ▁ .
▁t 12 ▁/ ▁pr ▁: ▁inci vo ▁for ▁12 ▁weeks ▁with ▁pe g inter fer on ▁alfa -2 a ▁and ▁riba vir in ▁for ▁24 ▁or ▁48 ▁weeks ▁;
▁spray ▁vaccin ation ▁or ▁for ▁use ▁in ▁drink ing ▁water ▁ .
▁difficult y ▁in ▁breath ing ▁with ▁w hee zing ▁or ▁co ugh ing ▁ .
▁multiple ▁pre gna ncy ▁may ▁lead ▁to ▁medical ▁complica tions ▁for ▁you ▁and ▁your ▁babi es ▁ .
▁for ▁in hal ation ▁use ▁only ▁ , ▁using ▁a ▁suitable ▁car rier ▁gas ▁ .
▁available ▁data ▁suggest ▁that ▁re - intro duction ▁of ▁hum ira ▁after ▁dis continu ation ▁for ▁70 ▁days ▁or ▁longer ▁result ed ▁in ▁the ▁same ▁magnitud es ▁of ▁clinic al ▁response ▁and ▁similar ▁safety ▁profile ▁as ▁before ▁dose ▁interrupt ion ▁ .
▁the ▁rate ▁of ▁severe ▁infection s ▁( ▁ nci ▁ct ca e ▁grade ▁ ≥ ▁3 ▁) ▁was ▁5.0 ▁% ▁versus ▁7.1 ▁% ▁ , ▁in ▁the ▁her cept in ▁intra ven ous ▁formula tion ▁arm ▁and ▁the ▁her cept in ▁sub cuta ne ous ▁formula tion ▁arm ▁respective ly ▁ .
▁the ▁active ▁substance ▁in ▁inf lec tra ▁ , ▁in flix ima b ▁ , ▁is ▁a ▁mono clo nal ▁anti body ▁ .
▁no ▁recommend ation ▁on ▁pos ology ▁can ▁be ▁made ▁for ▁children ▁under ▁12 ▁ .
▁t wyn sta ▁40 ▁mg ▁/ ▁10 ▁mg ▁may ▁be ▁ad minister ed ▁in ▁patients ▁whose ▁blood ▁pressure ▁is ▁not ▁adequat ely ▁control led ▁with ▁am lo di pine ▁10 ▁mg ▁alone ▁ .
▁once ▁bro ach ed ▁use ▁by ▁: ▁6 ▁hours
▁son ata ▁should ▁not ▁be ▁taken ▁at ▁these ▁times ▁because ▁there ▁are ▁not ▁enough ▁clinic al ▁data ▁available ▁to ▁assess ▁its ▁safety ▁during ▁pre gna ncy ▁and ▁breast - feed ing ▁ .
▁de xa met has one ▁has ▁been ▁shown ▁to ▁be ▁ter ato ge nic ▁in ▁mi ce ▁and ▁rabbi ts ▁following ▁topic al ▁op h thal mic ▁application ▁ .
▁what ▁saber vel ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁od in ▁is ▁a ▁phase ▁i ii ▁ , ▁random ised ▁ , ▁open - label ▁trial ▁compar ing ▁prezi sta ▁/ ▁rito na vir ▁800 ▁/ ▁100 ▁mg ▁once ▁daily ▁versus ▁prezi sta ▁/ ▁rito na vir ▁600 ▁/ ▁100 ▁mg ▁twice ▁daily ▁in ▁art - exp erien ced ▁hi v -1 ▁infect ed ▁patients ▁with ▁screening ▁geno type ▁resist ance ▁testing ▁showing ▁no ▁dar una vir ▁ram s ▁( ▁i . e ▁ .
▁pede a ▁is ▁suppli ed ▁in ▁pack s ▁of ▁4 ▁x ▁2 ▁ml ▁am po ules ▁ .
▁if ▁the ▁solution ▁is ▁not ▁used ▁immediately ▁ , ▁storage ▁prior ▁to ▁use ▁is ▁the ▁responsibility ▁of ▁the ▁user ▁and ▁should ▁be ▁in ▁a ▁refrigera tor ▁at ▁2 ▁° ▁c ▁- ▁8 ▁° ▁c ▁ .
▁a ▁mono clo nal ▁anti body ▁is ▁an ▁anti body ▁( ▁a ▁type ▁of ▁protein ▁) ▁that ▁has ▁been ▁designed ▁to ▁recog ni se ▁and ▁att ach ▁to ▁a ▁specific ▁structure ▁( ▁called ▁an ▁anti gen ▁) ▁in ▁the ▁body ▁ .
▁mean ▁percent ▁changes ▁from ▁base line ▁in ▁se rum ▁ phos pha te ▁were ▁ 3.6 ▁% ▁and ▁5.1 ▁% ▁for ▁can a gli flo zin ▁100 ▁mg ▁and ▁300 ▁mg ▁ , ▁compared ▁to ▁1.5 ▁% ▁for ▁place bo ▁ .
▁de x raz ox ane ▁under go es ▁intra cel lular ▁hydro lys is ▁first ▁to ▁its ▁two ▁one - ring ▁open ▁intermedi ates ▁( ▁b ▁and ▁c ▁) ▁and ▁then ▁to ▁the ▁two - ring ▁opened ▁form ▁( ▁ad r -9 25 ▁) ▁which ▁has ▁a ▁structure ▁similar ▁to ▁ed ta ▁and ▁is ▁a ▁strong ▁che la tor ▁of ▁ir on ▁and ▁di valent ▁ca tions ▁as ▁calci um ▁ ions ▁ .
▁the ▁physician ▁information ▁should ▁encourage ▁the ▁pre scribe rs ▁to ▁report ▁serious ▁advers e ▁reaction s ▁and ▁clinic ally ▁significant ▁ad rs ▁of ▁special ▁interest ▁including ▁:
▁established ▁and ▁the ore tical ▁interaction s ▁between ▁ sime pre vir ▁and ▁selected ▁medicinal ▁products ▁are ▁listed ▁in ▁table ▁4 ▁( ▁least ▁ square ▁mean ▁ratio s ▁with ▁90 ▁% ▁confidence ▁interval s ▁( ▁90 ▁% ▁ci ▁) ▁are ▁presente d ▁ , ▁increase ▁is ▁indicate d ▁as ▁" ▁↑ ▁ , ▁" ▁decrease ▁as ▁" ▁ ↓ ▁ , ▁" ▁no ▁change ▁as ▁" ▁ ↔ ▁" ▁) ▁ .
▁cell cept ▁with ▁food ▁and ▁drink
▁do ▁not ▁push ▁the ▁tablet ▁through ▁the ▁foi l ▁ .
▁results ▁indicate ▁that ▁the ▁f d c ▁group ▁was ▁associated ▁with ▁a ▁similar ▁vir ologic ▁outcome ▁( ▁non - ▁inferior ▁) ▁compared ▁to ▁the ▁a baca vir ▁plus ▁la mi vu dine ▁group ▁ , ▁based ▁on ▁proportion s ▁of ▁subject s ▁with ▁hi v - ▁1 ▁ rna ▁< ▁50 ▁copie s ▁/ ▁ml ▁( ▁90 ▁% ▁and ▁85 ▁% ▁respective ly ▁ , ▁95 ▁% ▁ci ▁- 2. 7 ▁ , ▁13. 5 ▁) ▁ .
▁patients ▁random ized ▁to ▁to cili zum ab ▁had ▁few er ▁ac r 30 ▁fl ares ▁and ▁higher ▁overall ▁ac r ▁response s ▁than ▁patients ▁receiving ▁place bo ▁regardless ▁of ▁a ▁history ▁of ▁prior ▁biologi c ▁use ▁ .
▁c gi - c ▁much ▁improve d ▁( ▁95 ▁% ▁ci ▁)
▁the ▁study ▁population ▁included ▁those ▁ ≥ ▁65 ▁years ▁( ▁n ▁= ▁8 561 ▁) ▁and ▁ ≥ ▁75 ▁years ▁( ▁n ▁= ▁23 30 ▁) ▁ , ▁with ▁normal ▁or ▁mild ▁renal ▁im pair ment ▁( ▁n ▁= ▁1 3,9 16 ▁) ▁as ▁well ▁as ▁moderat e ▁( ▁n ▁= ▁22 40 ▁) ▁or ▁severe ▁( ▁n ▁= ▁3 36 ▁) ▁renal ▁im pair ment ▁ .
▁in ▁the ▁context ▁of ▁clinic al ▁experience ▁several ▁ble ed ing ▁episode s ▁have ▁been ▁observe d ▁ .
▁1 ère ▁a venue ▁20 65 ▁m ▁l . i . d
▁if ▁the ▁cap s ▁are ▁loo se ▁or ▁missing ▁ , ▁do ▁not ▁use ▁the ▁vi als ▁ .
▁a ▁subsequent ▁study ▁in vol ving ▁45 5 ▁children ▁looked ▁at ▁the ▁longer - term ▁persist ence ▁of ▁protect ive ▁anti bo dies ▁up ▁to ▁3 ▁years ▁after ▁a ▁boost er ▁dose ▁with ▁he x yon ▁ , ▁and ▁another ▁study ▁in ▁1,3 36 ▁children ▁evaluat ed ▁the ▁response ▁to ▁different ▁lots ▁of ▁the ▁vaccin e ▁and ▁what ▁happened ▁when ▁it ▁was ▁given ▁with ▁vaccin es ▁for ▁infection s ▁caused ▁by ▁the ▁bacteri um ▁stre pto co cc us ▁pneu monia e ▁( ▁ preven ar ▁) ▁and ▁rota virus ▁( ▁rota rix ▁) ▁ .
▁if ▁this ▁app lies ▁to ▁you ▁then ▁your ▁vaccin ation ▁will ▁usually ▁be ▁post pon ed ▁until ▁you ▁are ▁feeling ▁better ▁ .
▁gran iset ron ▁is ▁a ▁ potent ▁anti - eme tic ▁and ▁highly ▁select ive ▁anta gon ist ▁of ▁5- hydro xy try p tamine ▁( ▁5 ht 3 ▁receptor s ▁) ▁ .
▁duk oral ▁should ▁not ▁replace ▁standard ▁protect ive ▁measure s ▁ .
▁abdominal ▁pain ▁( ▁upp er ▁and ▁lower ▁) ▁ , ▁na use a ▁ , ▁di ar r ho e a ▁( ▁including ▁severe ▁with ▁electro ly te ▁im balance ▁) ▁ , ▁vom i ting ▁ , ▁dy spe psi a
▁at ▁the ▁end ▁of ▁che mo therapy ▁ , ▁with ▁a ▁minimal ▁interval ▁of ▁4 ▁weeks ▁and ▁a ▁maximal ▁interval ▁of ▁7 ▁weeks ▁ , ▁patients ▁whose ▁disease ▁did ▁not ▁progress ▁received ▁radio therapy ▁( ▁ rt ▁) ▁according ▁to ▁institution al ▁guidelines ▁for ▁7 ▁weeks ▁( ▁t pf ▁/ ▁ rt ▁) ▁ .
▁the ▁con com i tant ▁administration ▁of ▁cre se mba ▁and ▁keto con a zole ▁is ▁contra indica ted ▁ .
▁this ▁decrease ▁is ▁more ▁prono un ced ▁during ▁the ▁third ▁tri mester ▁( ▁up ▁to ▁60 ▁% ▁of ▁base line ▁concentration ▁before ▁pre gna ncy ▁) ▁ .
▁in ▁case ▁you ▁inject ▁an ▁incorrect ▁dose ▁ , ▁tell ▁your ▁doctor ▁immediately ▁ .
▁therefore ▁repeat ▁instructions ▁1 ▁to ▁12 ▁above ▁using ▁an ▁additional ▁package ▁contain ing ▁a ▁transfer ▁device ▁to ▁recon stitu te ▁the ▁second ▁of ▁two ▁powder ▁vi als ▁ .
▁such ▁as ▁blood ▁in ▁the ▁sto ol s ▁due ▁to ▁ble ed ing ▁in ▁the ▁stomach ▁or ▁gut ▁ , ▁or ▁such ▁as ▁ble ed ing ▁inside ▁your ▁head ▁ .
▁you ▁should ▁not ▁take ▁it ▁as ▁a ▁preventiv e ▁measure ▁ .
▁te no fo vir ▁ala fen ami de ▁exposure ▁is ▁not ▁expected ▁to ▁be ▁affected ▁by ▁mara vi roc ▁ , ▁ne vira pine ▁or ▁ra lte grav ir ▁ , ▁nor ▁is ▁it ▁expected ▁to ▁affect ▁the ▁metabol ic ▁and ▁ex cre tion ▁path ways ▁relevant ▁to ▁mara vi roc ▁ , ▁ne vira pine ▁or ▁ra lte grav ir ▁ .
▁there ▁are ▁limited ▁data ▁available ▁on ▁the ▁use ▁of ▁dolu te grav ir ▁ , ▁a baca vir ▁and ▁la mi vu dine ▁in ▁patients ▁a ged ▁65 ▁years ▁and ▁over ▁ .
▁1 0.0 ▁ml ▁/ ▁100 ▁kg ▁body ▁weight ▁) ▁in ▁combination ▁with ▁antibiotic ▁ therapy ▁or ▁with ▁oral ▁re - hydrat ion ▁ therapy ▁ , ▁as ▁appropriate ▁ .
▁following ▁rare ▁cases ▁of ▁na r cole psy ▁( ▁a ▁rare ▁sleep ▁disorder ▁that ▁causes ▁a ▁person ▁to ▁fall ▁a sleep ▁suddenly ▁and ▁unexpected ly ▁) ▁among ▁people ▁given ▁the ▁vaccin e ▁ , ▁it ▁was ▁conclude d ▁that ▁pande m rix ▁should ▁only ▁be ▁used ▁if ▁the ▁recommended ▁season al ▁influenza ▁vaccin e ▁is ▁not ▁available ▁and ▁if ▁immun isation ▁against ▁h 1 n 1 ▁is ▁still ▁needed ▁ .
▁linear ▁and ▁dose ▁proportion al ▁increase s ▁were ▁observe d ▁for ▁pe ak ▁plasma ▁concentration s ▁and ▁area ▁under ▁the ▁cur ve ▁ .
▁the ▁recommended ▁dose ▁is ▁one ▁75 ▁mg ▁tablet ▁of ▁clo pido gre l ▁kr ka ▁per ▁day ▁to ▁be ▁taken ▁oral ly ▁with ▁or ▁without ▁food ▁ , ▁and ▁at ▁the ▁same ▁time ▁each ▁day ▁ .
▁now ▁the ▁second ▁breath ▁sample ▁container ▁( ▁label led ▁" ▁sa mp ling ▁time ▁: ▁00 - minut e - valu e ▁" ▁) ▁has ▁to ▁be ▁filled ▁up ▁with ▁breath ▁in ▁the ▁same ▁way ▁as ▁described ▁above ▁ .
▁vi al ▁100 ▁ml ▁ , ▁250 ▁ml ▁ , ▁500 ▁ml
▁champ ix ▁ , ▁( ▁n ▁= ▁ 248 ▁)
▁if ▁you ▁are ▁less ▁than ▁12 ▁hours ▁late ▁: ▁take ▁the ▁tablet ▁immediately . ▁if ▁you ▁are ▁more ▁than ▁12 ▁hours ▁late ▁: ▁do ▁not ▁take ▁the ▁tablet ▁but ▁take ▁the ▁next ▁tablet ▁at ▁the ▁usual ▁time ▁ .
▁overall ▁response ▁rate 1 ▁( ▁or r ▁: ▁sc r ▁+ ▁cr ▁+ ▁v g pr ▁+ ▁pr ▁) ▁[ ▁n ▁( ▁% ▁) ▁]
▁joint ▁a che ▁or ▁pain ▁( ▁ arth ral gia ▁)
▁remind er ▁: ▁please ▁read ▁the ▁" ▁other ▁medicine s ▁" ▁section ▁of ▁the ▁package ▁le a flet ▁for ▁the ▁other ▁medicine s ▁used ▁in ▁combination ▁with ▁riba vir in ▁teva ▁before ▁you ▁begin ▁combination ▁treatment ▁with ▁this ▁medicine ▁ .
▁symptoms ▁may ▁include ▁a ▁general ▁feeling ▁of ▁being ▁un well ▁ , ▁with ▁or ▁without ▁possible ▁ja undi ce ▁( ▁yellow ing ▁of ▁the ▁skin ▁and ▁eyes ▁) ▁ .
▁the ▁training ▁course ▁for ▁health care ▁professionals ▁should ▁contain ▁the ▁following ▁key ▁elements ▁:
▁this ▁includes ▁any ▁possible ▁side ▁effects ▁not ▁listed ▁in ▁this ▁le a flet ▁ . ▁ .
▁media n ▁half - life ▁( ▁t 1 ▁/ ▁2 ▁) ▁of ▁uste kin um ab ▁was ▁approximately ▁3 ▁weeks ▁in ▁patients ▁with ▁psoriasis ▁ , ▁ps oria tic ▁ar thri tis ▁or ▁cro h n ▁' s ▁disease ▁ , ▁rang ing ▁from ▁15 ▁to ▁32 ▁days ▁across ▁all ▁psoriasis ▁and ▁ps oria tic ▁ar thri tis ▁studies ▁ .
▁the ▁score d ▁tablets ▁are ▁yellow ▁and ▁capsule - sha ped ▁and ▁are ▁provided ▁in ▁bli ster ▁pack s ▁contain ing ▁60 ▁tablets ▁ .
▁because ▁of ▁the ▁risk ▁of ▁severe ▁allergi c ▁reaction s ▁ , ▁resp re eza ▁must ▁not ▁be ▁used ▁in ▁patients ▁who ▁are ▁la cking ▁iga ▁ , ▁a ▁protein ▁in ▁the ▁blood ▁ , ▁and ▁who ▁have ▁developed ▁anti bo dies ▁against ▁it ▁because ▁these ▁patients ▁are ▁more ▁pro ne ▁to ▁allergi c ▁reaction s ▁ .
▁the ▁co - administration ▁of ▁tri valent ▁flu enz ▁with ▁the ▁live ▁att en u ated ▁vaccin es ▁: ▁me as les ▁ , ▁mum ps ▁ , ▁rub ella ▁ , ▁vari cella ▁ , ▁and ▁oral ly - ad minister ed ▁poli o virus ▁has ▁been ▁studie d ▁ .
▁symptoms ▁usually ▁appeared ▁within ▁the ▁first ▁six ▁weeks ▁( ▁media n ▁time ▁to ▁ons et ▁11 ▁days ▁) ▁of ▁initiat ion ▁of ▁treatment ▁with ▁a baca vir ▁ , ▁although ▁these ▁reaction s ▁may ▁occur ▁at ▁any ▁time ▁during ▁ therapy ▁ .
▁pen to xi fyll ine ▁ , ▁prop oxy phen e ▁ , ▁sa lic yla tes ▁( ▁such ▁as ▁a ce tyl sali cy lic ▁acid ▁ , ▁used ▁to ▁reli eve ▁pain ▁and ▁lower ▁fe ver ▁) ▁sul fon ami de ▁antibiotic s ▁ .
▁if ▁in fusion ▁is ▁not ▁possible ▁ , ▁repeat ed ▁dos ing ▁with ▁na lo xon e ▁may ▁be ▁required ▁ .
▁typical ▁advers e ▁reaction s ▁of ▁non - steroid al ▁anti - in flam ma tory ▁drugs ▁( ▁ nsa ids ▁) ▁such ▁as ▁loss ▁of ▁appetit e ▁ , ▁vom i ting ▁ , ▁di ar r ho e a ▁ , ▁fa e cal ▁occ ult ▁blood ▁ , ▁a pathy ▁and ▁renal ▁failure ▁have ▁occasion ally ▁been ▁reported ▁ .
▁in ▁a ▁clinic al ▁ pharma c ology ▁trial ▁ , ▁in ▁which ▁des lor ata dine ▁was ▁ad minister ed ▁at ▁a ▁dose ▁of ▁45 ▁mg ▁daily ▁( ▁ni ne ▁times ▁the ▁clinic al ▁dose ▁) ▁for ▁ten ▁days ▁ , ▁no ▁prolong ation ▁of ▁q t c ▁interval ▁was ▁seen ▁ .
▁one ▁carton ▁contain s ▁one ▁vi al ▁ .
▁di plo pia ▁( ▁when ▁used ▁in ▁combination ▁with ▁carb amaz e pine ▁)
▁only ▁a ▁small ▁ fraction ▁( ▁< ▁5 ▁% ▁) ▁of ▁the ▁radio activ ity ▁in ▁urin e ▁( ▁represent ing ▁< ▁3 ▁% ▁of ▁the ▁total ▁dose ▁) ▁was ▁made ▁up ▁of ▁parent ▁compound ▁; ▁therefore ▁ , ▁renal ▁ex cre tion ▁play s ▁a ▁minor ▁role ▁in ▁elimina tion ▁of ▁the ▁parent ▁compound ▁ .
▁no ▁a cute ▁symptoms ▁of ▁over dos e ▁have ▁been ▁identified ▁ .
▁you ▁must ▁carefully ▁read ▁all ▁the ▁information ▁under ▁' ▁hyper sensitiv ity ▁reaction s ▁' ▁in ▁the ▁panel ▁in ▁section ▁4 ▁ .
▁do ▁not ▁use ▁the ▁vi al ▁if ▁a ▁vacuum ▁is ▁not ▁present ▁ .
▁op ica pone ▁is ▁a ▁we ak ▁inhibi tor ▁of ▁o at p 1 b 1 ▁ .
▁a ▁definitiv e ▁mechanism ▁of ▁action ▁of ▁pe g inter fer on ▁beta -1 a ▁in ▁multiple ▁sc ler osis ▁( ▁ms ▁) ▁is ▁not ▁known ▁ .
▁do ▁not ▁use ▁if ▁the ▁date ▁has ▁passed ▁the ▁last ▁day ▁of ▁the ▁month ▁shown ▁ .
▁kar ve a ▁150 ▁mg ▁tablets ▁are ▁suppli ed ▁in ▁bli ster ▁pack s ▁of ▁14 ▁ , ▁28 ▁ , ▁56 ▁or ▁98 ▁tablets ▁ .
▁there ▁was ▁a ▁statistic ally ▁significant ▁improvement ▁in ▁os ▁for ▁patients ▁treated ▁with ▁a bra xan e ▁/ ▁gem cita bine ▁versus ▁gem cita bine ▁alone ▁ , ▁with ▁1.8 ▁months ▁increase ▁in ▁media n ▁os ▁ , ▁28 ▁% ▁overall ▁re duction ▁in ▁risk ▁of ▁death ▁ , ▁59 ▁% ▁improvement ▁in ▁1- year ▁survival ▁ , ▁and ▁125 ▁% ▁improvement ▁in ▁2- year ▁survival ▁rates ▁ .
▁from ▁a ▁micro bi ological ▁point ▁of ▁view ▁ , ▁dilu tion ▁must ▁take ▁place ▁in ▁control led ▁and ▁a se ptic ▁conditions ▁and ▁the ▁medicinal ▁product ▁should ▁be ▁used ▁immediately ▁ .
▁afin itor ▁5 ▁mg ▁tablets ▁eu ▁/ ▁1 ▁/ ▁09 ▁/ ▁ 538 ▁/ ▁ 001 ▁eu ▁/ ▁1 ▁/ ▁09 ▁/ ▁ 538 ▁/ ▁ 003 ▁eu ▁/ ▁1 ▁/ ▁09 ▁/ ▁ 538 ▁/ ▁ 007
▁content s ▁of ▁the ▁pack ▁and ▁other ▁information ▁what ▁clo pido gre l ▁h cs ▁contain s
▁when ▁driving ▁vehicles ▁or ▁operating ▁machines ▁it ▁should ▁be ▁taken ▁into ▁account ▁that ▁occasion ally ▁di zzi ness ▁or ▁fatigue ▁may ▁occur ▁ .
▁adults ▁with ▁class ▁i ii ▁disease ▁could ▁walk ▁an ▁average ▁of ▁3 26 ▁m ▁at ▁the ▁start ▁of ▁the ▁study ▁ .
▁this ▁is ▁a ▁summary ▁of ▁the ▁european ▁public ▁assessment ▁report ▁( ▁e par ▁) ▁for ▁tel mis ar tan ▁act avis ▁ .
▁the ▁percentage ▁of ▁subject s ▁with ▁op a ▁titre s ▁8 ▁and ▁g m ts ▁observe d ▁post - prima ry ▁and ▁post - boo ster ▁were ▁lower ▁in ▁the ▁2 ▁dose ▁schedule ▁than ▁that ▁in ▁the ▁3 ▁dose ▁schedule ▁ .
▁urin e ▁leuk o cy te ▁este rase ▁positive ▁ , ▁n ▁( ▁% ▁)
▁other ▁medicine s ▁and ▁har vo ni
▁a ▁: ▁1 ▁morning ▁ , ▁2 ▁evening ▁b ▁: ▁2 ▁morning ▁ , ▁2 ▁evening
▁further ▁ , ▁ad her ence ▁and ▁extra vas ation ▁of ▁leuk o cy tes ▁is ▁increased ▁ , ▁leading ▁to ▁infiltra tion ▁of ▁the ▁tum our ▁by ▁lymph o cy tes ▁ , ▁mono cy tes ▁ , ▁and ▁granul o cy tes ▁ .
▁ben zal kon ium ▁chlor ide ▁has ▁been ▁reported ▁to ▁cause ▁eye ▁irrita tion ▁ , ▁punct u ate ▁kera to pathy ▁and ▁/ ▁or ▁ toxic ▁ul cer ative ▁kera to pathy ▁ .
▁pack ▁size ▁of ▁1 ▁ .
▁effects ▁on ▁se rum ▁calci um ▁concentration s
▁the ▁safety ▁of ▁using ▁sen shi o ▁con com i tant ly ▁with ▁o estro gens ▁or ▁other ▁ser ms ▁ , ▁such ▁as ▁tamo xi fen ▁ , ▁ torem ife ne ▁ , ▁baze do xi fen e ▁and ▁ra lo xi fen e ▁ , ▁has ▁not ▁been ▁studie d ▁and ▁its ▁concurrent ▁use ▁is ▁not ▁recommended ▁ .
▁e per zan ▁is ▁suppli ed ▁as ▁a ▁pen ▁for ▁self ▁inject ion ▁ .
▁in ▁clinic al ▁studies ▁ , ▁the ▁following ▁unde sir able ▁effects ▁have ▁been ▁reported ▁: ▁common ▁reported ▁side ▁effects ▁included ▁:
▁the ▁effect ▁of ▁voli bris ▁on ▁human ▁testi cular ▁function ▁and ▁male ▁fertil ity ▁is ▁not ▁known ▁ .
▁further more ▁ , ▁educational ▁material ▁for ▁h cp s ▁should ▁provide ▁information ▁on ▁the ▁following ▁safety ▁concern s ▁and ▁on ▁the ▁actions ▁needed ▁to ▁reduce ▁the ▁risk s ▁:
▁if ▁you ▁are ▁allergi c ▁to ▁pi og lita zone ▁ , ▁met form in ▁or ▁any ▁of ▁the ▁other ▁ingredients ▁of ▁this ▁medicine ▁( ▁listed ▁in ▁section ▁6 ▁) ▁ .
▁the ▁ef fica cy ▁of ▁amb ris en tan ▁as ▁mono therapy ▁has ▁not ▁been ▁established ▁in ▁patients ▁with ▁who ▁functional ▁class ▁i v ▁pah ▁ .
▁em trici ta bine ▁and ▁te no fo vir ▁ala fen ami de ▁demonstrat ed ▁syn er g istic ▁anti vir al ▁activity ▁in ▁cell ▁culture ▁ .
▁there ▁may ▁be ▁an ▁increased ▁possibility ▁of ▁becoming ▁pregnant ▁because ▁you ▁may ▁ovu late ▁again ▁when ▁you ▁take ▁glu stin ▁ .
▁due ▁to ▁the ▁risk ▁of ▁ble ed ing ▁and ▁ha e mat ological ▁advers e ▁reaction s ▁ , ▁blood ▁cell ▁count ▁determina tion ▁and ▁/ ▁or ▁other ▁appropriate ▁testing ▁should ▁be ▁prompt ly ▁considered ▁whenever ▁clinic al ▁symptoms ▁suggest ive ▁of ▁ble ed ing ▁a rise ▁during ▁the ▁course ▁of ▁treatment ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁eu ▁/ ▁1 ▁/ ▁09 ▁/ ▁ 573 ▁/ ▁02 2 ▁6 ▁pre - fill ed ▁sy ring es ▁with ▁safety ▁device ▁eu ▁/ ▁1 ▁/ ▁09 ▁/ ▁ 573 ▁/ ▁03 7 ▁1 ▁pre - fill ed ▁sy ringe ▁with ▁safety ▁need le ▁eu ▁/ ▁1 ▁/ ▁09 ▁/ ▁ 573 ▁/ ▁03 8 ▁4 ▁pre - fill ed ▁sy ring es ▁with ▁safety ▁need le ▁eu ▁/ ▁1 ▁/ ▁09 ▁/ ▁ 573 ▁/ ▁03 9 ▁6 ▁pre - fill ed ▁sy ring es ▁with ▁safety ▁need le
▁in ▁clinic al ▁studies ▁ , ▁the ▁safety ▁profile ▁of ▁ preven ar ▁13 ▁was ▁similar ▁to ▁ preven ar ▁ .
▁progressive ▁multi fo cal ▁leuk o ence pha lo pathy ▁( ▁pm l ▁)
▁to ▁establish ▁and ▁keep ▁an ▁observation al ▁eu - based ▁registr y ▁of ▁men ▁with ▁m cr pc ▁to ▁evaluat e ▁overall ▁survival ▁ , ▁the ▁risk ▁of ▁ ische mic ▁stroke ▁or ▁my o card ial ▁in far ction ▁following ▁treatment ▁with ▁proven ge ▁and ▁other ▁identified ▁and ▁potential ▁risk s ▁( ▁observation al ▁study ▁p 13 -1 ▁)
▁the ▁full ▁e par ▁for ▁insu man ▁can ▁be ▁found ▁on ▁the ▁agency ▁' s ▁website ▁: ▁ema . europa . eu ▁/ ▁find ▁medicine ▁/ ▁human ▁medicine s ▁/ ▁european ▁public ▁assessment ▁reports ▁ .
▁treatment ▁with ▁om e pra zole ▁40 ▁mg ▁q d ▁had ▁no ▁effect ▁on ▁the ▁exposure ▁of ▁lo pina vir ▁( ▁with ▁con com i tant ▁rito na vir ▁) ▁ .
▁it ▁is ▁not ▁intended ▁to ▁provide ▁practical ▁advice ▁on ▁how ▁to ▁use ▁can igen ▁l 4 ▁ .
▁both ▁70 ▁mg ▁and ▁50 ▁mg ▁vi als ▁are ▁available ▁ .
▁at osi ban ▁sun ▁is ▁used ▁in ▁pregnant ▁adult ▁women ▁ , ▁from ▁week ▁24 ▁to ▁week ▁33 ▁of ▁the ▁pre gna ncy ▁ .
▁animal ▁studies ▁did ▁not ▁reveal ▁any ▁evidence ▁of ▁im pair ed ▁female ▁and ▁male ▁fertil ity ▁ .
▁show ▁this ▁card ▁to ▁any ▁doctor ▁involved ▁in ▁your ▁treatment ▁ .
▁each ▁film - co ated ▁tablet ▁contain s ▁6 ▁mg ▁per am panel ▁ .
▁ ↔ ▁c max ▁1. 12 ▁( ▁0 . 88 ▁ , ▁1. 42 ▁)
▁the ▁european ▁commission ▁gran ted ▁a ▁marketing ▁author isation ▁valid ▁throughout ▁the ▁european ▁union ▁for ▁im van ex ▁on ▁31 ▁jul y ▁2013 ▁ .
▁how ▁has ▁ne vana c ▁been ▁studie d ▁?
▁vi al ▁label ▁for ▁the ▁powder ▁( ▁bax ject ▁i ii ▁system ▁)
▁the ▁selected ▁virus es ▁were ▁un able ▁to ▁grow ▁in ▁the ▁presence ▁of ▁dar una vir ▁concentration s ▁above ▁400 ▁n m ▁ .
▁of ev ▁100 ▁mg ▁soft ▁capsule s ▁/ ▁of ev ▁150 ▁mg ▁soft ▁capsule s ▁are ▁available ▁in ▁the ▁following ▁pack - size s ▁:
▁it ▁is ▁not ▁known ▁whether ▁al dura zy me ▁appears ▁in ▁breast ▁milk ▁ .
▁the ▁active ▁substance ▁in ▁cubi cin ▁powder ▁for ▁solution ▁for ▁inject ion ▁or ▁in fusion ▁is ▁da pto my cin ▁ .
▁some ▁patients ▁were ▁as ym pto matic ▁or ▁had ▁minimal ▁symptoms ▁with ▁pneu moni tis ▁detect ed ▁on ▁com put ed ▁tom ography ▁scan ▁or ▁che st ▁radio graph ▁ .
▁fluid ▁and ▁electro ly te ▁balance
▁eu ▁/ ▁2 ▁/ ▁14 ▁/ ▁176 ▁/ ▁0 15 ▁6 ▁x ▁50 ▁dos es
▁posterior ▁rever sible ▁en cep halo pathy ▁syndrome ▁( ▁pres ▁) ▁/ ▁rever sible ▁posterior ▁le u co ence pha lo pathy ▁syndrome ▁( ▁r pl s ▁)
▁each ▁tablet ▁contain s ▁60 ▁mg ▁la ctos e ▁( ▁as ▁mono hydrat e ▁) ▁ .
▁this ▁medicinal ▁product ▁contain s ▁less ▁than ▁23 ▁mg ▁of ▁so dium ▁in ▁each ▁dose ▁and ▁therefore ▁is ▁essential ly ▁so dium - free ▁ .
▁le di pas vir ▁/ ▁sof os bu vir ▁( ▁90 ▁mg ▁/ ▁400 ▁mg ▁q . d . ▁) ▁+ ▁em trici ta bine ▁/ ▁ri lp ivi rine ▁/ ▁te no fo ▁vir ▁di so prox il ▁fumar ate ▁( ▁200 ▁mg ▁/ ▁25 ▁mg ▁/ ▁300 ▁mg ▁q . d . ▁)
▁if ▁dose ▁re duction ▁is ▁required ▁due ▁to ▁any ▁advers e ▁drug ▁reaction ▁( ▁ad r ▁) ▁ , ▁then ▁this ▁should ▁be ▁achieve d ▁by ▁de cre ments ▁of ▁150 ▁mg ▁daily ▁ .
▁see ▁the ▁box ▁at ▁the ▁end ▁of ▁this ▁le a flet ▁for ▁more ▁information ▁ .
▁vi al ▁label ▁- ▁10 ▁ml ▁vi al
▁inject ▁the ▁air ▁into ▁the ▁vi al ▁contain ing ▁fast - ac ting ▁insulin ▁ .
▁talk ▁to ▁your ▁doctor ▁or ▁nurse ▁before ▁you ▁are ▁given ▁ro acte m ra ▁ .
▁refer ▁to ▁section s ▁4.4 ▁and ▁ 4.6 ▁ .
▁if ▁any ▁of ▁the ▁above ▁apply ▁to ▁you ▁( ▁or ▁you ▁are ▁not ▁sure ▁) ▁ , ▁talk ▁to ▁your ▁doctor ▁straight ▁away ▁before ▁taking ▁my cla us en ▁ .
▁general ▁disorder s ▁and ▁administration ▁side ▁conditions
▁poly arti cular ▁juvenil e ▁ idio pathi c ▁ar thri tis ▁is ▁an ▁infla mma tory ▁disease ▁of ▁the ▁joint s ▁ .
▁limited ▁data ▁in ▁patients ▁with ▁cir r ho sis ▁suggest ▁that ▁accumula tion ▁of ▁zid ovu dine ▁may ▁occur ▁in ▁patients ▁with ▁he pati c ▁im pair ment ▁because ▁of ▁decrease d ▁glu cu ron id ation ▁ .
▁anti thro mbo tic ▁ad ju nc tive ▁ therapy ▁with ▁plate let ▁inhibi tors ▁and ▁antico a gul ants ▁should ▁be ▁ad minister ed ▁according ▁to ▁the ▁current ▁relevant ▁treatment ▁guidelines ▁for ▁the ▁management ▁of ▁patients ▁with ▁st - ▁eleva tion ▁my o card ial ▁in far ction ▁ .
▁in ▁study ▁tax 3 16 ▁ , ▁per i pher al ▁oed ema ▁was ▁observe d ▁to ▁be ▁ongoing ▁in 19 ▁patients ▁out ▁of ▁the ▁119 ▁patients ▁with ▁per i pher al ▁oed ema ▁in ▁the ▁tac ▁arm ▁and ▁4 ▁patients ▁out ▁of ▁the ▁23 ▁patients ▁with ▁per i pher al ▁oed ema ▁in ▁the ▁fac ▁arm ▁ .
▁decrease s ▁in ▁sensor y ▁function s ▁are ▁generally ▁minor ▁and ▁temporar y ▁( ▁including ▁to ▁the r mal ▁and ▁sharp ▁stimul i ▁) ▁ , ▁however ▁ , ▁a ▁single ▁case ▁of ▁persist ent ▁hypo es the sia ▁has ▁been ▁reported ▁in ▁clinic al ▁studies ▁in ▁pain ful ▁diabet ic ▁neuro pathy ▁ .
▁this ▁over fill ▁ensure s ▁that ▁after ▁initial ▁dilu tion ▁with ▁the ▁entire ▁content ▁of ▁the ▁solve nt ▁vi al ▁ , ▁the ▁concentration ▁of ▁ca bazi ta xel ▁is ▁10 ▁mg ▁/ ▁ml ▁ .
▁do ▁not ▁use ▁this ▁medicine ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁bottle ▁and ▁carton ▁after ▁" ▁exp ▁ . ▁"
▁your ▁blood ▁sugar ▁levels ▁may ▁increase ▁when ▁you ▁stop ▁taking ▁traje nta ▁ .
▁the ▁estima ted ▁hazard ▁ratio ▁was ▁using ▁co x ▁proportion al ▁hazard ▁model ▁with ▁treatment ▁group ▁as ▁the ▁factor ▁ .
▁of ▁the ▁140 ▁subject s ▁who ▁completed ▁the ▁study ▁ 332 ▁114 ▁subject s ▁( ▁8 1.4 ▁% ▁) ▁had ▁enter ed ▁the ▁extension ▁phase ▁ .
▁each ▁90 ▁mg ▁tablet ▁contain s ▁approximately ▁24 ▁mg ▁la ctos e ▁( ▁as ▁mono hydrat e ▁) ▁ .
▁where ▁de lay ▁is ▁una vo id able ▁ , ▁the ▁solution ▁must ▁be ▁protected ▁from ▁light ▁ .
▁integr ilin ▁0 . 75 ▁mg ▁/ ▁ml ▁solution ▁for ▁in fusion ▁e pti fi bati de
▁un com mon ▁side ▁effects ▁( ▁may ▁affect ▁up ▁to ▁1 ▁in ▁100 ▁people ▁) ▁:
▁if ▁you ▁forget ▁to ▁use ▁izba
▁how ▁has ▁to pote can ▁ho spira ▁been ▁studie d ▁?
▁c max ▁: ▁↑ ▁50 ▁% ▁( ▁↑ ▁20 ▁to ▁↑ ▁80 ▁) ▁( ▁cy p 2 b 6 ▁in duction ▁)
▁in ▁patients ▁not ▁adequat ely ▁control led ▁on ▁25 ▁mg ▁hydro ch lor o thi azi de ▁alone ▁ , ▁the ▁addition ▁of ▁ir besar tan ▁gave ▁an ▁added ▁place bo - sub tra cted ▁sy sto lic ▁/ ▁dia sto lic ▁mean ▁re duction ▁of ▁11. 1 ▁/ ▁7.2 ▁mm ▁h g ▁ .
▁for ▁the ▁full ▁list ▁of ▁all ▁side ▁effects ▁reported ▁with ▁tru vada ▁ , ▁see ▁the ▁package ▁le a flet ▁ .
▁foc li via ▁contain s ▁thi om er sal ▁as ▁a ▁preserva tive ▁and ▁it ▁is ▁possible ▁that ▁you ▁may ▁experience ▁an ▁allergi c ▁reaction ▁ .
▁a ▁risk ▁management ▁plan ▁has ▁been ▁developed ▁to ▁ensure ▁that ▁iba ndro nic ▁acid ▁sand oz ▁is ▁used ▁as ▁safe ly ▁as ▁possible ▁ .
▁this ▁will ▁help ▁to ▁open ▁the ▁air ways ▁and ▁help ▁you ▁to ▁breath e ▁more ▁easily ▁ .
▁8 ▁ml ▁/ ▁hour ▁( ▁100 ▁μ g ▁/ ▁min ▁)
▁an ▁increased ▁incide nce ▁of ▁severe ▁hyper tension ▁was ▁reported ▁in ▁patients ▁receiving ▁ram uci rum ab ▁as ▁compared ▁to ▁place bo ▁ .
▁in ▁case ▁of ▁severe ▁or ▁persist ent ▁unde sir able ▁effects ▁ , ▁the ▁dose ▁of ▁re bi f ▁may ▁be ▁temporar ily ▁lower ed ▁or ▁interrupt ed ▁ , ▁at ▁the ▁discret ion ▁of ▁the ▁physician ▁ .
▁disc ard ▁any ▁un used ▁content s ▁ .
▁ever e ▁ble ed ing ▁from ▁your ▁nos e ▁ ,
▁if ▁you ▁are ▁given ▁bort ez om ib ▁sun ▁for ▁the ▁treatment ▁of ▁multiple ▁mye loma ▁the ▁side ▁effects ▁you ▁may ▁get ▁are ▁listed ▁below ▁:
▁detailed ▁information ▁on ▁this ▁veterinar y ▁medicinal ▁product ▁is ▁available ▁on ▁the ▁website ▁of ▁the ▁european ▁medicine s ▁agency ▁( ▁http ▁: ▁/ ▁/ ▁www . ema . europa . eu ▁/ ▁) ▁ .
▁gala fold ▁can ▁only ▁be ▁obtain ed ▁with ▁a ▁pre scription ▁and ▁treatment ▁should ▁only ▁be ▁started ▁and ▁super vis ed ▁by ▁a ▁doctor ▁who ▁is ▁experienced ▁in ▁the ▁ diagnos is ▁and ▁treatment ▁of ▁fa bry ▁disease ▁ .
▁if ▁symptoms ▁suggest ive ▁of ▁serious ▁a cute ▁ar se nic ▁ toxic ity ▁( ▁e . g . ▁convuls ions ▁ , ▁muscle ▁we ak ness ▁and ▁confusion ▁) ▁appear ▁ , ▁tri sen ox ▁must ▁be ▁immediately ▁dis continu ed ▁and ▁che la ting ▁ therapy ▁with ▁pe nici lla mine ▁at ▁a ▁daily ▁dose ▁ ≤ ▁1 ▁g m ▁per ▁day ▁may ▁be ▁considered ▁ .
▁she lf - life ▁: ▁18 ▁months ▁at ▁2 ▁- ▁8 ▁° ▁c . ▁bro ach ed ▁vi al ▁: ▁3 ▁hours ▁ .
▁the ▁most ▁common ly ▁reported ▁advers e ▁reaction s ▁observe d ▁during ▁clinic al ▁trial s ▁are ▁di zzi ness ▁ , ▁para es the sia ▁ , ▁dys ge usia ▁ , ▁na use a ▁ , ▁skin ▁disco lor ation ▁ , ▁chr omat uria ▁ , ▁sweat ing ▁ , ▁inject ion ▁site ▁pain ▁and ▁pain ▁in ▁extrem ity ▁ .
▁in ▁other ▁studies ▁ , ▁un change d ▁le flu nom ide ▁levels ▁in ▁plasma ▁have ▁rare ly ▁been ▁detect ed ▁ , ▁however ▁ , ▁at ▁ng ▁/ ▁ml ▁plasma ▁levels ▁ .
▁ riste mpa ▁has ▁no ▁or ▁negli gi ble ▁influence ▁on ▁the ▁ability ▁to ▁drive ▁and ▁use ▁machines ▁ .
▁manufacture r ▁responsible ▁for ▁bat ch ▁release
▁serious ▁wo und ▁hea ling ▁complica tions ▁ , ▁including ▁an asto mo tic ▁complica tions ▁ , ▁have ▁been ▁reported ▁ , ▁some ▁of ▁which ▁had ▁a ▁fatal ▁outcome ▁ .
▁from ▁a ▁micro bi ological ▁point ▁of ▁view ▁ , ▁once ▁opened ▁ , ▁the ▁product ▁may ▁be ▁store d ▁for ▁a ▁maximum ▁of ▁28 ▁days ▁at ▁2 ▁° ▁c ▁- ▁8 ▁° ▁c . ▁nu tropi na q ▁is ▁designed ▁to ▁with stand ▁a ▁nominal ▁( ▁one ▁hour ▁maximum ▁) ▁period ▁of ▁time ▁outside ▁of ▁the ▁refrigera tor ▁on ▁a ▁daily ▁basis ▁ .
▁animal ▁studies ▁with ▁sal meter ol ▁have ▁shown ▁em bry of e tal ▁ toxic ity ▁only ▁at ▁high ▁exposure ▁levels ▁ .
▁further more ▁ , ▁the ▁ pharma co dynamic ▁activity ▁of ▁clo pido gre l ▁was ▁not ▁significantly ▁influence d ▁by ▁the ▁co administration ▁of ▁ phen oba rbi tal ▁or ▁o est rogen ▁ .
▁gras p ▁the ▁clear ▁cap ▁with ▁the ▁other ▁hand ▁and ▁remove ▁it ▁ .
▁a ▁previous ▁cos ▁cycle ▁that ▁result ed ▁in ▁more ▁than ▁30 ▁fol li cles ▁11 ▁mm ▁measure d ▁by ▁ultra sound ▁examina tion ▁ .
▁thu s ▁ , ▁dog s ▁with ▁socio pathi c ▁disorder s ▁and ▁showing ▁episode s ▁of ▁intra - specific ▁( ▁dog ▁to ▁dog ▁) ▁and ▁/ ▁or ▁inter - specific ▁( ▁dog ▁to ▁another ▁species ▁) ▁aggressi ons ▁should ▁not ▁be ▁castra ted ▁either ▁sur g ically ▁or ▁with ▁the ▁implant ▁ .
▁the ▁in fusion ▁bag ▁solution ▁should ▁be ▁used ▁within ▁6 ▁hours ▁below ▁25 ▁° ▁c ▁and ▁normal ▁ lighting ▁conditions ▁including ▁the ▁one ▁hour ▁in fusion ▁to ▁the ▁patient ▁ .
▁in ▁these ▁studies ▁ , ▁be va ci zum ab ▁was ▁ad minister ed ▁at ▁the ▁following ▁dos ing ▁regime ns ▁in ▁combination ▁with ▁fol fox -4 ▁( ▁5- fu ▁/ ▁ lv ▁/ ▁o xa li plat in ▁) ▁ , ▁xe lo x ▁( ▁cap e cita bine ▁/ ▁o xa li plat in ▁) ▁ , ▁and ▁fluor op y rimi dine ▁/ ▁i rino te can ▁and ▁fluor op y rimi dine ▁/ ▁o xa li plat in ▁:
▁during ▁these ▁two ▁phase ▁i ii ▁studies ▁ , ▁the ▁safety ▁profile ▁of ▁doce ta xel ▁was ▁consistent ▁with ▁the ▁safety ▁profile ▁observe d ▁in ▁phase ▁i i ▁studies ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁following ▁an ▁oral ▁dose ▁ , ▁the ▁apparent ▁terminal ▁elimina tion ▁half - life ▁is ▁approximately ▁6.5 ▁hours ▁ .
▁do ▁not ▁use ▁this ▁medicine ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁carton ▁and ▁the ▁bli ster ▁pack ▁after ▁" ▁exp ▁ . ▁"
▁most ▁of ▁the ▁patients ▁studie d ▁were ▁ca uca sian ▁ .
▁therefore ▁ , ▁the ▁lack ▁of ▁significant ▁colour ▁change ▁should ▁not ▁be ▁taken ▁as ▁an ▁ assurance ▁of ▁adequat e ▁hydrat ion ▁ .
▁head ache ▁ , ▁tired ness ▁ , ▁na use a ▁ , ▁vom i ting ▁ , ▁di ar r ho e a ▁ , ▁abdominal ▁pain ▁ , ▁muscle ▁or ▁joint ▁pain ▁ , ▁che st ▁pain ▁ , ▁fe ver ▁ , ▁feeling ▁we ak ▁or ▁un well ▁ .
▁ha emo phil ic ▁patients ▁with ▁cardiovascular ▁risk ▁factors ▁or ▁disease s ▁may ▁be ▁at ▁the ▁same ▁risk ▁to ▁develop ▁cardiovascular ▁events ▁as ▁non - ha emo phil ic ▁patients ▁when ▁clo tting ▁has ▁been ▁normal ised ▁by ▁treatment ▁with ▁f vii i ▁ .
▁if ▁you ▁get ▁some ▁or ▁all ▁of ▁these ▁symptoms ▁:
▁in hal ed ▁ni tric ▁oxid e ▁ therapy ▁may ▁cause ▁an ▁increase ▁in ▁met ha emo glob in ▁ .
▁the ▁first ▁20 ▁mg ▁dose ▁should ▁be ▁given ▁within ▁2 ▁hours ▁prior ▁to ▁transplant ation ▁surgery ▁ .
▁therefore ▁ , ▁the ▁treatment ▁with ▁cep lene ▁and ▁il -2 ▁must ▁not ▁be ▁used ▁during ▁pre gna ncy ▁ .
▁this ▁study ▁support s ▁500 ▁μ g ▁once ▁every ▁three ▁weeks ▁being ▁comparable ▁to ▁once ▁week ly ▁administration ▁with ▁respect ▁to ▁the ▁incide nce ▁of ▁subject s ▁receiving ▁at ▁least ▁one ▁red ▁blood ▁cell ▁trans fusion ▁from ▁week ▁5 ▁to ▁the ▁end ▁of ▁treatment ▁phase ▁ .
▁the ▁recon stitu ted ▁solution ▁is ▁preserva tive ▁free ▁and ▁should ▁be ▁used ▁immediately ▁after ▁preparation ▁ .
▁renal ▁clear ance ▁( ▁about ▁60 ▁ml ▁/ ▁min ▁in ▁healthy ▁post meno paus al ▁female s ▁) ▁account s ▁for ▁50-60 ▁% ▁of ▁total ▁clear ance ▁and ▁is ▁related ▁to ▁creati nine ▁clear ance ▁ .
▁co xe vac ▁is ▁a ▁veterinar y ▁vaccin e ▁that ▁contain s ▁in activa ted ▁( ▁killed ▁) ▁co xi ella ▁bur ne tii ▁bacteria ▁ .
▁keep ▁the ▁can ister s ▁in ▁the ▁bottle ▁ .
▁mild ▁he pati c ▁im pair ment ▁( ▁child - p ugh ▁a ▁) ▁: ▁the ▁recommended ▁dose ▁is ▁7.5 ▁mg ▁daily ▁ .
▁increase ▁of ▁dose ▁of ▁pro bene cid ▁or ▁sul fin pyr a zone ▁may ▁be ▁necessary ▁ .
▁pa e dia tric ▁anti thro mbin ▁levels ▁may ▁be ▁different ▁from ▁adult ▁levels ▁ , ▁particularly ▁in ▁ne onate s ▁ .
▁the ▁study ▁in ▁young er ▁children ▁( ▁a ged ▁2 ▁to ▁4 ▁years ▁) ▁showed ▁that ▁the ▁majority ▁of ▁children ▁responde d ▁well ▁to ▁hum ira ▁treatment ▁and ▁this ▁response ▁was ▁maintain ed ▁after ▁24 ▁weeks ▁ .
▁irregular ▁rapid ▁con traction ▁of ▁the ▁heart ▁ , ▁ab normal ▁per ception ▁of ▁heart beat ▁ , ▁un control led ▁blood ▁pressure ▁ , ▁head ache ▁ , ▁di zzi ness ▁and ▁blu r red ▁vision ▁( ▁cloud y ▁vision ▁) ▁ .
▁although ▁no ▁formal ▁car cino geni city ▁studies ▁have ▁been ▁perform ed ▁with ▁asa ▁ , ▁it ▁has ▁been ▁shown ▁that ▁it ▁is ▁not ▁a ▁tum our ▁promote r ▁ .
▁plate let ▁count s ▁above ▁the ▁normal ▁range ▁present ▁a ▁risk ▁for ▁ thro mbo tic ▁/ ▁ thro mbo e mbol ic ▁complica tions ▁ .
▁in ▁two ▁of ▁these ▁studies ▁ , ▁lumin ity ▁was ▁compared ▁with ▁place bo ▁( ▁a ▁dum my ▁treatment ▁) ▁ .
▁do ▁not ▁use ▁if ▁medicine ▁is ▁cloud y ▁ , ▁ha zy ▁ , ▁disco lor ed ▁or ▁contain s ▁parti cles
▁since ▁the ▁ hib ▁cap s ular ▁poly s ac char ide ▁anti gen ▁is ▁ex cre ted ▁in ▁the ▁urin e ▁ , ▁a ▁positive ▁urin e ▁test ▁can ▁be ▁observe d ▁within ▁1 ▁to ▁2 ▁weeks ▁following ▁vaccin ation ▁ .
▁particular ▁cau tion ▁is ▁recommended ▁when ▁na te gli ni de ▁is ▁co - ad minister ed ▁with ▁other ▁more ▁ potent ▁inhibi tors ▁of ▁cy p 2 c 9 ▁( ▁e . g . ▁flu con a zole ▁ , ▁gem fi bro zil ▁or ▁sul fin pyr a zone ▁) ▁ , ▁or ▁in ▁patients ▁known ▁to ▁be ▁poor ▁metabol iser s ▁for ▁cy p 2 c 9 ▁ .
▁de spite ▁this ▁ , ▁your ▁doctor ▁may ▁pre scribe ▁cy mbal ta ▁for ▁patients ▁under ▁18 ▁because ▁he ▁/ ▁she ▁decide s ▁that ▁this ▁is ▁in ▁their ▁best ▁interest s ▁ .
▁pull ▁the ▁plu nger ▁to ▁draw ▁in ▁a ▁volume ▁of ▁air ▁equal ▁to ▁the ▁total ▁amount ▁of ▁solve nt ▁in ▁the ▁solve nt ▁vi al ▁ .
▁no ▁re bound ▁effect ▁was ▁observe d ▁ .
▁animal ▁reproduc tion ▁studies ▁have ▁not ▁been ▁conduct ed ▁with ▁factor ▁ ix ▁ .
▁advers e ▁reaction s ▁that ▁occur ▁more ▁frequently ▁with ▁combination ▁ therapy ▁compared ▁to ▁len vati ni b ▁mono therapy ▁are ▁hypo thy roid ism ▁ , ▁( ▁including ▁increased ▁blood ▁thy roid ▁stimula ting ▁hormone ▁) ▁ , ▁hyper ch olesterol a emia ▁ , ▁and ▁severe ▁di ar r ho e a ▁ .
▁since ▁no ▁data ▁are ▁available ▁on ▁the ▁compatibil ity ▁of ▁zo le dro nic ▁acid ▁teva ▁with ▁other ▁intra ven ously ▁ad minister ed ▁substance s ▁ , ▁zo le dro nic ▁acid ▁teva ▁must ▁not ▁be ▁mix ed ▁with ▁other ▁medication s ▁/ ▁substance s ▁and ▁should ▁always ▁be ▁given ▁through ▁a ▁separate ▁in fusion ▁line ▁ .
▁name ▁and ▁address ▁of ▁the ▁marketing ▁author isation ▁holder ▁and ▁of ▁the ▁manufacturing ▁author isation ▁holder ▁responsible ▁for ▁bat ch ▁release ▁ , ▁if ▁different
▁of ▁the ▁c p - cm l ▁patients ▁with ▁no ▁mutation ▁detect ed ▁at ▁entry ▁ , ▁49 ▁% ▁( ▁66 ▁/ ▁136 ▁) ▁achieve d ▁a ▁m cy r ▁ .
▁no ▁dos age ▁adjust ment ▁is ▁necessary ▁if ▁met ha done ▁is ▁co - ▁ad minister ed ▁with ▁rey ata z ▁and ▁rito na vir ▁ .
▁after ▁suspens ion ▁ , ▁the ▁deliver ed ▁dose ▁is ▁2 ▁mg ▁/ ▁0 . 65 ▁ml ▁ .
▁other ▁rare ly ▁observe d ▁side ▁effects ▁with ▁this ▁type ▁of ▁medicine ▁may ▁include ▁allergi c ▁reaction s ▁ .
▁as ▁with ▁all ▁insulin ▁preparation s ▁ , ▁the ▁du ration ▁of ▁action ▁of ▁ huma log ▁kwi k pen ▁is ▁dependent ▁on ▁dose ▁ , ▁site ▁of ▁inject ion ▁ , ▁blood ▁supply ▁ , ▁temperature ▁ , ▁and ▁physical ▁activity ▁ .
▁stop ping ▁your ▁treatment ▁with ▁cop alia ▁may ▁cause ▁your ▁disease ▁to ▁get ▁worse ▁ .
▁very ▁common ▁: ▁51 ▁( ▁50 ▁)
▁con com i tant ▁stable ▁dos es ▁of ▁one ▁non - biologi c ▁immun os up press ant ▁were ▁permit ted ▁ .
▁she ▁understand s ▁the ▁expected ▁ter ato ge nic ▁risk ▁to ▁the ▁un born ▁child
▁res liz um ab ▁has ▁not ▁been ▁studie d ▁in ▁patients ▁with ▁he pati c ▁im pair ment ▁ .
▁e yle a ▁ad minister ed ▁at ▁2 ▁mg ▁every ▁4 ▁weeks ▁( ▁e yle a ▁2 q 4 ▁) ▁;
▁if ▁you ▁have ▁intestinal ▁block age ▁( ▁pyl oral ▁or ▁duo den al ▁block age ▁)
▁you ▁should ▁not ▁take ▁v izar sin ▁more ▁than ▁once ▁a ▁day ▁ .
▁this ▁medicinal ▁product ▁contain s ▁ 0.7 ▁mg ▁( ▁0.0 3 ▁mm ol ▁) ▁so dium ▁per ▁ml ▁ .
▁60 ▁x ▁1 ▁film - co ated ▁tablet
▁for ▁individual ▁dose ▁adjust ments ▁ , ▁the ▁following ▁two ▁tit ration ▁guidelines ▁are ▁recommended ▁for ▁adults ▁:
▁patients ▁with ▁he pati c ▁im pair ment ▁: ▁in ▁a ▁study ▁perform ed ▁in ▁patients ▁with ▁moderat e ▁he pati c ▁im pair ment ▁( ▁child - p ugh ▁score ▁7 -9 ▁) ▁ , ▁( ▁n ▁= ▁8 ▁) ▁ , ▁the ▁ pharma cok ine tics ▁of ▁mica fung in ▁did ▁not ▁significantly ▁differ ▁from ▁those ▁in ▁healthy ▁subject s ▁( ▁n ▁= ▁8 ▁) ▁ .
▁manufacture r ▁responsible ▁for ▁bat ch ▁release ▁: ▁zo et is ▁manufacturing ▁& ▁research ▁spa in ▁ , ▁s . l . ▁c tra ▁ .
▁op ta flu ▁is ▁given ▁to ▁you ▁by ▁your ▁doctor ▁or ▁nurse ▁ .
▁method ▁and ▁route ▁( ▁s ▁) ▁of ▁administration
▁each ▁tablet ▁contain s ▁30 ▁mg ▁pi og lita zone ▁( ▁as ▁hydro ch lor ide ▁) ▁ .
▁the ▁report ▁shall ▁include ▁the ▁following ▁table s ▁of ▁ aggregat e ▁data ▁using ▁the ▁agreed ▁template s ▁:
▁more ▁specific ▁methods ▁for ▁the ▁evaluation ▁and ▁monitoring ▁of ▁cardiac ▁function s ▁as ▁compared ▁to ▁ec g ▁are ▁a ▁measure ment ▁of ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁by ▁e cho card i ography ▁or ▁prefer ably ▁by ▁multi ga ted ▁ang i ography ▁( ▁muga ▁) ▁ .
▁among ▁patients ▁taking ▁met form in ▁ , ▁at ▁week ▁24 ▁ , ▁the ▁increase ▁in ▁daily ▁insulin ▁dose ▁was ▁19 ▁iu ▁/ ▁day ▁in ▁patients ▁treated ▁with ▁si tag lip tin ▁and ▁24 ▁iu ▁/ ▁day ▁in ▁patients ▁treated ▁with ▁place bo ▁ .
▁however ▁ , ▁if ▁this ▁cannot ▁be ▁avoid ed ▁ , ▁the ▁vaccin es ▁should ▁be ▁inject ed ▁into ▁separate ▁lim bs ▁ .
▁the ▁ absence ▁of ▁upp er ▁respirator y ▁tract ▁infection ▁or ▁structura l ▁ab normal ities ▁ , ▁as ▁well ▁as ▁patient ▁history ▁ , ▁physical ▁examina tions ▁ , ▁and ▁appropriate ▁laborator y ▁and ▁skin ▁tests ▁should ▁be ▁considered ▁ .
▁out er ▁carton ▁1,000 ▁mg ▁presentation
▁use ▁of ▁ rescu e ▁medication
▁because ▁of ▁the ▁nature ▁of ▁the ▁advers e ▁events ▁seen ▁with ▁combination ▁of ▁eta ner cept ▁and ▁anak in ra ▁ therapy ▁ , ▁similar ▁ toxic ities ▁may ▁also ▁result ▁from ▁the ▁combination ▁of ▁anak in ra ▁and ▁other ▁t n f ▁- block ing ▁agents ▁ .
▁change ▁at ▁week ▁52 ▁( ▁n ▁= ▁38 2 ▁)
▁what ▁you ▁need ▁to ▁know ▁before ▁you ▁take ▁up tra vi ▁do ▁not ▁take ▁up tra vi
▁if ▁you ▁suddenly ▁stop ▁taking ▁stale vo ▁and ▁other ▁anti park in son ian ▁medicine s ▁it ▁may ▁result ▁in ▁un wan ted ▁side ▁effects ▁ .
▁conflict ing ▁reports ▁in ▁the ▁literature ▁ , ▁based ▁on ▁in ▁vi tro ▁finding s ▁from ▁human ▁tum our ▁sample s ▁ , ▁suggest ▁er y thro po iet ins ▁may ▁play ▁a ▁role ▁as ▁tum our ▁prolifera tors ▁ .
▁this ▁enzym e ▁is ▁produced ▁by ▁leuk a emia ▁cell s ▁ , ▁and ▁causes ▁them ▁to ▁multi ply ▁un control lab ly ▁ .
▁reproduc tion ▁is ▁author ised ▁provided ▁the ▁source ▁is ▁acknowledge d . ▁worse ▁or ▁side ▁effects ▁become ▁un accepta ble ▁ .
▁the ▁ons et ▁of ▁ef fica cy ▁is ▁within ▁8 ▁hours ▁for ▁fle as ▁( ▁c . ▁felis ▁) ▁and ▁12 ▁hours ▁for ▁ti cks ▁( ▁i . ▁ rici nus ▁) ▁ .
▁radio pharma ce u tical s ▁should ▁be ▁received ▁ , ▁used ▁and ▁ad minister ed ▁only ▁by ▁author ised ▁person s ▁in ▁design ated ▁clinic al ▁setting s ▁ .
▁if ▁you ▁are ▁having ▁any ▁vaccin ations ▁tell ▁your ▁doctor ▁ , ▁or ▁the ▁person ▁giving ▁you ▁the ▁vaccin e ▁ , ▁that ▁you ▁are ▁being ▁treated ▁with ▁ar zer ra ▁ .
▁large ▁dos es ▁of ▁som a trop in ▁may ▁im pair ▁gluco se ▁ tolerance ▁ .
▁before ▁starting ▁ , ▁the ▁hands ▁should ▁be ▁was hed ▁ .
▁one ▁vi al ▁of ▁powder ▁contain s ▁5 ▁mg ▁of ▁te du glut ide ▁ .
▁ner vous ▁system ▁side ▁effects ▁such ▁as ▁di zzi ness ▁may ▁be ▁higher ▁after ▁a ▁load ing ▁dose ▁ .
▁2.5 ▁ml ▁( ▁half ▁5 ▁ml ▁vi al ▁)
▁the ▁product ▁is ▁highly ▁flam m able ▁ .
▁heart ▁pain ▁( ▁ang ina ▁) ▁ , ▁ab normal ▁heart ▁ rhythm s ▁ , ▁rapid ▁heart ▁beat ▁ , ▁feeling ▁the ▁heart ▁ski pping ▁a ▁beat ▁ , ▁flutt ering ▁ , ▁or ▁be ating ▁too ▁hard ▁or ▁fast ▁( ▁palp it ations ▁)
▁levo do pa ▁over dos e ▁may ▁give ▁ rise ▁to ▁system ic ▁complica tions ▁ , ▁seconda ry ▁to ▁dop amine rg ic ▁over stimul ation ▁ .
▁the ▁reaction ▁was ▁trans ient ▁ .
▁bri vi act ▁100 ▁mg ▁tablets ▁bri vara ce tam
▁instructions ▁how ▁to ▁handle ▁possible ▁advers e ▁events ▁including ▁providing ▁of ▁bat ch ▁number ▁when ▁report ing ▁advers e ▁drug ▁reaction s
▁cy to ch rom e ▁p 450 ▁enzym es ▁ , ▁ eff lux ▁pump s ▁and ▁protein - binding ▁mechanism s ▁are ▁not ▁involved ▁in ▁the ▁clear ance ▁of ▁me poli zum ab ▁ .
▁15 ▁to ▁less ▁than ▁35 ▁200 ▁mg ▁100 ▁mg ▁at ▁least ▁35 ▁300 ▁mg ▁100 ▁mg
▁gem cita bine ▁/ ▁ci s plat in ▁( ▁n ▁= ▁8 30 ▁)
▁ami oda rone ▁ , ▁qui ni dine ▁( ▁used ▁to ▁correct ▁irregular ▁heart beat s ▁)
▁vot ubi a ▁2.5 ▁mg ▁tablets ▁are ▁white ▁to ▁slightly ▁yellow ish ▁ , ▁e long ated ▁tablets ▁ .
▁non - clin ical ▁data ▁on ▁met form in ▁reveal ▁no ▁special ▁hazard ▁for ▁humans ▁based ▁on ▁convention al ▁studies ▁of ▁safety ▁ pharma c ology ▁ , ▁repeat ed ▁dose ▁ toxic ity ▁ , ▁geno toxic ity ▁ , ▁car cino ge nic ▁potential ▁and ▁ toxic ity ▁to ▁reproduc tion ▁ .
▁air ▁bu bble s ▁are ▁not ▁a ▁problem ▁with ▁this ▁type ▁of ▁inject ion ▁ .
▁other ▁medicine s ▁and ▁re pag lini de ▁accord
▁to pote can ▁in ▁combination ▁with ▁ci s plat in ▁is ▁indicate d ▁for ▁patients ▁with ▁car cino ma ▁of ▁the ▁cer vi x ▁re current ▁after ▁radio therapy ▁and ▁for ▁patients ▁with ▁stage ▁i v b ▁disease ▁ .
▁feeling ▁irrita ble ▁swe lling ▁ , ▁pain ▁and ▁red ness ▁where ▁the ▁inject ion ▁is ▁given ▁ .
▁date ▁of ▁first ▁author isation ▁: ▁26 ▁/ ▁05 ▁/ ▁2016
▁do ▁not ▁replace ▁the ▁dose ▁that ▁has ▁been ▁vom i ted ▁ .
▁the ▁ pharma cok ine tics ▁of ▁var den a fil ▁in ▁patients ▁with ▁severe ly ▁im pair ed ▁he pati c ▁function ▁( ▁child - p ugh ▁c ▁) ▁has ▁not ▁been ▁studie d ▁( ▁see ▁section ▁4.3 ▁) ▁ .
▁in ▁addition ▁ , ▁the ▁company ▁that ▁market s ▁kol bam ▁will ▁provide ▁educational ▁material ▁with ▁information ▁on ▁the ▁correct ▁and ▁safe ▁use ▁of ▁kol bam ▁to ▁all ▁doctor s ▁expected ▁to ▁pre scribe ▁this ▁medicine ▁ .
▁champ ix ▁dos ing ▁should ▁usually ▁start ▁at ▁1-2 ▁weeks ▁before ▁this ▁date ▁( ▁see ▁section ▁5.1 ▁) ▁ .
▁patients ▁should ▁be ▁monitor ed ▁for ▁ha e mat ological ▁advers e ▁reaction s ▁ , ▁especially ▁neutro p enia ▁ .
▁the ▁combination ▁of ▁these ▁ingredients ▁has ▁an ▁addit ive ▁anti hy per tensi ve ▁effect ▁ , ▁ reducing ▁blood ▁pressure ▁to ▁a ▁greater ▁degree ▁than ▁either ▁component ▁alone ▁ .
▁un com mon ▁: ▁blu r red ▁vision ▁ , ▁visual ▁disturb ance ▁ , ▁di plo pia ▁ .
▁no ▁dose ▁adjust ment ▁is ▁necessary ▁ .
▁the ▁recommended ▁dose ▁is ▁ 0.4 ▁mg ▁/ ▁kg ▁( ▁up ▁to ▁a ▁maximum ▁of ▁25 ▁mg ▁per ▁dose ▁) ▁ , ▁given ▁twice ▁week ly ▁as ▁a ▁sub cuta ne ous ▁inject ion ▁with ▁an ▁interval ▁of ▁3-4 ▁days ▁between ▁dos es ▁or ▁ 0.8 ▁mg ▁/ ▁kg ▁( ▁up ▁to ▁a ▁maximum ▁of ▁50 ▁mg ▁per ▁dose ▁) ▁given ▁once ▁week ly ▁ .
▁do ▁not ▁touch ▁this ▁area ▁again ▁before ▁giving ▁the ▁inject ion ▁ .
▁you ▁will ▁be ▁given ▁da co gen ▁when ▁you ▁are ▁first ▁diagnose d ▁with ▁am l ▁ .
▁other ▁information ▁about ▁reli stor
▁after ▁recon stitu tion ▁ , ▁1 ▁ml ▁of ▁suspens ion ▁contain s ▁20 ▁mg ▁( ▁20 ▁mg ▁/ ▁ml ▁) ▁ .
▁if ▁your ▁baby ▁is ▁too ▁small ▁to ▁drink ▁from ▁a ▁glass ▁or ▁a ▁cup ▁you ▁may ▁ad minister ▁the ▁disso l ved ▁preparation ▁of ▁kuvan ▁via ▁the ▁oral ▁dos ing ▁sy ringe ▁ .
▁the ▁patient ▁' s ▁weight ▁should ▁be ▁divide d ▁by ▁3 ▁ , ▁and ▁round ed ▁up ▁to ▁the ▁next ▁higher ▁whole ▁number ▁ .
▁in ▁a ▁compara tor ▁study ▁in vol ving ▁60 ▁ evalua ble ▁patients ▁ , ▁the ▁rates ▁of ▁successful ▁ab lation ▁of ▁thy roid ▁rem nant s ▁with ▁100 ▁m ci ▁/ ▁ 3.7 ▁ gb q ▁( ▁ ± ▁10 ▁% ▁) ▁radio io dine ▁in ▁post - thy roid ecto my ▁patients ▁with ▁thy roid ▁cancer ▁ , ▁were ▁comparable ▁for ▁patients ▁treated ▁after ▁thy roid ▁hormone ▁withdraw al ▁versus ▁patients ▁treated ▁after ▁thy rogen ▁administration ▁ .
▁important ▁things ▁to ▁know ▁about ▁combine d ▁hormonal ▁contra cep tives ▁( ▁ch cs ▁) ▁:
▁what ▁doce ta xel ▁accord ▁looks ▁like ▁and ▁content s ▁of ▁the ▁pack
▁plate let ▁ aggregat ion ▁and ▁ble ed ing ▁time ▁gradual ly ▁returned ▁to ▁base line ▁values ▁ , ▁generally ▁within ▁5 ▁days ▁after ▁treatment ▁was ▁dis continu ed ▁ .
▁the ▁other ▁ingredient ▁is ▁la ctos e ▁mono hydrat e ▁ .
▁125 ▁dos es ▁( ▁250 ▁ml ▁) ▁ .
▁the ▁cholesterol ▁draw n ▁out ▁of ▁the ▁blood ▁in ▁this ▁way ▁is ▁the ▁' ▁bad ▁' ▁cholesterol ▁ .
▁general ▁side ▁effects ▁: ▁short ness ▁of ▁breath ▁ , ▁increased ▁allergi c ▁symptoms ▁ , ▁facial ▁swe lling ▁ , ▁ drow si ness ▁ , ▁general ized ▁we ak ness ▁ , ▁na use a ▁ , ▁vom i ting ▁ , ▁sinus ▁infection ▁ , ▁skin ▁red ness ▁and ▁it ching ▁ .
▁age ▁does ▁not ▁affect ▁the ▁ pharma cok ine tics ▁of ▁palo nos et ron ▁ .
▁one ▁ml ▁contain s ▁100 ▁mg ▁of ▁human ▁normal ▁immun o glob ulin ▁ , ▁of ▁which ▁at ▁least ▁97 ▁% ▁is ▁i gg ▁ .
▁the ▁inject ion ▁procedure ▁should ▁be ▁carried ▁out ▁under ▁a se ptic ▁conditions ▁ .
▁nor vir ▁did ▁not ▁appear ▁to ▁increase ▁the ▁chance ▁of ▁developing ▁birth ▁defect s ▁compared ▁to ▁the ▁general ▁population ▁ .
▁co - administration ▁of ▁riba vir in ▁and ▁di dano sine ▁is ▁not ▁recommended ▁ .
▁growth ▁and ▁development ▁( ▁children ▁and ▁adolescents ▁) ▁: ▁during ▁the ▁course ▁of ▁pe ga sys ▁plus ▁riba vir in ▁ therapy ▁ lasting ▁up ▁to ▁48 ▁weeks ▁in ▁patients ▁a ged ▁5 ▁to ▁17 ▁years ▁ , ▁weight ▁loss ▁and ▁growth ▁inhibi tion ▁were ▁common ▁( ▁see ▁section s ▁4. 8 ▁and ▁5.1 ▁) ▁ .
▁how ▁does ▁equi s olon ▁work ▁?
▁li pro log ▁mix ▁is ▁a ▁mix ture ▁of ▁these ▁two ▁formula tions ▁ .
▁clo pido gre l ▁zen tiva ▁75 ▁mg ▁film - co ated ▁tablets ▁clo pido gre l
▁due ▁to ▁safety ▁concern s ▁( ▁see ▁section s ▁4.4 ▁and ▁5.3 ▁) ▁ , ▁this ▁medicinal ▁product ▁should ▁not ▁be ▁used ▁in ▁children ▁and ▁adolescents ▁a ged ▁below ▁18 ▁years ▁ .
▁muscle ▁spas ms ▁( ▁includes ▁leg ▁cr amp s ▁)
▁telephone ▁: ▁+ ▁31 ▁20 ▁ 572 ▁65 16
▁in ▁patients ▁with ▁pre - exist ing ▁ana emia ▁ , ▁le uc op enia ▁ , ▁and ▁/ ▁or ▁ thro mbo cy top enia ▁as ▁well ▁as ▁in ▁patients ▁with ▁im pair ed ▁bone ▁mar row ▁function ▁or ▁those ▁at ▁risk ▁of ▁bone ▁mar row ▁sup pression ▁ , ▁the ▁risk ▁of ▁ha e mat ological ▁disorder s ▁is ▁increased ▁ .
▁excessive ▁sleep ines s ▁during ▁the ▁day ▁ , ▁often ▁at ▁the ▁wrong ▁times ▁( ▁a ▁long - term ▁condition ▁called ▁na r cole psy ▁) ▁ , ▁has ▁been ▁reported ▁very ▁rare ly ▁after ▁vaccin ation ▁with ▁pande m rix ▁in ▁several ▁european ▁countries ▁ .
▁if ▁you ▁have ▁heart ▁failure
▁in ▁non - clin ical ▁studies ▁ , ▁sa prop ter in ▁was ▁primari ly ▁distribu ted ▁to ▁the ▁ki dne ys ▁ , ▁ad ren al ▁g lands ▁ , ▁and ▁ liver ▁as ▁assess ed ▁by ▁levels ▁of ▁total ▁and ▁reduce d ▁bi opter in ▁concentration s ▁ .
▁the ▁use ▁of ▁glo ves ▁ , ▁go ggle s ▁ , ▁and ▁protect ive ▁clothing ▁is ▁recommended ▁ .
▁general ▁side ▁effects ▁: ▁ rash ▁or ▁it ching ▁of ▁the ▁skin
▁in ▁study ▁i ▁ , ▁40 4 ▁patients ▁were ▁random ly ▁assign ed ▁to ▁receive ▁place bo ▁( ▁138 ▁patients ▁) ▁ , ▁rasa gi line ▁1 ▁mg ▁/ ▁day ▁( ▁134 ▁patients ▁) ▁or ▁rasa gi line ▁2 ▁mg ▁/ ▁day ▁( ▁132 ▁patients ▁) ▁and ▁were ▁treated ▁for ▁26 ▁weeks ▁ , ▁there ▁was ▁no ▁active ▁compara tor ▁ .
▁you ▁may ▁get ▁a ▁dry ▁mouth ▁ .
▁in ▁patients ▁with ▁pre exist ing ▁at rial ▁fi bril lation ▁requiri ng ▁antico agu lant ▁ therapy ▁ , ▁alternative ▁treatment ▁options ▁to ▁im bru vica ▁should ▁be ▁considered ▁ .
▁weight ▁decrease ▁ , ▁decrease ▁of ▁appetit e
▁after ▁repeat ed ▁sub cuta ne ous ▁administration ▁of ▁40 ▁mg ▁once ▁daily ▁and ▁1.5 ▁mg ▁/ ▁kg ▁once ▁daily ▁regime ns ▁in ▁healthy ▁volunteer s ▁ , ▁the ▁stea dy - state ▁is ▁reached ▁on ▁day ▁2 ▁with ▁an ▁average ▁exposure ▁ratio ▁about ▁15 ▁% ▁higher ▁than ▁after ▁a ▁single ▁dose ▁ .
▁multi - drug ▁resist ant ▁my coba cter ium ▁tubercul osis ▁( ▁m dr h ▁& ▁r - t b ▁) ▁: ▁isola te ▁resist ant ▁to ▁at ▁least ▁is onia zi d ▁and ▁rif ampi cin ▁ , ▁but ▁susceptible ▁to ▁fluor o quin olon es ▁and ▁second ▁line ▁inject able ▁agents ▁ .
▁avoid ▁gra pe fru it ▁juice ▁during ▁treatment ▁with ▁pro cor alan ▁ .
▁known ▁photo aller gy ▁or ▁photo toxic ▁reaction ▁during ▁treatment ▁with ▁fibra tes ▁or ▁keto profe n
▁it ▁is ▁effective ▁against ▁m rsa ▁bacteria ▁ , ▁which ▁are ▁resist ant ▁to ▁other ▁common ly ▁used ▁groups ▁of ▁antibiotic s ▁such ▁as ▁pe nici llin s ▁( ▁including ▁met hi ci llin ▁and ▁o xa ci llin ▁) ▁and ▁cep halo spor ins ▁ .
▁the ▁survival ▁rate ▁was ▁9 3.7 ▁% ▁in ▁the ▁tac ▁arm ▁and ▁9 1.4 ▁% ▁in ▁the ▁fac ▁arm ▁ , ▁at ▁the ▁8- year ▁follow - up ▁time point ▁ , ▁and ▁9 1.3 ▁% ▁in ▁the ▁tac ▁arm ▁and ▁89 ▁% ▁in ▁the ▁fac ▁arm ▁ , ▁at ▁the ▁10- year ▁follow - up ▁time point ▁ .
▁amino transfer ase ▁( ▁alt ▁) ▁increased ▁as parta te ▁amino transfer ase ▁( ▁a st ▁) ▁increased ▁gamma ▁glu tam yl ▁transfer ase ▁( ▁g gt ▁)
▁if ▁influenza ▁anti vir al ▁agents ▁and ▁flu enz ▁are ▁ad minister ed ▁con com i tant ly ▁ , ▁re vac cin ation ▁should ▁be ▁considered ▁when ▁appropriate ▁ .
▁the ▁tablet ▁can ▁be ▁divide d ▁into ▁equal ▁halve s ▁ .
▁novos even ▁recon stitu ted ▁solution ▁is ▁colour less ▁and ▁should ▁be ▁inspect ed ▁visual ly ▁for ▁parti cula te ▁matter ▁and ▁disco lou ration ▁prior ▁to ▁administration ▁ .
▁250 ▁mg ▁film - co ated ▁tablets ▁: ▁brilliant ▁blue ▁f cf ▁( ▁e 133 ▁) ▁and ▁indi go tine ▁( ▁e 132 ▁) ▁ .
▁tru licit y ▁is ▁indicate d ▁in ▁adults ▁with ▁type ▁2 ▁diabetes ▁mell itus ▁to ▁improve ▁gly ca e mic ▁control ▁as ▁:
▁" ▁tas mar ▁" ▁and ▁" ▁200 ▁" ▁are ▁en grave d ▁on ▁one ▁side ▁ .
▁content s ▁of ▁the ▁pack ▁and ▁other ▁information ▁what ▁riba vir in ▁teva ▁contain s
▁the ▁study ▁compared ▁the ▁safety ▁and ▁ef fica cy ▁of ▁tras tuz um ab ▁em tan sine ▁with ▁that ▁of ▁la pati ni b ▁plus ▁cap e cita bine ▁ .
▁the ▁european ▁commission ▁gran ted ▁a ▁marketing ▁author isation ▁valid ▁throughout ▁the ▁european ▁union ▁for ▁rey ata z ▁on ▁2 ▁march ▁2004 ▁ .
▁sive x tro ▁is ▁indicate d ▁for ▁the ▁treatment ▁of ▁a cute ▁bacteria l ▁skin ▁and ▁skin ▁structure ▁infection s ▁( ▁abs ssi ▁) ▁in ▁adults ▁( ▁see ▁section s ▁4.4 ▁and ▁5.1 ▁) ▁ .
▁each ▁levo do pa ▁/ ▁car bido pa ▁/ ▁en ta ca pone ▁or ion ▁175 ▁mg ▁/ ▁43 . 75 ▁mg ▁/ ▁200 ▁mg ▁tablet ▁contain s ▁175 ▁mg ▁of ▁levo do pa ▁ , ▁43 . 75 ▁mg ▁of ▁car bido pa ▁and ▁200 ▁mg ▁of ▁en ta ca pone ▁ .
▁if ▁you ▁have ▁a ▁severe ▁ki dne y ▁problem ▁ .
▁you ▁do ▁not ▁eat ▁enough ▁ , ▁or ▁eat ▁food ▁contain ing ▁less ▁sugar ▁( ▁car bo hydrat e ▁) ▁than ▁normal ▁- ▁artificial ▁sweet en ers ▁are ▁not ▁car bo hydrat es ▁ .
▁changes ▁in ▁he pati c ▁function ▁are ▁un like ly ▁to ▁have ▁any ▁effect ▁on ▁the ▁elimina tion ▁of ▁dar atum um ab ▁since ▁i gg 1 ▁mole cules ▁such ▁as ▁dar atum um ab ▁are ▁not ▁metabol ised ▁through ▁he pati c ▁path ways ▁ .
▁( ▁a ▁) ▁cim zia ▁ad minister ed ▁every ▁2 ▁weeks ▁preced ed ▁by ▁a ▁load ing ▁dose ▁of ▁400 ▁mg ▁at ▁weeks ▁0 ▁ , ▁2 ▁and ▁4
▁these ▁linear ▁mp eg ▁groups ▁extend ▁from ▁the ▁lipo some ▁surface ▁creating ▁a ▁protect ive ▁coa ting ▁that ▁reduce s ▁interaction s ▁between ▁the ▁lipid ▁bila yer ▁membran e ▁and ▁the ▁plasma ▁component s ▁ .
▁re vac cin ation ▁: ▁5 ▁months ▁after ▁primary ▁vaccin ation ▁course ▁followed ▁by ▁annual ▁boost er ▁inject ions ▁ .
▁this ▁means ▁that ▁pre gabal in ▁accord ▁is ▁similar ▁to ▁a ▁' ▁reference ▁medicine ▁' ▁already ▁author ised ▁in ▁the ▁european ▁union ▁( ▁eu ▁) ▁called ▁ly rica ▁ .
▁cau tion ▁should ▁be ▁exercise d ▁when ▁pra da xa ▁is ▁co - ad minister ed ▁with ▁posa con a zole ▁ .
▁pasi ▁75 ▁and ▁pga ▁of ▁clear ▁or ▁minimal ▁response ▁rates ▁in ▁these ▁patients ▁were ▁74 . 7 ▁% ▁and ▁59 . 0 ▁% ▁ , ▁respective ly ▁ , ▁after ▁an ▁additional ▁108 ▁weeks ▁of ▁open - label ▁ therapy ▁( ▁total ▁of ▁160 ▁weeks ▁) ▁ .
▁the ▁remo val ▁of ▁ne xo brid ▁and ▁of ▁disso l ved ▁es char
▁in ▁the ▁third ▁study ▁ , ▁byd ure on ▁reduce d ▁h ba 1 c ▁levels ▁by ▁an ▁average ▁of ▁1.4 ▁points ▁after ▁26 ▁weeks ▁of ▁treatment ▁ , ▁compared ▁with ▁an ▁average ▁re duction ▁of ▁ 0.8 ▁or ▁1.1 ▁points ▁with ▁si tag lip tin ▁or ▁pi og lita zone ▁respective ly ▁ .
▁during ▁treatment ▁with ▁fast ur tec ▁ , ▁your ▁doctor ▁will ▁carry ▁out ▁blood ▁tests ▁to ▁check ▁the ▁levels ▁of ▁u ric ▁acid ▁and ▁decide ▁how ▁long ▁you ▁will ▁be ▁treated ▁for ▁ .
▁abil ify ▁5 ▁mg ▁tablets ▁are ▁recta ngu lar ▁and ▁blue ▁ , ▁marked ▁with ▁' ▁a - 007 ▁' ▁and ▁' ▁5 ' ▁on ▁one ▁side ▁ .
▁when ▁transition ing ▁between ▁formula tions ▁ , ▁a ▁change ▁in ▁dose ▁may ▁be ▁needed ▁ .
▁suv ax yn ▁a ujesz ky ▁ 783 ▁+ ▁o ▁/ ▁w ▁ , ▁powder ▁and ▁solve nt ▁for ▁em ul sion ▁for ▁inject ion ▁for ▁pig s
▁blue ▁ , ▁round ▁ , ▁shall ow - con ve x ▁ , ▁de bos sed ▁with ▁" ▁o t suka ▁" ▁and ▁" ▁30 ▁" ▁on ▁one ▁side ▁ .
▁patients ▁should ▁be ▁monitor ed ▁for
▁name ▁and ▁address ▁of ▁the ▁manufacture r ▁responsible ▁for ▁bat ch ▁release ▁penn ▁ pharma ce u tical ▁services ▁limited
▁the ▁strength ▁of ▁tablet ▁to ▁use ▁depend s ▁on ▁the ▁dose ▁of ▁the ▁other ▁diabetes ▁medicine s ▁that ▁the ▁patient ▁was ▁taking ▁before ▁ .
▁for ▁more ▁information ▁about ▁treatment ▁with ▁en ta ca pone ▁teva ▁ , ▁read ▁the ▁package ▁le a flet ▁( ▁also ▁part ▁of ▁the ▁e par ▁) ▁or ▁contact ▁your ▁doctor ▁or ▁ pharma ci st ▁ .
▁the ▁oral ▁sy ringe ▁should ▁be ▁insert ed ▁into ▁the ▁pi ba ▁and ▁the ▁dose ▁withdraw n ▁from ▁the ▁invert ed ▁bottle ▁ .
▁medicine s ▁for ▁fit s ▁( ▁se iz ures ▁) ▁( ▁like ▁ phen y to in ▁or ▁ phen oba rbi tal ▁) ▁may ▁decrease ▁the ▁effective ness ▁of ▁vitamin ▁d ▁ .
▁solution ▁for ▁inject ion ▁4 ▁cart ridge s ▁of ▁3 ▁ml ▁ .
▁round ▁ , ▁bi con ve x ▁ , ▁white ▁film - co ated ▁tablet ▁( ▁approximately ▁ 7.9 ▁mm ▁in ▁diameter ▁) ▁de bos sed ▁with ▁' ▁g s ▁m z 1 ▁' ▁and ▁' ▁12. 5 ▁' ▁on ▁one ▁side ▁ .
▁the ▁bi expo n ential ▁decline ▁of ▁the ▁se rum ▁concentration ▁of ▁cla dri bine ▁after ▁sub cuta ne ous ▁bol us ▁inject ion ▁is ▁comparable ▁to ▁elimina tion ▁parameter s ▁after ▁2- ho ur ▁intra ven ous ▁in fusion ▁with ▁an ▁initial ▁and ▁terminal ▁half - life ▁of ▁approximately ▁2 ▁hours ▁and ▁11 ▁hours ▁ , ▁respective ly ▁ .
▁if ▁not ▁used ▁immediately ▁ , ▁in - use ▁storage ▁times ▁and ▁conditions ▁prior ▁to ▁use ▁are ▁the ▁responsibility ▁of ▁the ▁user ▁and ▁would ▁normal ly ▁not ▁be ▁longer ▁than ▁24 ▁hours ▁at ▁2 ▁to ▁8 ▁° ▁c ▁ , ▁unless ▁dilu tion ▁has ▁taken ▁place ▁in ▁control led ▁and ▁valida ted ▁a se ptic ▁conditions ▁ .
▁as ▁a ▁precau tion ary ▁measure ▁ , ▁oss e or ▁treatment ▁should ▁be ▁suspend ed ▁during ▁treatment ▁with ▁oral ▁te tra cycli ne ▁or ▁qui no lone ▁antibiotic s ▁ .
▁see ▁also ▁section ▁" ▁tax o tere ▁contain s ▁et han ol ▁( ▁alcohol ▁) ▁" ▁below ▁ .
▁189 ▁dog s ▁were ▁treated ▁with ▁si mpar ica ▁for ▁three ▁months ▁whilst ▁96 ▁dog s ▁were ▁given ▁another ▁medicine ▁ , ▁spin os ad ▁ .
▁rey ata z ▁oral ▁powder ▁should ▁be ▁store d ▁in ▁the ▁original ▁sa chet ▁and ▁should ▁not ▁be ▁opened ▁until ▁ready ▁to ▁use ▁ .
▁flu shing ▁events ▁tend ▁to ▁begin ▁early ▁in ▁the ▁course ▁of ▁treatment ▁( ▁primari ly ▁during ▁the ▁first ▁month ▁) ▁and ▁in ▁patients ▁who ▁experience ▁flu shing ▁ , ▁these ▁events ▁may ▁continue ▁to ▁occur ▁inter mitten t ly ▁throughout ▁treatment ▁with ▁ tec fi dera ▁ .
▁because ▁ar ipi pra zole ▁my lan ▁ pharma ▁is ▁a ▁generic ▁medicine ▁and ▁is ▁bio e qui valent ▁to ▁the ▁reference ▁medicine ▁ , ▁its ▁benefits ▁and ▁risk s ▁are ▁taken ▁as ▁being ▁the ▁same ▁as ▁the ▁reference ▁medicine ▁' s ▁ .
▁fatigue ▁( ▁feeling ▁tired ▁) ▁head ache
▁in ▁vi tro ▁studies ▁with ▁human ▁ liver ▁micro some s ▁indicate d ▁that ▁cy p 3 a 4 ▁is ▁the ▁only ▁p 450 ▁iso zy me ▁that ▁play s ▁a ▁major ▁role ▁in ▁the ▁oxid ative ▁metabolism ▁of ▁in dina vir ▁ .
▁no ▁dos ing ▁adjust ments ▁are ▁required ▁for ▁patients ▁with ▁mild ▁ , ▁moderat e ▁ , ▁or ▁severe ▁he pati c ▁im pair ment ▁ .
▁patients ▁being ▁treated ▁with ▁op ry mea ▁and ▁present ing ▁with ▁som nol ence ▁and ▁/ ▁or ▁sud den ▁sleep ▁episode s ▁must ▁be ▁informe d ▁to ▁ref rain ▁from ▁driving ▁or ▁enga ging ▁in ▁activities ▁where ▁im pair ed ▁alert ness ▁may ▁put ▁themselves ▁or ▁others ▁at ▁risk ▁of ▁serious ▁injury ▁or ▁death ▁( ▁e . g . ▁operating ▁machines ▁) ▁until ▁such ▁re current ▁episode s ▁and ▁som nol ence ▁have ▁resolve d ▁( ▁see ▁also ▁section s ▁4.4 ▁ , ▁4.5 ▁ , ▁and ▁4. 8 ▁) ▁ .
▁in ▁ex tensi ve ▁post - registra tion ▁observation al ▁studies ▁with ▁heli xa te ▁ne x gen ▁ , ▁in vol ving ▁more ▁than ▁1000 ▁patients ▁the ▁following ▁was ▁observe d ▁: ▁less ▁than ▁0.2 ▁% ▁pt p ▁developed ▁de - novo ▁inhibi tors ▁ .
▁y mpa thom imet ic ▁medicine s ▁( ▁such ▁as ▁e pine ph rine ▁[ ▁adrenalin e ▁] ▁ , ▁sal but a mol ▁ , ▁ter but a line ▁used ▁to ▁treat ▁as th ma ▁) ▁ ,
▁the ▁european ▁medicine s ▁agency ▁has ▁de fer red ▁the ▁obliga tion ▁to ▁submit ▁the ▁results ▁of ▁studies ▁with ▁sir tur o ▁in ▁one ▁or ▁more ▁sub set s ▁of ▁the ▁pa e dia tric ▁population ▁in ▁the ▁treatment ▁of ▁multi - drug ▁resist ant ▁my coba cter ium ▁tubercul osis ▁( ▁see ▁section ▁4.2 ▁for ▁information ▁on ▁pa e dia tric ▁use ▁) ▁ .
▁air ▁bu bble s ▁must ▁be ▁removed ▁from ▁the ▁cart ridge ▁before ▁inject ion ▁( ▁see ▁instructions ▁for ▁using ▁the ▁pen ▁) ▁ .
▁the ▁need ▁to ▁refer ▁the ▁patient ▁to ▁a ▁specialist ▁physician
▁no ▁dedicated ▁studies ▁investiga ting ▁the ▁effect ▁of ▁ni nte dan ib ▁on ▁wo und ▁hea ling ▁were ▁perform ed ▁ .
▁have ▁severe ▁heart ▁disease
▁eu ▁/ ▁1 ▁/ ▁02 ▁/ ▁231 ▁/ ▁ 011 ▁1 ▁cart ridge ▁of ▁3 ▁ml ▁eu ▁/ ▁1 ▁/ ▁02 ▁/ ▁231 ▁/ ▁01 2 ▁5 ▁cart ridge s ▁of ▁3 ▁ml ▁eu ▁/ ▁1 ▁/ ▁02 ▁/ ▁231 ▁/ ▁01 3 ▁10 ▁cart ridge s ▁of ▁3 ▁ml
▁s - me tha done ▁cm in ▁ ↓ ▁26 ▁%
▁1 ▁unit ▁insulin ▁de te mir ▁correspond s ▁to ▁1 ▁international ▁unit ▁of ▁human ▁insulin ▁ .
▁no ▁relevant ▁effect ▁of ▁gender ▁was ▁identified ▁ .
▁cart ridge ▁ , ▁cart ridge ▁for ▁op tic lik ▁ , ▁opt iset ▁pre - fill ed ▁pen ▁ , ▁solo star ▁pre - fill ed ▁pen ▁each ▁cart ridge ▁contain s ▁3 ▁ml ▁of ▁solution ▁for ▁inject ion ▁ , ▁equivalent ▁to ▁300 ▁unit s
▁in ▁patients ▁with ▁normal ▁renal ▁function ▁ , ▁define d ▁as ▁cl cr ▁> ▁60 ▁ml ▁/ ▁min ▁ , ▁zo le dro nic ▁acid ▁4 ▁mg ▁/ ▁100 ▁ml ▁solution ▁for ▁in fusion ▁must ▁not ▁be ▁further ▁dilu ted ▁ .
▁see ▁also ▁section ▁" ▁over dos e ▁ . ▁"
▁what ▁foc li via ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁the ▁daily ▁dose ▁depend s ▁on ▁the ▁patient ▁' s ▁body ▁weight ▁ .
▁7.5 ▁ml ▁twice ▁daily
▁do ▁not ▁use ▁this ▁medicine ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁out er ▁carton ▁and ▁pre - fill ed ▁sy ringe ▁label ▁after ▁' ▁exp ▁' ▁ .
▁an ▁in fusion - related ▁reaction ▁is ▁define d ▁as ▁any ▁advers e ▁drug ▁reaction ▁occur ring ▁within ▁24 ▁hours ▁after ▁the ▁initiat ion ▁of ▁ve lag lu cera se ▁alfa ▁in fusion ▁ .
▁pre vention ▁of ▁ha e mor r hage ▁in ▁case ▁of ▁surgery
▁not ▁for ▁children ▁who ▁we igh ▁under ▁22 ▁kg ▁or ▁28 ▁kg ▁and ▁over ▁ .
▁for ▁patients ▁with ▁reduce d ▁muscle ▁mass ▁the ▁dose ▁should ▁be ▁adjust ed ▁according ▁to ▁individual ▁patient ▁need ▁ .
▁this ▁could ▁be ▁because ▁of ▁a ▁blood ▁problem ▁( ▁ thro mbo cy top enia ▁) ▁ .
▁if ▁there ▁is ▁evidence ▁of ▁ therapy ▁induc ed ▁bron chos pas m ▁ , ▁the ▁physician ▁should ▁carefully ▁evaluat e ▁whether ▁the ▁benefits ▁of ▁continued ▁use ▁of ▁bron chi tol ▁out we igh ▁the ▁risk s ▁to ▁the ▁patient ▁ .
▁the ▁capsule ▁ shell ▁consist s ▁of ▁gelatin e ▁ , ▁indi go ▁car mine ▁( ▁e 132 ▁) ▁ , ▁titan ium ▁ dioxid e ▁( ▁e 171 ▁) ▁and ▁edib le ▁prin ting ▁in k ▁ .
▁what ▁is ▁rota rix ▁used ▁for ▁?
▁zo meta ▁must ▁only ▁be ▁pre scribe d ▁and ▁ad minister ed ▁to ▁patients ▁by ▁health care ▁professionals ▁experienced ▁in ▁the ▁administration ▁of ▁intra ven ous ▁bis phos phon ates ▁ .
▁preparation ▁should ▁be ▁perform ed ▁by ▁train ed ▁personnel ▁in ▁accordance ▁with ▁good ▁practice s ▁rules ▁ , ▁especially ▁with ▁respect ▁to ▁a se psis ▁ .
▁feeling ▁we ak ▁general ▁feeling ▁of ▁being ▁un well
▁for ▁infants ▁less ▁than ▁1 ▁year ▁of ▁age ▁: ▁the ▁recommended ▁pro phy la xis ▁dose ▁for ▁infants ▁less ▁than ▁12 ▁months ▁during ▁a ▁pande mic ▁influenza ▁out break ▁is ▁half ▁of ▁the ▁daily ▁treatment ▁dose ▁ .
▁signifo r ▁should ▁only ▁be ▁ad minister ed ▁by ▁a ▁train ed ▁health care ▁professional ▁ .
▁ pharma co therapeut ic ▁group ▁: ▁influenza ▁vaccin es ▁ , ▁at c ▁code ▁j 07 bb 01 ▁clinic al ▁studies ▁with ▁cel va pan ▁( ▁h 1 n 1 ▁) ▁v ▁currently ▁provide ▁:
▁seconda ry ▁mortal ity ▁was ▁observe d ▁1-2 ▁days ▁later ▁ .
▁not ▁known ▁: ▁er y thema ▁multi forme ▁ , ▁er y thema ▁no dos um ▁ , ▁skin ▁ul cer ▁ , ▁palma r - plan tar ▁er y th rody sa es the sia ▁syndrome ▁ , ▁pe tech iae ▁ , ▁photo sensitiv ity ▁ , ▁bli ster ▁ , ▁der mal ▁cyst s ▁ , ▁seba ce ous ▁hyper plas ia ▁ , ▁skin ▁a trop hy ▁ , ▁skin ▁disco lou ration ▁ , ▁skin ▁ex folia tion ▁ , ▁skin ▁hyper pigment ation ▁ , ▁skin ▁hyper trop hy ▁ , ▁hyper kera tos is ▁ , ▁psoriasis ▁ .
▁what ▁if ▁i ▁un lock ed ▁the ▁pre - fill ed ▁pen ▁and ▁presse d ▁the ▁green ▁inject ion ▁button ▁before ▁i ▁twist ed ▁off ▁the ▁base ▁cap ▁?
▁hold ▁the ▁plastic ▁cap ▁under ▁the ▁need le ▁protector ▁tight en ▁the ▁need le ▁and ▁cap ▁by ▁slightly ▁turning ▁and ▁push ing ▁it ▁towards ▁the ▁sy ringe ▁ .
▁media n ▁dor ▁( ▁months ▁) ▁( ▁95 ▁% ▁ci ▁) ▁for ▁media n
▁based ▁on ▁this ▁plan ▁ , ▁safety ▁information ▁has ▁been ▁included ▁in ▁the ▁summary ▁of ▁product ▁character istic s ▁and ▁the ▁package ▁le a flet ▁for ▁i clusi g ▁ , ▁including ▁the ▁appropriate ▁precau tions ▁to ▁be ▁followed ▁by ▁health care ▁professionals ▁and ▁patients ▁ .
▁using ▁a se ptic ▁technique ▁ , ▁recon stitu te ▁each ▁vi al ▁of ▁il aris ▁at ▁room ▁temperature ▁( ▁typically ▁15 ▁° ▁c ▁to ▁25 ▁° ▁c ▁) ▁by ▁slowly ▁inject ing ▁1.0 ▁ml ▁water ▁for ▁inject ions ▁with ▁a ▁1 ▁ml ▁sy ringe ▁and ▁an
▁if ▁the ▁first ▁in fusion ▁is ▁to ler ated ▁ , ▁then ▁subsequent ▁in fusion s ▁may ▁be ▁ad minister ed ▁over ▁30 ▁to ▁60 ▁minutes ▁ .
▁gastro o es op hage al ▁ref lux ▁disease ▁ , ▁pan creati tis
▁not ▁known ▁: ▁fre que ncy ▁cannot ▁be ▁estima ted ▁from ▁the ▁available ▁data
▁yellow ▁colour ed ▁ , ▁ oval ▁ , ▁bi con ve x ▁ , ▁film ▁co ated ▁tablet ▁ , ▁de bos sed ▁' ▁l ▁65 ▁' ▁and ▁break ▁line ▁on ▁one ▁side ▁and ▁plain ▁on ▁the ▁other ▁side ▁ .
▁by ▁re plac ing ▁the ▁missing ▁hormone s ▁ , ▁per gov eris ▁allows ▁women ▁with ▁low ▁levels ▁of ▁f sh ▁and ▁l h ▁to ▁develop ▁a ▁fol lic le ▁ .
▁un com mon ▁: ▁con jun cti viti s ▁ , ▁increased ▁lac rim ation ▁;
▁clinic al ▁studies ▁of ▁fam pyr a ▁did ▁not ▁include ▁ sufficient ▁numbers ▁of ▁subject s ▁a ged ▁65 ▁and ▁over ▁to ▁determine ▁whether ▁they ▁respond ▁different ly ▁from ▁young er ▁patients ▁ .
▁if ▁you ▁get ▁tight ness ▁of ▁the ▁che st ▁ , ▁co ugh ing ▁ , ▁w hee zing ▁or ▁breath less ness ▁immediately ▁after ▁using ▁your ▁la venta ir ▁in hal er ▁:
▁the ▁factor ▁vii i ▁/ ▁von ▁will e brand ▁factor ▁complex ▁consist s ▁of ▁2 ▁mole cules ▁( ▁factor ▁vii i ▁and ▁von ▁will e brand ▁factor ▁) ▁with ▁different ▁physio logic al ▁function s ▁ .
▁a erius ▁oral ▁solution ▁is ▁available ▁in ▁bottle s ▁of ▁30 ▁ , ▁50 ▁ , ▁60 ▁ , ▁100 ▁ , ▁120 ▁ , ▁150 ▁ , ▁225 ▁and ▁300 ▁ml ▁ , ▁with ▁a ▁child proof ▁cap ▁ .
▁spec tri la ▁should ▁not ▁be ▁used ▁during ▁pre gna ncy ▁unless ▁the ▁clinic al ▁condition ▁of ▁the ▁woman ▁requires ▁treatment ▁with ▁as para gina se ▁ .
▁regarding ▁safety ▁ , ▁no ▁major ▁issues ▁have ▁been ▁identified ▁and ▁serious ▁side ▁effects ▁were ▁rare ▁or ▁manage able ▁ .
▁it ▁is ▁un know n ▁whether ▁na lo xon e ▁is ▁ex cre ted ▁in ▁human ▁breast ▁milk ▁ .
▁cy ram za ▁has ▁no ▁known ▁influence ▁on ▁the ▁ability ▁to ▁drive ▁and ▁use ▁machines ▁ .
▁only ▁your ▁physician ▁can ▁ad minister ▁li pro log ▁by ▁the ▁intra ven ous ▁route ▁ .
▁next ▁ , ▁keeping ▁the ▁need le ▁under ▁the ▁skin ▁at ▁all ▁times ▁ , ▁withdraw ▁the ▁need le ▁tip ▁from ▁the ▁ cord ▁and ▁re position ▁it ▁in ▁a ▁slightly ▁more ▁di stal ▁location ▁( ▁approximately ▁2-3 ▁mm ▁) ▁to ▁the ▁initial ▁inject ion ▁in ▁the ▁ cord ▁and ▁inject ▁another ▁one - thir d ▁of ▁the ▁dose ▁ .
▁the ▁holder ▁of ▁this ▁marketing ▁author isation ▁must ▁inform ▁the ▁european ▁commission ▁about ▁the ▁marketing ▁plans ▁for ▁the ▁medicinal ▁product ▁author ised ▁by ▁this ▁decision ▁ .
▁you ▁must ▁keep ▁in ▁regular ▁contact ▁with ▁your ▁doctor ▁ .
▁low ▁or ▁irregular ▁heart beat ▁or ▁heart ▁ rhythm ▁problems ▁short ness ▁of ▁breath ▁or ▁worse ning ▁of ▁any ▁short ness ▁of ▁breath ▁you ▁already ▁have
▁there ▁are ▁no ▁studies ▁on ▁the ▁ pharma cok ine tics ▁of ▁levo do pa ▁and ▁car bido pa ▁when ▁ad minister ed ▁as ▁num ient ▁in ▁children ▁ .
▁1 ▁x ▁3 ▁ml ▁+ ▁7 ▁novo fine ▁need les ▁1 ▁x ▁3 ▁ml ▁+ ▁7 ▁novo tw ist ▁need les ▁5 ▁x ▁3 ▁ml
▁due ▁to ▁the ▁hydro ch lor o thi azi de ▁component ▁ , ▁i firma com bi ▁is ▁not ▁recommended ▁for ▁patients ▁with ▁severe ▁renal ▁dys function ▁( ▁creati nine ▁clear ance ▁< ▁30 ▁ml ▁/ ▁min ▁) ▁ .
▁you ▁may ▁need ▁extra ▁check - ups ▁ , ▁including ▁blood ▁tests ▁ , ▁while ▁you ▁are ▁taking ▁your ▁medicine ▁ .
▁cabo zan tin ib ▁was ▁an ▁inhibi tor ▁( ▁ ic 50 ▁= ▁ 7.0 ▁μ m ▁) ▁ , ▁but ▁not ▁a ▁substrat e ▁ , ▁of ▁p - gly co prote in ▁( ▁p - gp ▁) ▁transport ▁activities ▁in ▁a ▁bi - direct ional ▁as say ▁system ▁using ▁m d ck - m dr 1 ▁cell s ▁ .
▁melo xi cam ▁50 ▁mg ▁/ ▁g ▁ben zy l ▁alcohol ▁10 ▁mg ▁/ ▁g
▁ky pro lis ▁30 ▁mg ▁powder ▁for ▁solution ▁for ▁in fusion ▁car fil zom ib
▁a ▁risk ▁management ▁plan ▁has ▁been ▁developed ▁to ▁ensure ▁that ▁syl vant ▁is ▁used ▁as ▁safe ly ▁as ▁possible ▁ .
▁advers e ▁drug ▁reaction s ▁are ▁groupe d ▁according ▁to ▁their ▁fre que ncies ▁ .
▁appropriate ▁a se ptic ▁precau tions ▁should ▁be ▁taken ▁ .
▁there ▁was ▁a ▁significant ▁association ▁between ▁the ▁intens ity ▁of ▁local ▁skin ▁reaction s ▁( ▁e . g . ▁er y thema ▁) ▁seen ▁during ▁the ▁treatment ▁period ▁and ▁complete ▁clear ance ▁of ▁the ▁bas al ▁cell ▁car cino ma ▁ .
▁ potent ▁cy p 3 a 4 ▁induc ers ▁such ▁as ▁rif ampi cin ▁ , ▁ phen oba rbi tal ▁ , ▁carb amaz e pine ▁ , ▁ phen y to in ▁or ▁st ▁joh n ▁' s ▁ wort ▁are ▁not ▁recommended ▁ .
▁olan za pine ▁ci pla ▁10 ▁mg ▁co ated ▁tablets ▁olan za pine
▁multi pack ▁compris ing ▁25 ▁pack s ▁( ▁6 ▁capsule s ▁+ ▁1 ▁in hal er ▁)
▁the ▁solve nt ▁vi al ▁has ▁a ▁blue ▁strip e ▁ .
▁however ▁ , ▁ ixe ki zum ab ▁is ▁ex cre ted ▁at ▁low ▁levels ▁in ▁the ▁milk ▁of ▁cyn om ol gus ▁mon key s ▁ .
▁however ▁ , ▁at ▁the ▁test ed ▁dos es ▁in ▁the ▁study ▁ , ▁the ▁statistic ally ▁significant ▁ki ne tic ▁difference s ▁are ▁un like ly ▁to ▁be ▁of ▁clinic al ▁relevan ce ▁ .
▁content s ▁of ▁the ▁pack ▁and ▁other ▁information ▁what ▁sus tiva ▁contain s
▁this ▁summary ▁was ▁last ▁updated ▁in ▁07 -2014 ▁ .
▁the ▁site ▁of ▁the ▁so dium ▁chlor ide ▁9 ▁mg ▁/ ▁ml ▁( ▁ 0.9 ▁% ▁) ▁solution ▁for ▁inject ion ▁bag ▁where ▁the ▁need le ▁is ▁going ▁to ▁be ▁insert ed ▁should ▁be ▁s wab bed ▁with ▁an ▁alcohol ▁pad ▁ .
▁treatment ▁with ▁ri lu tek ▁should ▁only ▁be ▁initiat ed ▁by ▁specialist ▁physician s ▁with ▁experience ▁in ▁the ▁management ▁of ▁motor ▁neuron e ▁disease s ▁ .
▁however ▁ , ▁cau tion ▁should ▁be ▁exercise d ▁when ▁e some pra zole ▁is ▁given ▁at ▁high ▁dos es ▁in ▁el der ly ▁patients ▁ .
▁it ▁is ▁not ▁recommended ▁to ▁co -
▁in ▁a ▁re lapse ▁pre vention ▁study ▁ , ▁patients ▁respond ing ▁to ▁12- week s ▁of ▁a cute ▁treatment ▁with ▁open - label ▁du lo xe tine ▁li lly ▁60 ▁mg ▁once ▁daily ▁were ▁random ised ▁to ▁either ▁du lo xe tine ▁li lly ▁60 ▁mg ▁once ▁daily ▁or ▁place bo ▁for ▁a ▁further ▁6- mont h s ▁ .
▁it ▁is ▁recommended ▁that ▁patients ▁suspect ed ▁of ▁receiving ▁an ▁over dos e ▁be ▁monitor ed ▁ , ▁and ▁general ▁support ive ▁measure s ▁be ▁initiat ed ▁as ▁no ▁specific ▁anti do te ▁has ▁been ▁identified ▁ .
▁symptoms ▁include ▁trem ors ▁ , ▁pain ▁ , ▁ cra mping ▁;
▁the ▁most ▁frequently ▁reported ▁defect s ▁are ▁cle ft ▁lip ▁ , ▁cardiovascular ▁mal form ations ▁and ▁ne ural ▁tube ▁defect s ▁ .
▁the ▁use ▁of ▁antico a gul ants ▁is ▁known ▁to ▁increase ▁the ▁risk ▁of ▁gastro inte stin al ▁ha e mor r hage ▁ .
▁therefore ▁it ▁is ▁not ▁expected ▁to ▁potentia te ▁bra dyk inin media ted ▁advers e ▁effects ▁ .
▁it ▁is ▁intended ▁to ▁be ▁given ▁before ▁or ▁during ▁the ▁next ▁pande mic ▁influenza ▁( ▁flu ▁) ▁to ▁prevent ▁flu ▁caused ▁by ▁the ▁h 5 n 1 ▁type ▁of ▁the ▁virus ▁ .
▁patients ▁with ▁mb c ▁should ▁be ▁treated ▁with ▁her cept in ▁until ▁progression ▁of ▁disease ▁ .
▁however ▁ , ▁as ▁long ▁as ▁the ▁patient ▁does ▁not ▁develop ▁in fusion ▁reaction s ▁( ▁ rash ▁ , ▁it ching ▁ , ▁fe ver ▁ , ▁head ache ▁ , ▁high ▁blood ▁pressure ▁or ▁flu shing ▁) ▁ , ▁the ▁du ration ▁of ▁the ▁in fusion ▁can ▁be ▁gradual ly ▁reduce d ▁to ▁one ▁hour ▁ .
▁talk ▁to ▁your ▁doctor ▁or ▁ pharma ci st ▁before ▁receiving ▁ cia mbra ▁ .
▁the ▁study ▁showed ▁that ▁after ▁24 ▁weeks ▁ , ▁79 ▁% ▁of ▁the ▁patients ▁given ▁sir tur o ▁( ▁52 ▁out ▁of ▁66 ▁patients ▁) ▁test ed ▁negative ▁for ▁the ▁bacteria ▁in ▁the ▁spu tum ▁( ▁ph leg m ▁) ▁compared ▁with ▁58 ▁% ▁of ▁patients ▁given ▁place bo ▁( ▁38 ▁out ▁of ▁66 ▁patients ▁) ▁ .
▁key tru da ▁is ▁a ▁human ised ▁mono clo nal ▁anti body ▁which ▁bind s ▁to ▁the ▁programme d ▁cell ▁death -1 ▁( ▁p d -1 ▁) ▁receptor ▁and ▁block s ▁its ▁interaction ▁with ▁liga nd s ▁p d - l 1 ▁and ▁p d - l 2 ▁ .
▁rem s ima ▁100 ▁mg ▁powder ▁for ▁concentrat e ▁for ▁solution ▁for ▁in fusion ▁in flix ima b
▁49 41 ▁v x ▁raam s don ks ve er ▁the ▁ne ther lands
▁e mode psi de ▁may ▁interact ▁with ▁other ▁veterinar y ▁medicinal ▁products ▁using ▁the ▁same ▁transport ▁system ▁( ▁e . g . ▁macro cycli c ▁la cto nes ▁) ▁ .
▁take ▁200 ▁mg ▁( ▁2 ▁tablets ▁of ▁100 ▁mg ▁) ▁once ▁a ▁day ▁for ▁3 ▁days ▁of ▁each ▁week ▁only ▁ .
▁concentration ▁monitoring ▁of ▁seda tives ▁/ ▁hypno tics ▁is ▁recommended ▁and ▁dose ▁re duction ▁may ▁be ▁considered ▁ .
▁3 ▁pre - fill ed ▁pens ▁( ▁single - dos e ▁)
▁upon ▁co - administration ▁with ▁the ▁moderat e ▁cy p 3 a ▁induc er ▁pro be ▁efa vir enz ▁ , ▁te no fo vir ▁ala fen ami de ▁exposure ▁was ▁not ▁significantly ▁affected ▁ .
▁brief ▁contact ▁of ▁the ▁animal ▁with ▁water ▁within ▁the ▁month ▁following ▁application ▁is ▁un like ly ▁to ▁reduce ▁the ▁ef fica cy ▁of ▁the ▁product ▁ .
▁following ▁initiat ion ▁of ▁in dina vir ▁/ ▁rito na vir ▁800 ▁/ ▁100 ▁bid ▁or ▁lo pina vir ▁/ ▁rito na vir ▁400 ▁/ ▁100 ▁bid ▁ , ▁dose ▁re duction ▁of ▁ cyclo spor ine ▁a ▁to
▁mean ▁values ▁for ▁both ▁parameter s ▁remain ed ▁within ▁normal ▁range ▁ .
▁ pharma co therapeut ic ▁group ▁: ▁anti thro mbo tic ▁agents ▁ , ▁plate let ▁ aggregat ion ▁inhibi tors ▁ excl . ▁hep arin ▁ , ▁at c ▁code ▁: ▁b 01 ac 04 ▁ .
▁it ▁is ▁especially ▁important ▁to ▁tell ▁your ▁doctor ▁if ▁you ▁are ▁taking ▁: ▁ cyclo spor ine ▁a ▁( ▁a ▁medicine ▁used ▁after ▁transplant s ▁and ▁to ▁treat ▁psoriasis ▁) ▁ , ▁which ▁must ▁not ▁be ▁used ▁together ▁with ▁tra cle er ▁si rol imus ▁or ▁tac rol imus ▁ , ▁which ▁are ▁medicine s ▁used ▁after ▁transplant s ▁ , ▁as ▁these ▁are ▁not ▁recommended ▁to ▁be ▁used ▁together ▁with ▁tra cle er ▁gli ben clam ide ▁( ▁a ▁diabetes ▁medicine ▁) ▁ , ▁rif ampi cin ▁( ▁a ▁tubercul osis ▁medicine ▁) ▁or ▁flu con a zole ▁( ▁a ▁medicine ▁against ▁fun gal ▁infection s ▁) ▁ , ▁ne vira pine ▁( ▁an ▁hi v ▁medicine ▁) ▁as ▁these ▁medicine s ▁are ▁not ▁recommended ▁to ▁be ▁used ▁together ▁with ▁tra cle er ▁other ▁medicine s ▁for ▁the ▁treatment ▁of ▁hi v ▁infection ▁ , ▁which ▁may ▁require ▁special ▁monitoring ▁if ▁used ▁together ▁with ▁tra cle er ▁hormonal ▁contra cep tives ▁ , ▁which ▁are ▁not ▁effective ▁as ▁the ▁sole ▁method ▁of ▁contra ception ▁when ▁you ▁take ▁tra cle er ▁ .
▁pull ▁up ▁the ▁edge ▁of ▁the ▁foi l ▁and ▁pe el ▁the ▁foi l ▁off ▁completely ▁ .
▁detailed ▁information ▁on ▁this ▁medicinal ▁product ▁is ▁available ▁on ▁the ▁website ▁of ▁the ▁european ▁medicine s ▁agency ▁: ▁http ▁: ▁/ ▁/ ▁www . ema . europa . eu ▁/ ▁ .
▁visual isation ▁is ▁possible ▁in ▁the ▁large ▁majority ▁of ▁cases ▁ .
▁traditional ▁non - clin ical ▁studies ▁were ▁not ▁perform ed ▁ , ▁but ▁there ▁are ▁no ▁non - clin ical ▁concern s ▁considered ▁relevant ▁to ▁clinic al ▁safety ▁beyond ▁data ▁included ▁in ▁other ▁section s ▁of ▁the ▁summary ▁of ▁product ▁character istic s ▁( ▁sm pc ▁) ▁ .
▁do ▁not ▁use ▁in ▁dog s ▁less ▁than ▁6 ▁weeks ▁of ▁age ▁ .
▁this ▁medicinal ▁product ▁contain s ▁less ▁than ▁1 ▁mm ol ▁so dium ▁( ▁23 ▁mg ▁) ▁per ▁pre - fill ed ▁sy ringe ▁ , ▁i . e . ▁essential ly ▁' ▁so dium - free ▁' ▁ .
▁zo le dro nic ▁acid ▁ho spira ▁5 ▁mg ▁/ ▁100 ▁ml ▁solution ▁for ▁in fusion ▁zo le dro nic ▁acid
▁each ▁ml ▁of ▁the ▁solution ▁contain s ▁600 ▁iu ▁( ▁equivalent ▁to ▁44 ▁micro gram s ▁) ▁fol li trop in ▁alfa ▁ .
▁as ▁bero mun ▁is ▁always ▁ad minister ed ▁by ▁experienced ▁and ▁qualified ▁hospital ▁doctor s ▁ , ▁accident al ▁over dos e ▁is ▁extremely ▁un like ly ▁ .
▁information ▁about ▁the ▁ pharma co vigil ance ▁monitoring ▁programme ▁regarding ▁the ▁potential ▁risk ▁of ▁clinic ally ▁relevant ▁hypo tension ▁and ▁related ▁problems ▁to ▁be ▁put ▁into ▁place ▁with ▁the ▁use ▁of ▁the ▁d cf ▁ .
▁this ▁is ▁because ▁za vice fta ▁is ▁removed ▁from ▁your ▁body ▁by ▁the ▁ki dne ys ▁ .
▁in ▁el der ly ▁patients ▁ , ▁normal ▁age ing ▁with ▁ac company ing ▁renal ▁decline ▁has ▁no ▁clinic ally ▁significant ▁effect ▁on ▁la mi vu dine ▁exposure ▁ , ▁except ▁in ▁patients ▁with ▁creati nine ▁clear ance ▁of ▁< ▁50 ▁ml ▁/ ▁min ▁ .
▁each ▁ml ▁of ▁solution ▁for ▁inject ion ▁contain s ▁10 ▁mg ▁of ▁lip eg fil gra s tim ▁ .
▁if ▁you ▁touch ▁the ▁spi ke ▁on ▁the ▁vi al ▁adapter ▁germ s ▁from ▁your ▁finger s ▁can ▁be ▁transfer red ▁ .
▁dispose ▁of ▁in ▁accordance ▁with ▁local ▁regulations
▁this ▁medicinal ▁product ▁must ▁be ▁radio label led ▁before ▁administration ▁to ▁the ▁patient ▁ .
▁after ▁proper ▁training ▁in ▁sub cuta ne ous ▁inject ion ▁technique ▁ , ▁patients ▁may ▁self - in ject ▁with ▁si mpon i ▁if ▁their ▁physician ▁determine s ▁that ▁this ▁is ▁appropriate ▁ , ▁with ▁medical ▁follow - up ▁as ▁necessary ▁ .
▁bone ▁his t ology ▁was ▁evaluat ed ▁in ▁62 ▁post meno paus al ▁women ▁with ▁osteo por osis ▁or ▁with ▁low ▁bone ▁mass ▁who ▁were ▁either ▁na ï ve ▁to ▁osteo por osis ▁ therapie s ▁or ▁had ▁transition ed ▁from ▁previous ▁ale ndr onate ▁ therapy ▁following ▁1-3 ▁years ▁treatment ▁with ▁pro lia ▁ .
▁rapid ▁re duction ▁in ▁the ▁dose ▁of ▁steroid s ▁can ▁induc e ▁a cute ▁ad ren al ▁crisis ▁ .
▁co - administration ▁of ▁rasa gi line ▁and ▁the op hyl line ▁( ▁a ▁substrat e ▁of ▁cy p 1 a 2 ▁) ▁did ▁not ▁affect ▁the ▁ pharma cok ine tics ▁of ▁either ▁product ▁ .
▁form ote rol ▁is ▁elimina ted ▁primari ly ▁by ▁metabolism ▁ .
▁suc rose ▁sor bit ol ▁de x tran ▁40
▁tube s ▁should ▁be ▁disc ard ed ▁after ▁first ▁opening ▁ .
▁pro tamine ▁sul fa te ▁and ▁vitamin ▁k ▁are ▁not ▁expected ▁to ▁affect ▁the ▁antico agu lant ▁activity ▁of ▁edo xa ban ▁ .
▁you ▁may ▁need ▁to ▁have ▁additional ▁treatment ▁with ▁other ▁medicine s ▁ , ▁to ▁take ▁a ▁lower ▁dose ▁of ▁len vima ▁ , ▁or ▁to ▁take ▁extra ▁care ▁due ▁to ▁an ▁increased ▁risk ▁of ▁side ▁effects ▁ .
▁this ▁is ▁a ▁test ▁where ▁patients ▁with ▁an ▁aller gy ▁who ▁are ▁not ▁currently ▁showing ▁any ▁allergi c ▁symptoms ▁receive ▁a ▁define d ▁dose ▁of ▁an ▁aller gen ▁( ▁the ▁substance ▁that ▁they ▁are ▁allergi c ▁to ▁) ▁to ▁trigger ▁an ▁allergi c ▁reaction ▁ .
▁one ▁subject ▁was ▁we an ed ▁off ▁their ▁parent er al ▁support ▁while ▁on ▁re vesti ve ▁ .
▁coa g ulation ▁factor ▁concentrat es ▁( ▁activa ted ▁or ▁non - activ i ated ▁) ▁or ▁reco mbin ant ▁factor ▁vi ia ▁may ▁be ▁taken ▁into ▁account ▁ .
▁do ▁not ▁expose ▁to ▁radio active ▁ir radi ation ▁( ▁x - ray s ▁) ▁ .
▁reco mbin ant ▁hemat opo ie tic ▁growth ▁factors ▁may ▁be ▁used ▁according ▁to ▁institution al ▁or ▁european ▁society ▁for ▁medical ▁on c ology ▁( ▁es mo ▁) ▁guidelines ▁ .
▁in ▁the ▁study ▁that ▁examine d ▁two ▁dose ▁groups ▁( ▁see ▁section ▁5.1 ▁) ▁ , ▁the ▁increase ▁in ▁body ▁weight ▁of ▁ ≥ ▁7 ▁% ▁was ▁3 ▁% ▁in ▁the ▁lower - dos e ▁( ▁3-6 ▁mg ▁) ▁group ▁ , ▁7 ▁% ▁in ▁the ▁higher - dos e ▁( ▁9 -12 ▁mg ▁) ▁group ▁ , ▁and ▁1 ▁% ▁in ▁the ▁place bo ▁group ▁ .
▁always ▁use ▁this ▁medicine ▁exactly ▁as ▁your ▁doctor ▁or ▁ pharma ci st ▁has ▁told ▁you ▁ .
▁viagra ▁is ▁a ▁medicine ▁that ▁contain s ▁the ▁active ▁substance ▁sil den a fil ▁ .
▁what ▁kad cy la ▁is ▁used ▁for
▁the ▁product ▁is ▁indicate d ▁for ▁use ▁in ▁la cta ting ▁dair y ▁co ws ▁and ▁can ▁be ▁used ▁during ▁pre gna ncy ▁ .
▁it ▁is ▁recommended ▁that ▁pa e dia tric ▁patients ▁ , ▁if ▁possible ▁ , ▁be ▁brought ▁up ▁to ▁date ▁with ▁all ▁immun isation s ▁in ▁agreement ▁with ▁current ▁immun isation ▁guidelines ▁prior ▁to ▁initiat ing ▁eta ner cept ▁ therapy ▁( ▁see ▁vaccin ations ▁ , ▁above ▁) ▁ .
▁the ▁ple grid y ▁initiat ion ▁pack ▁contain s ▁one ▁orang e ▁pre - fill ed ▁sy ringe ▁of ▁63 ▁micro gram s ▁and ▁one ▁blue ▁pre - fill ed ▁sy ringe ▁of ▁94 ▁micro gram s ▁ .
▁the ▁signature ▁mutation s ▁decrease ▁viral ▁sus cept i bility ▁to ▁ra lte grav ir ▁and ▁addition ▁of ▁other ▁mutation s ▁results ▁in ▁a ▁further ▁decrease ▁in ▁ra lte grav ir ▁sus cept i bility ▁ .
▁these ▁may ▁be ▁sign s ▁of ▁a ▁rare ▁but ▁serious ▁lung ▁disorder ▁called ▁eos ino phil ic ▁pneu monia ▁ .
▁manufacture r ▁organ on ▁( ▁i re land ▁) ▁l t d ▁ , ▁p . o . ▁box ▁28 57 ▁ ,
▁nu mb ness ▁or ▁we ak ness ▁in ▁the ▁lim bs
▁do ▁not ▁use ▁poly car bona te ▁sy ring es ▁with ▁bus il ve x ▁ .
▁it ▁is ▁recommended ▁that ▁pre - tre at ment ▁with ▁corti co steroid s ▁be ▁considered ▁for ▁patients ▁in ▁whom ▁local ▁tum our ▁exp an sion ▁may ▁compromis e ▁vital ▁anatomi c ▁structure s ▁ .
▁in ▁approximately ▁7 ▁% ▁of ▁the ▁women ▁ , ▁menstrua l ▁period s ▁occur red ▁more ▁than ▁7 ▁days ▁earlier ▁than ▁expected ▁ .
▁bene fix ▁contain s ▁reco mbin ant ▁coa g ulation ▁factor ▁ ix ▁ , ▁( ▁inn ▁= ▁non ac og ▁alfa ▁) ▁ .
▁events ▁were ▁reported ▁at ▁various ▁time ▁points ▁during ▁treatment ▁and ▁may ▁occur ▁after ▁several ▁years ▁of ▁treatment ▁with ▁inter fer on ▁beta ▁ .
▁in ▁the ▁neo ad ju vant ▁trial ▁try pha ena ▁ , ▁the ▁incide nce ▁of ▁l vd ▁( ▁during ▁the ▁overall ▁treatment ▁period ▁) ▁was ▁8. 3 ▁% ▁in ▁the ▁group ▁treated ▁with ▁per je ta ▁plus ▁tras tuz um ab ▁and ▁ fec ▁( ▁followed ▁by ▁per je ta ▁plus ▁tras tuz um ab ▁and ▁doce ta xel ▁) ▁; ▁9. 3 ▁% ▁in ▁the ▁group ▁treated ▁with ▁per je ta ▁plus ▁tras tuz um ab ▁and ▁doce ta xel ▁following ▁ fec ▁; ▁and ▁ 6.6 ▁% ▁in ▁the ▁group ▁treated ▁with ▁per je ta ▁in ▁combination ▁with ▁t ch ▁ .
▁physician s ▁and ▁patients ▁should ▁be ▁aware ▁of ▁the ▁increased ▁risk ▁of ▁infection ▁with ▁vot ubi a ▁ .
▁each ▁vi al ▁contain s ▁250 ▁micro gram s ▁palo nos et ron ▁( ▁as ▁hydro ch lor ide ▁) ▁in ▁5 ▁ml ▁( ▁50 ▁micro gram s ▁/ ▁ml ▁)
▁these ▁changes ▁may ▁be ▁seen ▁on ▁an ▁ec g ▁( ▁electro card i ogram ▁) ▁ .
▁the ▁effective ness ▁of ▁z ul vac ▁s b v ▁has ▁been ▁investiga ted ▁in ▁laborator y ▁studies ▁in ▁ca ttle ▁and ▁she ep ▁ .
▁the ▁most ▁serious ▁side ▁effects ▁with ▁bond ron at ▁are ▁ana phy la ctic ▁reaction ▁( ▁severe ▁allergi c ▁reaction ▁) ▁ , ▁a typ ical ▁fra c tures ▁of ▁the ▁fem ur ▁( ▁an ▁unusual ▁type ▁of ▁fra c ture ▁of ▁the ▁bone ▁of ▁the ▁upp er ▁leg ▁) ▁ , ▁osteo ne cro sis ▁of ▁the ▁ja w ▁( ▁damage ▁to ▁the ▁bone s ▁of ▁the ▁ja w ▁ , ▁which ▁could ▁lead ▁to ▁pain ▁ , ▁so res ▁in ▁the ▁mouth ▁or ▁loo se ning ▁of ▁te eth ▁) ▁ , ▁and ▁eye ▁ inflammation ▁ .
▁how ▁to ▁store ▁ ekli ra ▁genu air
▁if ▁you ▁stop ▁taking ▁is cover
▁do ▁not ▁use ▁in ▁known ▁cases ▁of ▁hyper sensitiv ity ▁to ▁the ▁active ▁substance ▁ , ▁to ▁corti co steroid s ▁and ▁to ▁any ▁other ▁ingredient ▁of ▁the ▁product ▁ .
▁in ▁this ▁case ▁the ▁vaccin es ▁should ▁be ▁inject ed ▁into ▁separate ▁lim bs ▁ .
▁what ▁doce ta xel ▁win thro p ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁10 ▁ml ▁vi als ▁and ▁15 ▁ml ▁vi als ▁contain ▁less ▁than ▁1 ▁mm ol ▁so dium ▁; ▁i . e . ▁they ▁are ▁essential ly ▁' ▁so dium ▁free ▁' ▁ .
▁name ▁and ▁address ▁of ▁the ▁manufacture r ▁responsible ▁for ▁bat ch ▁release ▁for ▁film - co ated ▁tablets
▁the ▁recommended ▁dose ▁of ▁ir besar tan ▁/ ▁hydro ch lor o thi azi de ▁teva ▁is ▁one ▁or ▁two ▁tablets ▁a ▁day ▁ .
▁media n ▁tro ugh ▁se rum ▁as para gina se ▁activities ▁were ▁measure d ▁in ▁81 ▁children ▁/ ▁adolescents ▁with ▁de ▁novo ▁all ▁three ▁days ▁after ▁in fusion ▁of ▁as para gina se ▁( ▁just ▁before ▁the ▁next ▁dose ▁had ▁to ▁be ▁given ▁) ▁during ▁in duction ▁treatment ▁and ▁range d ▁from ▁168 ▁to ▁184 ▁u ▁/ ▁l ▁( ▁study ▁m c - as p . 5 ▁/ ▁all ▁) ▁ .
▁after ▁administration ▁of ▁the ▁medicine ▁radio label led ▁with ▁cup ry mina ▁has ▁been ▁perform ed
▁his t ological ▁examina tion ▁of ▁the ▁repair ▁bio psy ▁at ▁12 ▁months ▁showed ▁superior ▁structura l ▁repair ▁in ▁the ▁cho ndro c elect ▁arm ▁compared ▁to ▁the ▁micro frac ture ▁arm ▁ .
▁if ▁you ▁have ▁not ▁previously ▁received ▁dos es ▁of ▁prep andri x ▁or ▁pre pande mic ▁influenza ▁vaccin e ▁( ▁h 5 n 1 ▁) ▁( ▁split ▁vir ion ▁ , ▁in activa ted ▁ , ▁ad ju vante d ▁) ▁gla xo smith k line ▁bi ological s ▁3. 75 ▁μ g
▁other ▁significant ▁advers e ▁events ▁leading ▁to ▁dis continu ation ▁of ▁study ▁medication ▁for ▁patients ▁receiving ▁pra mi pe xo le ▁were ▁confusion al ▁state ▁ , ▁speech ▁disorder ▁and ▁ag grav ated ▁condition ▁( ▁see ▁section ▁4.2 ▁) ▁ .
▁other ▁medicine s ▁and ▁e ffen tora
▁if ▁you ▁are ▁breast - feed ing ▁or ▁are ▁planning ▁to ▁breast - feed ▁ , ▁talk ▁to ▁your ▁doctor ▁before ▁using ▁this ▁medicine ▁ .
▁the ▁main ▁circula ting ▁metabol ites ▁of ▁re gora fen ib ▁in ▁human ▁plasma ▁are ▁m -2 ▁( ▁n - oxid e ▁) ▁and ▁m -5 ▁( ▁n - oxid e ▁and ▁n - des met hyl ▁) ▁ , ▁which ▁are ▁ pharma c ological ly ▁active ▁and ▁have ▁similar ▁concentration s ▁as ▁re gora fen ib ▁at ▁stea dy ▁state ▁ .
▁tum our ▁p d - l 1 ▁expression ▁was ▁determine d ▁using ▁the ▁p d - l 1 ▁ih c ▁28 -8 ▁phar md x ▁as say ▁ .
▁safety ▁and ▁ef fica cy ▁in ▁children ▁a ged ▁less ▁than ▁1 ▁month ▁have ▁not ▁yet ▁been ▁established ▁ .
▁oed ema ▁( ▁in c ▁per i pher al ▁) ▁ , ▁chill s ▁ , ▁pain ▁* ▁ , ▁mala ise ▁*
▁please ▁refer ▁to ▁the ▁package ▁le a flet ▁of ▁( ▁pe g ▁) ▁inter fer on ▁alfa ▁for ▁more ▁detailed ▁information ▁on ▁these ▁safety ▁issues ▁ .
▁what ▁ gile nya ▁is ▁and ▁what ▁it ▁is ▁used ▁for ▁what ▁ gile nya ▁is
▁ve nous ▁ thro mbo e mbol ic ▁events ▁( ▁v te ▁) ▁and ▁arterial ▁ thro mbo e mbol ic ▁events ▁( ▁a te ▁) ▁ , ▁including ▁fatal ▁cases ▁ , ▁were ▁observe d ▁with ▁nec itum um ab ▁in ▁combination ▁with ▁gem cita bine ▁and ▁ci s plat in ▁( ▁see ▁also ▁section ▁4. 8 ▁) ▁ .
▁patients ▁with ▁severe ly ▁im pair ed ▁ liver ▁or ▁ki dne y ▁function ▁should ▁not ▁take ▁more ▁than ▁10 ▁mg ▁in ▁one ▁dose ▁ .
▁onge ntys ▁may ▁increase ▁their ▁effect ▁; ▁medicine s ▁used ▁to ▁treat ▁heart ▁failure ▁such ▁as ▁dobu tamine ▁ , ▁dop amine ▁or ▁dop ex amine ▁ .
▁no ▁dose ▁adjust ment ▁of ▁da klin za ▁or ▁azi thro my cin ▁or ▁ci pro flo xa cin ▁is ▁required ▁ .
▁dis continu ation ▁of ▁ therapy ▁with ▁in van z ▁and ▁the ▁administration ▁of ▁specific ▁treatment ▁for ▁clo stri dium ▁difficile ▁should ▁be ▁considered ▁ .
▁the ▁daily ▁dose ▁is ▁ad minister ed ▁in ▁equal ly ▁divide d ▁dos es ▁3 ▁times ▁a ▁day ▁ .
▁detailed ▁information ▁on ▁this ▁veterinar y ▁medicinal ▁product ▁is ▁available ▁on ▁the ▁website ▁of ▁the ▁european ▁medicine s ▁agency ▁http ▁: ▁/ ▁/ ▁www . eme a . europa . eu ▁/ ▁ .
▁post - operativ e ▁ha e mar thro sis ▁occur s ▁main ly ▁in ▁patients ▁with ▁a ▁pred is position ▁to ▁ha e mor r hage ▁or ▁poor ▁sur g ical ▁ha e mor r hage ▁control ▁ .
▁inject ▁the ▁liquid ▁slowly ▁and ▁even ly ▁ , ▁always ▁keeping ▁your ▁skin ▁pin ched ▁ .
▁the ▁slow er ▁you ▁press ▁ , ▁the ▁easier ▁the ▁inject ion ▁will ▁feel ▁ .
▁bra dy car dia ▁( ▁ab normal ly ▁low ▁heart ▁rate ▁) ▁ ,
▁difference ▁in ▁or r ▁: ▁10. 8 ▁%
▁rasi lez ▁on ▁its ▁own ▁was ▁more ▁effective ▁than ▁place bo ▁and ▁as ▁effective ▁as ▁compara tor ▁treatment s ▁in ▁ reducing ▁blood ▁pressure ▁ .
▁the ▁in ▁vi tro ▁oxid ative ▁metabolism ▁of ▁reta pam ulin ▁in ▁human ▁ liver ▁micro some s ▁was ▁primari ly ▁media ted ▁by ▁cy p 3 a 4 ▁with ▁minor ▁contribution s ▁from ▁cy p 2 c 8 ▁and ▁cy p 2 d 6 ▁( ▁see ▁section ▁4.5 ▁) ▁ .
▁in ▁this ▁study ▁ , ▁leve ti race tam ▁ , ▁dose ▁was ▁3000 ▁mg ▁/ ▁day ▁given ▁in ▁2 ▁divide d ▁dos es ▁ .
▁the ▁primary ▁safety ▁database ▁is ▁the ▁phase ▁3 ▁clinic al ▁studies ▁in ▁which ▁ 662 ▁subject s ▁received ▁200 ▁mg ▁ ted izol id ▁ phos pha te ▁oral ly ▁and ▁/ ▁or ▁intra ven ously ▁( ▁3 31 ▁/ ▁ 662 ▁patients ▁) ▁for ▁a ▁maximum ▁of ▁6 ▁days ▁ .
▁if ▁you ▁forget ▁to ▁take ▁vite kta
▁plasma ▁ca ffe ine ▁concentration s ▁have ▁been ▁shown ▁to ▁decrease ▁after ▁exchange ▁trans fusion ▁ .
▁increase ▁in ▁blood ▁cholesterol ▁levels
▁unusual ▁sensation ▁of ▁pin s ▁and ▁need les ▁ , ▁nu mb ness ▁or ▁we ak ness ▁of ▁the ▁arms ▁and ▁leg s
▁novo e ight ▁is ▁now ▁ready ▁for ▁inject ion ▁ .
▁no ▁interaction ▁studies ▁have ▁been ▁perform ed ▁ .
▁treatment ▁with ▁pe ga sys ▁should ▁be ▁started ▁by ▁a ▁doctor ▁who ▁has ▁experience ▁in ▁the ▁treatment ▁of ▁hepatitis ▁b ▁or ▁c . ▁pe ga sys ▁is ▁given ▁by ▁inject ion ▁under ▁the ▁skin ▁in ▁the ▁ab dom en ▁( ▁tum my ▁) ▁or ▁th igh ▁ .
▁at ▁least ▁72 ▁hours ▁must ▁pass ▁between ▁two ▁dos es ▁of ▁bort ez om ib ▁ho spira ▁ .
▁stop ▁using ▁cre se mba ▁and ▁tell ▁your ▁doctor ▁straight ▁away ▁if ▁you ▁notice ▁any ▁of ▁the ▁following ▁side ▁effects ▁: ▁ rash ▁ , ▁swe lling ▁of ▁your ▁lips ▁ , ▁mouth ▁ , ▁ton gue ▁or ▁ thro at ▁with ▁difficult y ▁breath ing ▁- ▁these ▁may ▁be ▁sign s ▁of ▁an ▁allergi c ▁reaction ▁( ▁hyper sensitiv ity ▁) ▁ .
▁no ▁overall ▁difference s ▁in ▁safety ▁or ▁ef fica cy ▁were ▁reported ▁between ▁el der ly ▁patients ▁( ▁ ≥ ▁65 ▁years ▁) ▁and ▁young er ▁patients ▁( ▁< ▁65 ▁years ▁) ▁ .
▁tell ▁your ▁doctor ▁straight away ▁if ▁you ▁are ▁pregnant ▁ , ▁become ▁pregnant ▁during ▁treatment ▁with ▁this ▁medicine ▁ , ▁or ▁plan ▁to ▁become ▁pregnant ▁in ▁the ▁near ▁future ▁ .
▁what ▁ preven ar ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁to pote can ▁act avis ▁may ▁cause ▁a ▁decrease ▁in ▁the ▁number ▁of ▁blood ▁clo tting ▁cell s ▁( ▁plate let s ▁) ▁ .
▁non - clin ical ▁data ▁reveal ▁no ▁special ▁hazard ▁for ▁humans ▁ , ▁based ▁on ▁convention al ▁studies ▁of ▁safety ▁ pharma c ology ▁ , ▁repeat ed ▁dose ▁ toxic ity ▁ , ▁geno toxic ity ▁or ▁car cino ge nic ▁potential ▁ .
▁chi esi ▁ pharma ▁ab ▁tlf ▁: ▁+ ▁46 ▁8 ▁75 3 ▁35 ▁20
▁figure ▁1 ▁: ▁time ▁to ▁first ▁occur r ence ▁of ▁cv ▁death ▁ , ▁mi ▁ , ▁stroke ▁or ▁u cr ▁in ▁post - mi ▁or ▁pad ▁patients ▁with ▁no ▁history ▁of ▁stroke ▁or ▁tia
▁the ▁results ▁of ▁bio e qui val ence ▁studies ▁in ▁healthy ▁subject s ▁demonstrat ed ▁that ▁syn jar dy ▁( ▁em pag lif lozi n ▁/ ▁met form in ▁hydro ch lor ide ▁) ▁5 ▁mg ▁/ ▁850 ▁mg ▁ , ▁5 ▁mg ▁/ ▁1,000 ▁mg ▁ , ▁12. 5 ▁mg ▁/ ▁850 ▁mg ▁ , ▁and
▁animal ▁studies ▁do ▁not ▁indicate ▁direct ▁or ▁indirect ▁har m ful ▁effects ▁with ▁respect ▁to ▁pre gna ncy ▁ , ▁em bry onal ▁/ ▁fo e tal ▁development ▁ , ▁part uri tion ▁or ▁post na tal ▁development ▁( ▁see ▁section ▁5.3 ▁) ▁ .
▁( ▁treatment ▁in ▁the ▁ absence ▁of ▁a ▁stati n ▁)
▁if ▁you ▁have ▁any ▁further ▁questions ▁ , ▁ask ▁your ▁doctor ▁or ▁ pharma ci st ▁ .
▁if ▁blood ▁appears ▁at ▁the ▁inject ion ▁site ▁ , ▁press ▁light ly ▁with ▁a ▁cotton ▁s wab ▁ .
▁in ▁20 ▁place bo - control led ▁studies ▁ , ▁conduct ed ▁in ▁a ▁variety ▁of ▁ therapeut ic ▁indica tions ▁ , ▁a ▁total ▁of ▁2,4 86 ▁patients ▁were ▁treated ▁with ▁bo sent an ▁at ▁daily ▁dos es ▁rang ing ▁from ▁100 ▁mg ▁to ▁2000 ▁mg ▁and ▁1,8 38 ▁patients ▁were ▁treated ▁with ▁place bo ▁ .
▁efa vir enz ▁film - co ated ▁tablets ▁are ▁not ▁suitable ▁for ▁children ▁we igh ing ▁less ▁than ▁40 ▁kg ▁ .
▁in ▁patients ▁with ▁mild ▁to ▁moderat e ▁he pati c ▁im pair ment ▁ , ▁the ▁exposure s ▁of ▁sa cu bit ril ▁increased ▁by ▁1.5 - ▁and ▁3.4 - ▁ fold ▁ , ▁l b q 657 ▁increased ▁by ▁1.5 - ▁and ▁1.9 - fold ▁ , ▁and ▁val sar tan ▁increased ▁by ▁1.2 - fold ▁and ▁2.1 - fold ▁ , ▁respective ly ▁ , ▁compared ▁to ▁match ing ▁healthy ▁subject s ▁ .
▁the ▁advers e ▁reaction s ▁were ▁consistent ▁with ▁the ▁safety ▁profile ▁for ▁teri flu nom ide ▁in ▁ms ▁patients ▁ .
▁ar ipi pra zole ▁10 ▁mg ▁( ▁n ▁= ▁37 ▁)
▁when ▁die t ▁and ▁exercise ▁alone ▁do ▁not ▁provide ▁adequat e ▁gly ca e mic ▁control ▁in ▁patients ▁for ▁whom ▁use ▁of ▁met form in ▁is ▁considered ▁in appropria te ▁due ▁to ▁in tolerance ▁or ▁contra indica tions ▁ .
▁do ▁not ▁use ▁this ▁medicine ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁pen ▁label ▁and ▁carton ▁after ▁' ▁exp ▁' ▁ .
▁a ▁risk ▁management ▁plan ▁has ▁been ▁developed ▁to ▁ensure ▁that ▁foc li via ▁is ▁used ▁as ▁safe ly ▁as ▁possible ▁ .
▁you ▁may ▁also ▁have ▁blood ▁tests ▁ .
▁the ▁active ▁substance ▁in ▁x ge va ▁ , ▁de nos um ab ▁ , ▁is ▁a ▁mono clo nal ▁anti body ▁ .
▁the ▁ pharma cok ine tic ▁properties ▁of ▁amp rena vir ▁following ▁co - administration ▁of ▁tel zir ▁with ▁rito na vir ▁have ▁been ▁evaluat ed ▁in ▁healthy ▁adult ▁subject s ▁and ▁hi v - infect ed ▁patients ▁and ▁no ▁substantial ▁difference s ▁were ▁observe d ▁between ▁these ▁two ▁groups ▁ .
▁if ▁you ▁forget ▁to ▁take ▁a ky nze o
▁inject ion ▁site ▁pain ▁damage ▁to ▁the ▁ tiny ▁filter s ▁inside ▁your ▁ki dne ys ▁( ▁glo mer ul one ph riti s ▁)
▁the ▁volume ▁of ▁recon stitu ted ▁concentrat e ▁correspond ing ▁to ▁the ▁calcula ted ▁individual ▁dose ▁ , ▁should ▁be ▁further ▁dilu ted ▁with ▁either ▁so dium ▁chlor ide ▁9 ▁mg ▁/ ▁ml ▁( ▁ 0.9 ▁% ▁) ▁solution ▁for ▁inject ion ▁or ▁50 ▁mg ▁/ ▁ml ▁( ▁5 ▁% ▁) ▁gluco se ▁solution ▁for ▁in fusion ▁ , ▁to ▁a ▁final ▁concentration ▁of ▁between ▁25 ▁and ▁50 ▁micro gram ▁per ▁ml ▁in ▁the ▁solution ▁for ▁in fusion ▁ , ▁for ▁example ▁:
▁solve nt ▁for ▁lu veri s ▁water ▁for ▁inject ion ▁sc
▁other ▁information ▁about ▁versi can ▁plus ▁l 4 ▁:
▁in ▁place bo - control led ▁trial s ▁in ▁patients ▁with ▁hyper tension ▁ , ▁the ▁overall ▁incide nce ▁of ▁advers e ▁events ▁did ▁not ▁differ ▁between ▁the ▁ir besar tan ▁( ▁5 6.2 ▁% ▁) ▁and ▁the ▁place bo ▁groups ▁( ▁5 6.5 ▁% ▁) ▁ .
▁the ▁active ▁substance s ▁of ▁cop alia ▁are ▁am lo di pine ▁( ▁as ▁am lo di pine ▁bes yla te ▁) ▁and ▁val sar tan ▁ .
▁guidance ▁for ▁identify ing ▁women ▁of ▁child - be aring ▁potential ▁and ▁the ▁actions ▁the ▁physician ▁should ▁take ▁if ▁unsur e ▁ .
▁other ▁medicine s ▁and ▁prote los ▁:
▁resume ▁po mali domi de ▁treatment ▁at ▁1 ▁mg ▁less ▁than ▁the ▁previous ▁dose ▁ .
▁no ▁effects ▁on ▁q t ▁interval ▁( ▁correct ed ▁using ▁either ▁the ▁fri der i cia ▁or ▁ba zett ▁method ▁or ▁individual ly - ▁correct ed ▁) ▁were ▁observe d ▁when ▁ac li dini um ▁brom ide ▁( ▁200 ▁μ g ▁or ▁800 ▁μ g ▁) ▁was ▁ad minister ed ▁once ▁daily ▁for ▁3 ▁days ▁to ▁healthy ▁subject s ▁in ▁a ▁thorough ▁q t ▁study ▁ .
▁rasi lam lo ▁has ▁been ▁ad minister ed ▁to ▁more ▁than ▁2 , 800 ▁patients ▁in ▁completed ▁clinic al ▁trial s ▁ , ▁including ▁ 372 ▁patients ▁for ▁one ▁year ▁or ▁more ▁ .
▁be ▁familiar ▁with ▁your ▁war ning ▁symptoms ▁ .
▁the ▁safety ▁and ▁ef fica cy ▁of ▁multiple ▁dos es ▁of ▁hum ira ▁were ▁assess ed ▁in ▁adult ▁patients ▁with ▁moderat ely ▁to ▁severe ly ▁active ▁ul cer ative ▁col itis ▁( ▁mayo ▁score ▁6 ▁to ▁12 ▁with ▁en dos copy ▁sub s core ▁of ▁2 ▁to ▁3 ▁) ▁in ▁random ised ▁ , ▁double - blind ▁ , ▁place bo - control led ▁studies ▁ .
▁out er ▁carton ▁and ▁bli ster ▁po uch
▁trans ient ▁eleva tions ▁in ▁cs f ▁protein ▁and ▁white ▁blood ▁cell s ▁have ▁been ▁observe d ▁in ▁patients ▁following ▁de po cy te ▁administration ▁ , ▁and ▁have ▁also ▁been ▁not ed ▁after ▁intra the cal ▁treatment ▁with ▁met ho tre xa te ▁or ▁cy tara bine ▁ .
▁are ▁allergi c ▁to ▁levo do pa ▁ , ▁car bido pa ▁or ▁en ta ca pone ▁ , ▁or ▁any ▁of ▁the ▁other ▁ingredients ▁of ▁this ▁medicine ▁( ▁listed ▁in ▁section ▁6 ▁)
▁how ▁is ▁bara clu de ▁used ▁?
▁for ▁instructions ▁on ▁the ▁setup ▁and ▁handling ▁of ▁the ▁zal vis o ▁administration ▁device ▁before ▁administration ▁ , ▁see ▁section ▁ 6.6 ▁ .
▁ham p shire ▁ , ▁po 9 ▁2 ng ▁unit ed ▁king dom
▁if ▁you ▁are ▁using ▁leg anto ▁for ▁par kin son ▁' s ▁disease ▁the ▁following ▁side ▁effects ▁may ▁occur ▁:
▁the ▁apparent ▁elimina tion ▁half - life ▁of ▁fin go li mod ▁is ▁un change d ▁in ▁subject s ▁with ▁mild ▁he pati c ▁im pair ment ▁ , ▁but ▁is ▁prolong ed ▁by ▁about ▁50 ▁% ▁in ▁patients ▁with ▁moderat e ▁or ▁severe ▁he pati c ▁im pair ment ▁ .
▁cancer ▁( ▁second ▁primary ▁malign a ncies ▁)
▁in ▁the ▁post - marketing ▁period ▁there ▁was ▁one ▁reported ▁over dos e ▁of ▁10,000 ▁mg ▁of ▁bo sent an ▁taken ▁by ▁an ▁ adolescent ▁male ▁patient ▁ .
▁relative ▁to ▁patients ▁with ▁normal ▁he pati c ▁function ▁ , ▁the ▁sof os bu vir ▁au c 0 -24 ▁was ▁126 ▁% ▁and ▁143 ▁% ▁higher ▁in ▁moderat e ▁and ▁severe ▁he pati c ▁im pair ment ▁ , ▁while ▁the ▁g s -33 100 7 ▁au c 0 -24 ▁was ▁18 ▁% ▁and ▁9 ▁% ▁higher ▁ , ▁respective ly ▁ .
▁patients ▁ ≥ ▁75 ▁years ▁of ▁age ▁have ▁greater ▁ sensitiv ity ▁to ▁ble ed ing ▁and ▁higher ▁exposure ▁to ▁the ▁active ▁metabol ite ▁of ▁pra sug rel ▁( ▁see ▁section s ▁4.4 ▁ , ▁4. 8 ▁ , ▁5.1 ▁and ▁5.2 ▁) ▁ .
▁other ▁information ▁about ▁su tent
▁fund us co pic ▁examina tion ▁is ▁recommended ▁at ▁the ▁initiat ion ▁and ▁period ically ▁during ▁the ▁course ▁of ▁treatment ▁ .
▁eu ▁/ ▁1 ▁/ ▁00 ▁/ ▁142 ▁/ ▁02 3 ▁1 ▁pen ▁of ▁3 ▁ml ▁eu ▁/ ▁1 ▁/ ▁00 ▁/ ▁142 ▁/ ▁ 009 ▁5 ▁pens ▁of ▁3 ▁ml ▁eu ▁/ ▁1 ▁/ ▁00 ▁/ ▁142 ▁/ ▁ 010 ▁10 ▁pens ▁of ▁3 ▁ml
▁con com i tant ▁use ▁of ▁tra cle er ▁and ▁ cyclo spor ine ▁a ▁is ▁contra indica ted ▁( ▁see ▁section s ▁4.3 ▁and ▁4.5 ▁) ▁ .
▁about ▁75 ▁% ▁of ▁patients ▁achieve d ▁a ▁decrease ▁of ▁more ▁than ▁50 ▁% ▁of ▁u fc ▁levels ▁on ▁keto con a zole ▁ , ▁compared ▁to ▁pre - tre at ment ▁levels
▁if ▁the ▁patient ▁does ▁become ▁pregnant ▁ , ▁miss es ▁a ▁menstrua l ▁period ▁ , ▁or ▁suspect s ▁for ▁any ▁reason ▁that ▁she ▁may ▁be ▁pregnant ▁ , ▁she ▁must ▁not ify ▁her ▁treat ing ▁physician ▁immediately ▁ .
▁if ▁you ▁notice ▁any ▁changes ▁in ▁your ▁skin ▁while ▁taking ▁this ▁medicine ▁ , ▁please ▁talk ▁to ▁your ▁doctor ▁ , ▁ pharma ci st ▁or ▁nurse ▁as ▁soon ▁as ▁possible ▁ .
▁si f rol ▁0.0 88 ▁mg ▁tablets ▁si f rol ▁0 . 18 ▁mg ▁tablets ▁si f rol ▁0.3 5 ▁mg ▁tablets ▁si f rol ▁ 0.7 ▁mg ▁tablets ▁si f rol ▁1.1 ▁mg ▁tablets ▁pra mi pe xo le
▁arm ▁c ▁bi val ▁alone ▁( ▁n ▁= ▁ 4,6 12 ▁)
▁keep ▁the ▁bottle ▁tight ly ▁closed ▁ .
▁ 0.4 ▁% ▁of ▁patients ▁treated ▁with ▁ali ro cum ab ▁300 ▁mg ▁every ▁4 ▁weeks ▁/ ▁150 ▁mg ▁every ▁2 ▁weeks ▁developed ▁neutraliz ing ▁anti bo dies ▁( ▁na b ▁) ▁on ▁at ▁least ▁one ▁occasion ▁with ▁no ▁loss ▁of ▁ef fica cy ▁observe d ▁; ▁no ▁na b ▁were ▁observe d ▁in ▁patients ▁treated ▁with ▁control ▁ .
▁it ▁is ▁not ▁intended ▁to ▁provide ▁practical ▁advice ▁on ▁how ▁to ▁use ▁zin bry ta ▁ .
▁5.0 ▁ml ▁in ▁10- dos e ▁vi al ▁( ▁type ▁i ▁glass ▁) ▁with ▁stopper ▁( ▁hal o - but yl ▁rub ber ▁) ▁ .
▁ad minister ▁the ▁whole ▁content s ▁of ▁the ▁sy ringe ▁into ▁the ▁inside ▁of ▁the ▁upp er ▁lip ▁( ▁see ▁figure ▁3 ▁) ▁ .
▁the ▁single - use ▁tube ▁is ▁pack ed ▁in ▁a ▁card board ▁box ▁ .
▁cancer ▁cell s ▁can ▁produce ▁protein s ▁( ▁p d - l 1 ▁and ▁p d - l 2 ▁) ▁that ▁att ach ▁to ▁this ▁receptor ▁and ▁switch ▁off ▁the ▁activity ▁of ▁the ▁t ▁cell s ▁ , ▁prevent ing ▁them ▁from ▁attack ing ▁the ▁cancer ▁ .
▁chlo as ma ▁is ▁often ▁not ▁fully ▁rever sible ▁ .
▁grade ▁3 ▁or ▁4 ▁eleva tions ▁in ▁creati nine ▁were ▁reported ▁in ▁< ▁1 ▁% ▁of ▁patients ▁with ▁chronic ▁phase ▁cm l ▁and ▁were ▁reported ▁with ▁an ▁increased ▁fre que ncy ▁of ▁1 ▁to ▁4 ▁% ▁of ▁patients ▁with ▁advanced ▁phase ▁cm l ▁ .
▁blu r red ▁or ▁di stor ted ▁vision
▁rap am une ▁is ▁indicate d ▁for ▁the ▁pro phy la xis ▁of ▁organ ▁ reje ction ▁in ▁adult ▁patients ▁at ▁low ▁to ▁moderat e ▁immun ological ▁risk ▁receiving ▁a ▁renal ▁transplant ▁ .
▁e cze ma ▁ , ▁dry ▁skin ▁ , ▁ rash ▁ , ▁it ching ▁ ,
▁patients ▁treated ▁with ▁t pf ▁experienced ▁significantly ▁less ▁deteriora tion ▁of ▁their ▁global ▁health ▁score ▁compared ▁to ▁those ▁treated ▁with ▁ pf ▁( ▁p ▁= ▁ 0.01 ▁ , ▁using ▁the ▁e ort c ▁ ql q - c 30 ▁scale ▁) ▁ .
▁if ▁your ▁allergi c ▁r hin itis ▁is ▁inter mitten t ▁( ▁presence ▁of ▁symptoms ▁for ▁less ▁than ▁4 ▁days ▁per ▁week ▁or ▁for ▁less ▁than ▁4 ▁weeks ▁) ▁ , ▁your ▁doctor ▁will ▁recommend ▁you ▁a ▁treatment ▁schedule ▁that ▁will ▁depend ▁on ▁the ▁evaluation ▁of ▁the ▁history ▁of ▁your ▁disease ▁ .
▁content s ▁of ▁the ▁pack ▁and ▁other ▁information ▁what ▁lumi gan ▁0.3 ▁mg ▁/ ▁ml ▁single - dos e ▁contain s
▁this ▁medicine ▁should ▁not ▁be ▁used ▁for ▁the ▁treatment ▁of ▁osteo por osis ▁in ▁men ▁ .
▁do ▁not ▁use ▁this ▁veterinar y ▁medicinal ▁product ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁carton ▁or ▁bli ster ▁ .
▁each ▁vi al ▁contain s ▁to pote can ▁hydro ch lor ide ▁equivalent ▁to ▁1 ▁mg ▁or ▁4 ▁mg ▁of ▁to pote can ▁ .
▁your ▁doctor ▁will ▁use ▁blood ▁tests ▁and ▁/ ▁or ▁an ▁ultra sound ▁machine ▁to ▁check ▁when ▁this ▁is ▁ .
▁vie kira x ▁ , ▁give ▁one ▁fi ft h ▁of ▁the ▁total ▁daily ▁dose ▁of ▁ciclo spor in ▁once ▁daily ▁with ▁vie kira x ▁ .
▁induc ers ▁of ▁cy p 3 a 4 ▁and ▁p - gp
▁additional ▁sign s ▁may ▁include ▁eleva ted ▁creati ne ▁ phos pho kina se ▁ , ▁my o glob in uria ▁( ▁r hab dom yol ysis ▁) ▁ , ▁and ▁a cute ▁renal ▁failure ▁ .
▁some ▁of ▁these ▁cases ▁have ▁been ▁fatal ▁ .
▁there ▁is ▁a ▁clear ▁corre lation ▁between ▁plasma ▁da biga tran ▁concentration ▁and ▁degree ▁of ▁antico agu lant ▁effect ▁based ▁on ▁phase ▁i i ▁studies ▁ .
▁in ▁vi tro ▁studies ▁in ▁ liver ▁micro some s ▁showed ▁that ▁el ux ado line ▁is ▁not ▁an ▁inhibi tor ▁of ▁cy p 3 a 4 ▁at ▁clinic ally ▁relevant ▁concentration s ▁ , ▁but ▁in ▁intestinal ▁micro some s ▁ , ▁el ux ado line ▁inhibi ted ▁cy p 3 a 4 ▁with ▁a ▁ki ▁of ▁450 ▁μ m ▁( ▁256 ▁μ g ▁/ ▁ml ▁) ▁ .
▁ha e mat ological ▁ab normal ities ▁in ▁h c v ▁/ ▁hi v ▁co - infect ed ▁patients ▁:
▁as ▁a ▁result ▁ , ▁they ▁replica te ▁in ▁the ▁na so pha ryn x ▁and ▁induc e ▁protect ive ▁immun ity ▁ .
▁use ▁this ▁medicine ▁at ▁the ▁same ▁time ▁each ▁day ▁ .
▁a ▁similar ▁effect ▁may ▁occur ▁with ▁ang io ten sin ▁i i ▁receptor ▁anta gon ists ▁ .
▁the ▁impact ▁of ▁advanced ▁age ▁was ▁studie d ▁in ▁the ▁population ▁ pharma cok ine tic ▁analysis ▁of ▁eta ner cept ▁se rum ▁concentration s ▁ .
▁generally ▁ , ▁an ▁increased ▁fre que ncy ▁and ▁higher ▁sever ity ▁of ▁advers e ▁reaction s ▁may ▁result ▁from ▁over dos e ▁ .
▁bort ez om ib ▁sun ▁in ▁combination ▁with ▁de xa met has one ▁ , ▁or ▁with ▁de xa met has one ▁and ▁tha li domi de ▁ , ▁is ▁indicate d ▁for ▁the ▁in duction ▁treatment ▁of ▁adult ▁patients ▁with ▁previously ▁un tre ated ▁multiple ▁mye loma ▁who ▁are ▁eligible ▁for ▁high - dos e ▁che mo therapy ▁with ▁ha e mato po ie tic ▁stem ▁cell ▁transplant ation ▁ .
▁if ▁dos es ▁are ▁om it ted ▁for ▁ toxic ity ▁ , ▁these ▁dos es ▁should ▁not ▁be ▁replace d ▁ .
▁do ▁not ▁use ▁cep lene ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁carton ▁and ▁vi al ▁label ▁ .
▁if ▁over dos e ▁occur s ▁the ▁patient ▁should ▁be ▁monitor ed ▁ , ▁and ▁standard ▁support ive ▁treatment ▁applied ▁as ▁required ▁ .
▁hyper sensitiv ity ▁to ▁the ▁active ▁substance ▁ , ▁ris peri done ▁ , ▁or ▁to ▁any ▁of ▁the ▁ex cip ient s ▁listed ▁in ▁section ▁6.1 ▁ .
▁patients ▁with ▁a ▁history ▁of ▁a ▁w hip ple ▁procedure ▁have ▁a ▁higher ▁risk ▁of ▁serious ▁infection s ▁following ▁oni vy de ▁in ▁combination ▁with ▁5- fu ▁and ▁le u cov orin ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁what ▁heli xa te ▁ne x gen ▁250 ▁iu ▁looks ▁like ▁and ▁content ▁of ▁the ▁pack
▁fre que ncies ▁are ▁define d ▁as ▁very ▁common ▁( ▁ ≥ ▁1 ▁/ ▁10 ▁) ▁ , ▁common ▁( ▁ ≥ ▁1 ▁/ ▁100 ▁to ▁< ▁1 ▁/ ▁10 ▁) ▁ , ▁un com mon ▁( ▁ ≥ ▁1 ▁/ ▁1,000 ▁to ▁< ▁1 ▁/ ▁100 ▁) ▁and ▁very ▁rare ▁( ▁< ▁1 ▁/ ▁10,000 ▁) ▁ .
▁geometri c ▁mean ▁change ▁( ▁% ▁) ▁( ▁possible ▁mechanism ▁)
▁after ▁recon stitu tion ▁ , ▁chemical ▁and ▁physical ▁in - use ▁stabilit y ▁has ▁been ▁demonstrat ed ▁for ▁4 ▁days ▁at ▁2 ▁to ▁8 ▁° ▁c . ▁the ▁medicinal ▁product ▁is ▁photo sensitiv e ▁and ▁should ▁be ▁protected ▁from ▁light ▁when ▁not ▁store d ▁in ▁the ▁original ▁carton ▁ .
▁these ▁five ▁process es ▁take ▁place ▁in ▁the ▁analyser ▁of ▁a ▁mass ▁spec tro meter ▁ , ▁which ▁consist s ▁of ▁three ▁separate ▁section s ▁: ▁the ▁source ▁ , ▁flight ▁tube ▁ , ▁and ▁collect or ▁ .
▁results ▁showed ▁that ▁cabo met y x ▁is ▁effective ▁at ▁prolong ing ▁the ▁time ▁patients ▁lived ▁without ▁their ▁disease ▁getting ▁worse ▁( ▁progression - free ▁survival ▁) ▁: ▁patients ▁treated ▁with ▁cabo met y x ▁lived ▁for ▁an ▁average ▁of ▁7. 4 ▁months ▁without ▁their ▁disease ▁getting ▁worse ▁compared ▁with ▁ 3.8 ▁months ▁in ▁patients ▁treated ▁with ▁ever ol imus ▁ .
▁mean ▁average ▁change ▁in ▁ bc va ▁from ▁month ▁1 ▁to ▁month ▁12 a ▁( ▁s d ▁)
▁for ▁dos es ▁above ▁3.0 ▁ml ▁to ▁10 ▁ml ▁ , ▁10 ▁ml ▁oral ▁dispens er ▁should ▁be ▁used ▁ .
▁sign s ▁of ▁an ▁allergi c ▁reaction ▁may ▁include ▁it chy ▁skin ▁ rash ▁ , ▁short ness ▁of ▁breath ▁and ▁swe lling ▁of ▁the ▁face ▁or ▁ton gue ▁ .
▁in ▁both ▁studies ▁there ▁were ▁significant ▁decrease ▁of ▁individual ▁ser o type s ▁6 b ▁and ▁19 f . ▁in ▁the ▁neste d ▁fin nish ▁study ▁ , ▁a ▁significant ▁re duction ▁was ▁also ▁observe d ▁for ▁individual ▁ser o type s ▁14 ▁ , ▁23 f ▁and ▁ , ▁in ▁the ▁3 ▁dose ▁primary ▁schedule ▁ , ▁for ▁the ▁cross - re active ▁ser o type ▁19 a ▁ .
▁therefore ▁ , ▁it ▁is ▁recommended ▁that ▁patients ▁take ▁lyn par za ▁at ▁least ▁one ▁hour ▁after ▁food ▁ , ▁and ▁ref rain ▁from ▁eating ▁prefer ably ▁for ▁up ▁to ▁2 ▁hours ▁after ward s ▁( ▁see ▁section ▁4.2 ▁) ▁ .
▁the ▁mean ▁treatment ▁du ration ▁was ▁5 8.4 ▁weeks ▁ .
▁m - m - ▁ rva x pro ▁is ▁not ▁to ▁be ▁inject ed ▁directly ▁into ▁any ▁blood ▁ves sel ▁ .
▁if ▁you ▁have ▁any ▁ rash ▁during ▁this ▁period ▁ , ▁do ▁not ▁increase ▁the ▁dose ▁but ▁consult ▁your ▁doctor ▁ .
▁it ▁remain s ▁un know n ▁if ▁early ▁det ection ▁of ▁pm l ▁and ▁suspens ion ▁of ▁mab ther a ▁ therapy ▁may ▁lead ▁to ▁similar ▁stabil isation ▁or ▁improve d ▁outcome ▁ .
▁single ▁dos es ▁up ▁to ▁1 , 200 ▁mg ▁have ▁been ▁taken ▁by ▁healthy ▁volunteer s ▁without ▁symptom a tic ▁un to ward ▁effects ▁ .
▁therefore ▁ , ▁the ▁use ▁of ▁e darbi ▁is ▁not ▁recommended ▁in ▁these ▁patients ▁ .
▁if ▁you ▁have ▁some ▁disorder s ▁of ▁heart ▁ rhythm ▁( ▁heart ▁block ▁grade ▁2 ▁or ▁3 ▁) ▁ .
▁clinic al ▁studies ▁did ▁not ▁include ▁any ▁patients ▁a ged ▁over ▁55 ▁years ▁old ▁ .
▁amount s ▁to ▁be ▁ad minister ed ▁and ▁administration ▁route
▁do ▁not ▁use ▁her cept in ▁if ▁you ▁notice ▁any ▁parti cula te ▁matter ▁or ▁disco lor ation ▁prior ▁to ▁administration ▁ .
▁if ▁you ▁want ▁to ▁use ▁herbal ▁products ▁contain ing ▁st . ▁joh n ▁' s ▁ wort ▁while ▁you ▁are ▁already ▁using ▁zo ely ▁you ▁should ▁consult ▁your ▁doctor ▁first ▁ .
▁another ▁del to id ▁inject ion ▁one ▁week ▁later ▁( ▁day ▁8 ▁) ▁at ▁the ▁100 ▁mg ▁dose ▁resum p tion ▁of ▁the ▁normal ▁monthly ▁cycle ▁of ▁inject ions ▁in ▁either ▁the ▁del to id ▁or ▁glu te al ▁muscle ▁of ▁25 ▁mg ▁to ▁150 ▁mg ▁based ▁on ▁individual ▁patient ▁to ler ability ▁and ▁/ ▁or ▁ef fica cy
▁the ▁radio label led ▁product ▁is ▁a ▁clear ▁ , ▁colour less ▁solution ▁with ▁no ▁visible ▁parti cles ▁ .
▁stroke ▁ , ▁non - cn s ▁system ic ▁e mbol ism ▁ , ▁vas cular ▁death ▁and ▁my o card ial ▁in far ction
▁the ▁main ▁measure ▁of ▁effective ness ▁was ▁the ▁production ▁of ▁anti body ▁levels ▁known ▁to ▁be ▁protect ive ▁against ▁those ▁disease s ▁ .
▁proportion s ▁of ▁patients ▁in ▁gina ▁steps ▁4 ▁and ▁5 c
▁la mi vu dine ▁is ▁predomina tely ▁clear ed ▁by ▁renal ▁ex cre tion ▁of ▁un change d ▁substance ▁ .
▁if ▁the ▁patient ▁gets ▁an ▁infection ▁ , ▁treatment ▁with ▁fer ri prox ▁should ▁be ▁temporar ily ▁stopped ▁and ▁the ▁neutro phil ▁count ▁check ed ▁more ▁often ▁ .
▁at ▁the ▁cell ▁process ing ▁facility ▁ , ▁the ▁carti lage ▁cell s ▁will ▁be ▁grow n ▁a sept ically ▁in ▁culture ▁to ▁expand ▁the ▁number ▁of ▁cell s ▁and ▁placed ▁on to ▁a ▁steril e ▁collage n ▁membran e ▁ , ▁to ▁make ▁ma ci ▁ .
▁you ▁should ▁take ▁pre gabal in ▁my lan ▁in ▁addition ▁to ▁your ▁current ▁treatment ▁ .
▁this ▁rate ▁should ▁be ▁considered ▁in ▁the ▁context ▁of ▁the ▁under ly ing ▁eleva ted ▁incide nce ▁of ▁neutro p enia ▁in ▁tha lassa emia ▁patients ▁ , ▁particularly ▁in ▁those ▁with ▁hyper sp len ism ▁ .
▁1 ▁ha e mat ological ▁response ▁criteri a ▁( ▁all ▁response s ▁to ▁be ▁confirm ed ▁after ▁ ≥ ▁4 ▁weeks ▁) ▁:
▁however ▁ , ▁there ▁was ▁no ▁difference ▁in ▁exercise ▁du ration ▁between ▁the ▁two ▁dos es ▁( ▁24 ▁seconds ▁compared ▁to ▁place bo ▁; ▁p ▁0.0 3 ▁) ▁ .
▁remove ▁the ▁oral ▁sy ringe ▁from ▁the ▁bottle ▁ .
▁drone dar one ▁ , ▁a ▁medicine ▁used ▁to ▁help ▁regula te ▁your ▁heart ▁beat ▁ .
▁the ▁ pharma cok ine tics ▁of ▁da pto my cin ▁in ▁patients ▁with ▁severe ▁he pati c ▁im pair ment ▁( ▁child - p ugh ▁c ▁classifica tion ▁) ▁have ▁not ▁been ▁evaluat ed ▁ .
▁the ▁supra - therapeut ic ▁dos es ▁represent ▁approximately ▁2.6 - ▁and ▁6.5 - fold ▁the ▁exposure ▁of ▁the ▁ therapeut ic ▁dose ▁ , ▁respective ly ▁ .
▁if ▁you ▁have ▁hepatitis ▁b ▁or ▁c ▁ , ▁your ▁doctor ▁will ▁carefully ▁consider ▁the ▁best ▁treatment ▁regime n ▁for ▁you ▁ .
▁the ▁most ▁common ▁reason ▁for ▁withdraw al ▁from ▁study ▁in ▁kin eret - tre ated ▁patients ▁was ▁inject ion ▁site ▁reaction ▁ .
▁w bc ▁< ▁10 ▁x ▁109 ▁/ ▁l ▁ , ▁plate let ▁< ▁450 ▁x ▁109 ▁/ ▁l ▁ , ▁mye lo cy te ▁+ ▁met amy elo cy te ▁< ▁5 ▁% ▁in ▁blood ▁ , ▁no ▁blas ts ▁and ▁pro my elo cy tes ▁in ▁blood ▁ , ▁bas o phil s ▁< ▁20 ▁% ▁ , ▁no ▁extra me dulla ry ▁involve ment
▁a den uri c ▁80 ▁mg ▁is ▁available ▁in ▁pack ▁size s ▁of ▁14 ▁ , ▁28 ▁ , ▁42 ▁ , ▁56 ▁ , ▁84 ▁and ▁98 ▁film - co ated ▁tablets ▁ .
▁however ▁ , ▁in ▁the ▁ absence ▁of ▁ sufficient ▁data ▁ , ▁administration ▁of ▁rota te q ▁to ▁as ym pto matic ▁hi v - infect ed ▁infants ▁is ▁not ▁recommended ▁ .
▁your ▁doctor ▁should ▁determine ▁how ▁long ▁you ▁should ▁take ▁targ ret in ▁ , ▁and ▁when ▁treatment ▁may ▁be ▁stopped ▁ .
▁out er ▁carton ▁of ▁multi pack s ▁( ▁including ▁blue ▁box ▁)
▁ana phy la ctic - type ▁reaction s ▁may ▁occur ▁in ▁some ▁sensitive ▁animals ▁which ▁might ▁be ▁life - th rea te ning ▁ .
▁clinic ally ▁relevant ▁ct c ▁ toxic ity ▁that ▁was ▁reported ▁in ▁< ▁1 ▁% ▁of ▁the ▁patients ▁that ▁were ▁random ly ▁assign ed ▁to ▁pe metre x ed ▁include ▁: ▁allergi c ▁reaction ▁/ ▁hyper sensitiv ity ▁ , ▁er y thema ▁multi forme ▁ , ▁supra ven tri cular ▁ar rhythm ia ▁and ▁pulmonar y ▁e mbol ism ▁ .
▁ef fica cy ▁data ▁ , ▁both ▁overall ▁and ▁by ▁various ▁sub group s ▁ , ▁are ▁presente d ▁below ▁in ▁table ▁3 ▁ .
▁the ▁summary ▁of ▁the ▁opinion ▁of ▁the ▁committee ▁for ▁or phan ▁medicinal ▁products ▁for ▁stri m veli s ▁can ▁be ▁found ▁on ▁the ▁agency ▁' s ▁website ▁: ▁ema . europa . eu ▁/ ▁find ▁medicine ▁/ ▁human ▁medicine s ▁/ ▁rare ▁disease ▁design ation ▁ .
▁date ▁of ▁first ▁author isation ▁/ ▁rene wal ▁of ▁author isation
▁an ▁additional ▁line ▁of ▁ tki ▁ therapy ▁was ▁allowed ▁for ▁patients ▁with ▁known ▁eg fr ▁mutation ▁or ▁al k ▁trans location ▁ .
▁as ▁with ▁all ▁fent an yl ▁products ▁ , ▁the ▁clear ance ▁of ▁fent an yl ▁may ▁be ▁reduce d ▁in ▁el der ly ▁patients ▁ , ▁with ▁a ▁consequent ▁increase ▁in ▁half ▁life ▁ .
▁in ▁a ▁study ▁( ▁study ▁03 579 ▁) ▁of ▁136 ▁neutro pen ic ▁pa e dia tric ▁patients ▁11 ▁months ▁- ▁17 ▁years ▁treated ▁with ▁posa con a zole ▁oral ▁suspens ion ▁at ▁dos es ▁up ▁to ▁18 ▁mg ▁/ ▁kg ▁/ ▁day ▁divide d ▁tid ▁ , ▁approximately ▁50 ▁% ▁met ▁the ▁pre spec ified ▁target ▁( ▁day ▁7 ▁ca v ▁between ▁500 ▁ng ▁/ ▁ml -2 , 500 ▁ng ▁/ ▁ml ▁) ▁( ▁see ▁section ▁5.2 ▁) ▁ .
▁very ▁common ▁( ▁may ▁affect ▁more ▁than ▁1 ▁in ▁10 ▁people ▁) ▁:
▁4 ▁mg ▁/ ▁24 ▁h ▁may ▁be ▁an ▁effective ▁dose ▁in ▁some ▁patients ▁ .
▁tell ▁your ▁doctor ▁immediately ▁if ▁you ▁are ▁pregnant ▁or ▁if ▁you ▁are ▁breast - feed ing ▁ .
▁no ▁dose ▁adjust ments ▁are ▁needed ▁for ▁renal ▁transplant ▁patients ▁with ▁severe ▁he pati c ▁par en chy mal ▁disease ▁ .
▁ex cip ient s ▁: ▁ed ta ▁di so dium ▁salt ▁di hydrat e ▁ , ▁l - h isti dine ▁ , ▁l - h isti dine ▁mono hydro ch lor ide ▁mono hydrat e ▁ , ▁l - me thi on ine ▁ , ▁poly sor bate ▁80 ▁ , ▁suc rose ▁ , ▁water ▁for ▁inject ion ▁ .
▁temo dal ▁140 ▁mg ▁hard ▁capsule s ▁temo zo lom ide
▁what ▁bril ique ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁the ▁european ▁commission ▁gran ted ▁a ▁marketing ▁author isation ▁valid ▁throughout ▁the ▁european ▁union ▁for ▁vie kira x ▁on ▁15- jan uar y -2015 ▁ .
▁can ▁be ▁used ▁during ▁pre gna ncy ▁and ▁lac tation ▁in ▁co ws ▁ .
▁it ▁should ▁be ▁left ▁for ▁4 ▁hours ▁ , ▁and ▁then ▁be ▁removed ▁ .
▁que tiap ine ▁increased ▁plasma ▁concentration s ▁of ▁que tiap ine ▁which ▁may ▁lead ▁to ▁coma ▁ .
▁potential ▁to ▁affect ▁exposure s ▁to ▁other ▁medicinal ▁products
▁pra mi pe xo le ▁accord ▁0 . 18 ▁mg
▁the ▁point ▁estima te ▁of ▁the ▁hazard ▁ratio ▁( ▁hr ▁) ▁was ▁0 . 461 ▁( ▁95 ▁% ▁confidence ▁interval ▁ , ▁0.2 4 2-0 . 879 ▁) ▁in ▁the ▁full ▁population ▁ .
▁tela pre vir ▁/ ▁efa vir enz ▁( ▁1,1 25 ▁mg ▁q 8 h ▁/ ▁600 ▁mg ▁q . d . ▁)
▁in ▁clinic al ▁trial s ▁the ▁side ▁effects ▁reported ▁common ly ▁( ▁may ▁affect ▁up ▁to ▁1 ▁in ▁10 ▁people ▁) ▁were ▁facial ▁flu shing ▁ , ▁head ache ▁ , ▁low ▁blood ▁pressure ▁and ▁na use a ▁ .
▁if ▁you ▁have ▁symptoms ▁of ▁de lay ed ▁empty ing ▁of ▁stomach ▁content s ▁such ▁as ▁feeling ▁of ▁full ness ▁ , ▁na use a ▁and ▁/ ▁or ▁vom i ting
▁ propyl ene ▁gly col ▁mono met hyl ▁e ther ▁( ▁do wan ol ▁pm ▁)
▁when ▁var den a fil ▁film - co ated ▁tablets ▁are ▁taken ▁with ▁a ▁high ▁fat ▁meal ▁( ▁contain ing ▁57 ▁% ▁fat ▁) ▁ , ▁the ▁rate ▁of ▁ab sor p tion ▁is ▁reduce d ▁ , ▁with ▁an ▁increase ▁in ▁the ▁media n ▁t max ▁of ▁1 ▁hour ▁and ▁a ▁mean ▁re duction ▁in ▁c max ▁of ▁20 ▁% ▁ .
▁an c ▁= ▁absolute ▁neutro phil ▁count
▁sus tiva ▁200 ▁mg ▁hard ▁capsule s ▁for ▁bottle s ▁: ▁3 ▁years ▁ .
▁cr m 19 7 ▁ , ▁activa ted ▁sac char ides ▁ , ▁and ▁conjuga tes
▁for ▁ ruf inami de ▁ , ▁no ▁clinic al ▁data ▁on ▁expose d ▁pre gna ncies ▁are ▁available ▁ .
▁in vira se ▁is ▁a ▁medicine ▁contain ing ▁the ▁active ▁substance ▁sa quina vir ▁ .
▁each ▁pack ▁contain s ▁1 ▁or ▁10 ▁vi als ▁ .
▁each ▁film - co ated ▁tablet ▁contain s ▁20 ▁mg ▁vor tio xe tine ▁( ▁as ▁hydro bro mi de ▁)
▁patients ▁should ▁be ▁test ed ▁for ▁ hb v ▁infection ▁before ▁initiat ing ▁treatment ▁with ▁en bre l ▁ .
▁auto logo us ▁means ▁that ▁your ▁own ▁cell s ▁are ▁used ▁to ▁make ▁cho ndro c elect ▁ .
▁en ox apa rin ▁so dium ▁is ▁a ▁low ▁clear ance ▁active ▁substance ▁with ▁a ▁mean ▁anti - xa ▁plasma ▁clear ance ▁of ▁0 . 74 ▁l ▁/ ▁h ▁after ▁a ▁1.5 ▁mg ▁/ ▁kg ▁bw ▁6- ho ur ▁intra ven ous ▁in fusion ▁ .
▁if ▁you ▁stop ▁taking ▁waki x
▁the ▁intra ven ous ▁l d 50 ▁of ▁cho lic ▁acid ▁in ▁mi ce ▁is ▁350 ▁mg ▁/ ▁kg ▁body ▁weight ▁ .
▁in ▁the ▁patients ▁who ▁fail ▁to ▁respond ▁to ▁these ▁conserva tive ▁measure s ▁ , ▁judici ous ▁use ▁of ▁trans fusion ▁products ▁may ▁be ▁indicate d ▁ .
▁the ▁european ▁medicine s ▁agency ▁has ▁de fer red ▁the ▁obliga tion ▁to ▁submit ▁the ▁results ▁of ▁studies ▁with ▁ rista ben ▁in ▁one ▁or ▁more ▁sub set s ▁of ▁the ▁pa e dia tric ▁population ▁in ▁type ▁2 ▁diabetes ▁mell itus ▁( ▁see ▁section ▁4.2 ▁for ▁information ▁on ▁pa e dia tric ▁use ▁) ▁ .
▁di zzi ness ▁ , ▁na use a ▁ , ▁it ching ▁red ▁er up tion ▁of ▁the ▁skin ▁( ▁ rash ▁) ▁ , ▁black ▁na ils ▁( ▁melan onych ia ▁) ▁ , ▁and ▁hair ▁loss ▁ .
▁ha e mato crit ▁control ▁was ▁achieve d ▁in ▁60 ▁% ▁of ▁patients ▁in ▁the ▁jak avi ▁arm ▁compared ▁to ▁19. 6 ▁% ▁in ▁the ▁bat ▁arm ▁and ▁a ▁ ≥ ▁35 ▁% ▁re duction ▁in ▁spl een ▁volume ▁was ▁achieve d ▁in ▁3 8.2 ▁% ▁of ▁patients ▁in ▁the ▁jak avi ▁arm ▁compared ▁to ▁ 0.9 ▁% ▁in ▁the ▁bat ▁arm ▁( ▁figure ▁1 ▁) ▁ .
▁ri va stig mine ▁is ▁we ak ly ▁ bound ▁to ▁plasma ▁protein s ▁( ▁approximately ▁40 ▁% ▁) ▁ .
▁the ▁recommended ▁dose ▁for ▁pre vention ▁of ▁skelet al ▁events ▁in ▁patients ▁with ▁breast ▁cancer ▁and ▁bone ▁metas tas es ▁is ▁6 ▁mg ▁intra ven ous ▁inject ion ▁given ▁every ▁3-4 ▁weeks ▁ .
▁other ▁than ▁those ▁patients ▁contra indica ted ▁( ▁see ▁sm pc ▁section ▁4.3 ▁) ▁where ▁o zur dex ▁should ▁not ▁be ▁used ▁ , ▁o zur dex ▁should ▁be ▁used ▁with ▁cau tion ▁and ▁only ▁following ▁a ▁care ful ▁risk ▁benefit ▁assessment ▁ .
▁what ▁is ▁inta nza ▁used ▁for ▁?
▁no ▁additional ▁contra cep tive ▁is ▁needed ▁ .
▁what ▁you ▁need ▁to ▁know ▁before ▁you ▁take ▁pr andin ▁do ▁not ▁take ▁pr andin
▁if ▁an ▁ana phy lac to id ▁/ ▁ana phy la ctic ▁reaction ▁occur s ▁the ▁in fusion ▁should ▁be ▁immediately ▁suspend ed ▁and ▁appropriate ▁treatment ▁and ▁observation ▁initiat ed ▁ .
▁advers e ▁reaction s ▁are ▁listed ▁below ▁ , ▁by ▁system ▁organ ▁class ▁and ▁absolute ▁fre que ncy ▁( ▁all ▁reported ▁events ▁) ▁ .
▁from ▁an ▁environmental ▁point ▁of ▁view ▁ , ▁it ▁is ▁considered ▁good ▁practice ▁to ▁use ▁char co al ▁filter s ▁with ▁sc ave nging ▁equipment ▁ .
▁fre que ncy ▁of ▁advers e ▁reaction s ▁of ▁pi og lita zone ▁by ▁treatment ▁regime n
▁the ▁company ▁that ▁makes ▁vy nda q el ▁will ▁carry ▁out ▁a ▁study ▁on ▁the ▁effects ▁of ▁the ▁medicine ▁in ▁a ▁sub group ▁of ▁patients ▁with ▁certain ▁genetic ▁mutation s ▁ .
▁a ▁larger ▁decrease ▁in ▁exposure ▁of ▁mida zola m ▁( ▁or ▁other ▁sensitive ▁cy p 3 a ▁substrat es ▁) ▁at ▁higher ▁fy com pa ▁dos es ▁cannot ▁be ▁exclu ded ▁ .
▁3 ▁some ▁of ▁these ▁path ogen s ▁( ▁e . g ▁ .
▁nu mb ness ▁or ▁ting ling ▁sensation s ▁ , ▁in volu ntar y ▁muscle ▁contract ions ▁or ▁ thro mbo cy top enia ▁( ▁re duction ▁in ▁the ▁number ▁of ▁certain ▁types ▁of ▁parti cles ▁in ▁the ▁blood ▁called ▁plate les ▁; ▁a ▁low ▁number ▁of ▁these ▁can ▁result ▁in ▁excessive ▁bru ising ▁or ▁ble ed ing ▁) ▁ .
▁in ▁neo sphere ▁ , ▁8. 3 ▁% ▁of ▁asian ▁patients ▁treated ▁with ▁neo ad ju vant ▁per je ta ▁ , ▁tras tuz um ab ▁and ▁doce ta xel ▁experienced ▁febr ile ▁neutro p enia ▁compared ▁with ▁4.0 ▁% ▁of ▁asian ▁patients ▁treated ▁with ▁neo ad ju vant ▁tras tuz um ab ▁and ▁doce ta xel ▁ .
▁if ▁you ▁are ▁allergi c ▁to ▁any ▁other ▁bis phos phon ates ▁if ▁you ▁have ▁high ▁or ▁low ▁levels ▁of ▁vitamin ▁d ▁ , ▁calci um ▁or ▁any ▁other ▁mineral s ▁if ▁you ▁have ▁ki dne y ▁problems ▁ .
▁the ▁safety ▁and ▁ef fica cy ▁of ▁v fen d ▁in ▁children ▁below ▁2 ▁years ▁has ▁not ▁been ▁established ▁ .
▁the ▁full ▁e par ▁for ▁pande mic ▁influenza ▁vaccin e ▁h 5 n 1 ▁med im mu ne ▁can ▁be ▁found ▁on ▁the ▁agency ▁' s ▁website ▁: ▁ema . europa . eu ▁/ ▁find ▁medicine ▁/ ▁human ▁medicine s ▁/ ▁european ▁public ▁assessment ▁reports ▁ .
▁however ▁ , ▁the ▁mah ▁acknowledge s ▁that ▁rosto ker ▁and ▁co hen ▁recommend ▁a ▁minimum ▁of ▁6 ▁months ▁between ▁fer um oxy tol ▁' s ▁administration ▁ , ▁which ▁they ▁base ▁on ▁the ▁study ▁with ▁6 ▁healthy ▁volunteer s ▁published ▁by ▁store y ▁et ▁al ▁ .
▁n altre xon e ▁and ▁6- beta - n altre x ol ▁are ▁not ▁metabol ised ▁by ▁cy to ch rom e ▁p 450 ▁enzym es ▁and ▁in ▁vi tro ▁studies ▁indicate ▁that ▁there ▁is ▁no ▁potential ▁for ▁inhibi tion ▁or ▁in duction ▁of ▁important ▁iso zy mes ▁ .
▁in ▁7 ▁pa e dia tric ▁patients ▁under ▁2 ▁years ▁of ▁age ▁who ▁received ▁ravi cti ▁for ▁up ▁to ▁12 ▁months ▁ , ▁the ▁concentration s ▁of ▁paa ▁ , ▁p ba ▁ , ▁and ▁pag n ▁did ▁not ▁increase ▁over ▁the ▁treatment ▁period ▁and ▁the ▁overall ▁media n ▁paa ▁ , ▁p ba ▁ , ▁and ▁pag n ▁concentration s ▁in ▁these ▁patients ▁were ▁similar ▁to ▁those ▁observe d ▁in ▁older ▁pa e dia tric ▁age ▁groups ▁ .
▁syn jar dy ▁12. 5 ▁mg ▁/ ▁1,000 ▁mg ▁film - co ated ▁tablets ▁eu ▁/ ▁1 ▁/ ▁15 ▁/ ▁100 3 ▁/ ▁0 28
▁if ▁your ▁finger ▁is ▁still ▁not ▁able ▁to ▁straight en ▁during ▁a ▁follow - up ▁visit ▁with ▁your ▁doctor ▁ , ▁you ▁may ▁need ▁additional ▁treatment s ▁with ▁xi ap ex ▁which ▁may ▁be ▁ad minister ed ▁approximately ▁4 ▁weeks ▁after ▁the ▁first ▁treatment ▁ .
▁death s ▁due ▁to ▁m ds ▁/ ▁am l ▁included ▁five ▁( ▁2.5 ▁% ▁) ▁patients ▁in ▁the ▁ze val in ▁arm ▁compared ▁to ▁no ▁patients ▁in ▁the ▁control ▁arm ▁ .
▁you ▁should ▁not ▁drive ▁or ▁use ▁machines ▁if ▁you ▁are ▁affected ▁by ▁these ▁symptoms ▁ .
▁some ▁people ▁using ▁this ▁medicine ▁can ▁develop ▁anti bo dies ▁to ▁factor ▁vii i ▁( ▁also ▁known ▁as ▁factor ▁vii i ▁inhibi tors ▁) ▁ .
▁in ▁clinic al ▁studies ▁with ▁pa zo pan ib ▁ , ▁events ▁of ▁q t ▁prolong ation ▁and ▁tor sade ▁de ▁point es ▁have ▁occur red ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁during ▁bis phos phon ate ▁treatment ▁patients ▁should ▁be ▁advise d ▁to ▁report ▁any ▁th igh ▁ , ▁hip ▁or ▁gro in ▁pain ▁and ▁any ▁patient ▁present ing ▁with ▁such ▁symptoms ▁should ▁be ▁evaluat ed ▁for ▁an ▁incomp lete ▁fem ur ▁fra c ture ▁ .
▁what ▁measure s ▁are ▁being ▁taken ▁to ▁ensure ▁the ▁safe ▁and ▁effective ▁use ▁of ▁del ty ba ▁?
▁this ▁event ▁appears ▁to ▁be ▁related ▁to ▁the ▁use ▁of ▁spray ▁devices ▁at ▁higher ▁than ▁recommended ▁pressure s ▁and ▁/ ▁or ▁in ▁close ▁proximi ty ▁to ▁the ▁tissu e ▁surface ▁ .
▁this ▁is ▁a ▁summary ▁of ▁the ▁european ▁public ▁assessment ▁report ▁( ▁e par ▁) ▁for ▁ty bost ▁ .
▁patients ▁may ▁experience ▁temporar ily ▁reduce d ▁vision ▁after ▁receiving ▁o zur dex ▁by ▁intra vit real ▁inject ion ▁( ▁see ▁sm pc ▁section ▁4. 8 ▁) ▁ .
▁the ▁other ▁ingredients ▁are ▁micro c ry stal line ▁cell ul ose ▁ , ▁magnesium ▁stea rate ▁and ▁collo i dal ▁an hydro us ▁si lica ▁ .
▁as ▁with ▁any ▁vaccin e ▁ , ▁ preven ar ▁13 ▁may ▁not ▁protect ▁all ▁individuals ▁receiving ▁the ▁vaccin e ▁from ▁pneu moc oc cal ▁disease ▁ .
▁there ▁was ▁an ▁overall ▁higher ▁incide nce ▁of ▁non - se rious ▁o cular ▁advers e ▁reaction s ▁ , ▁main ly ▁related ▁to ▁sign s ▁of ▁local ▁irrita tion ▁ , ▁in ▁the ▁brin zola mi de ▁/ ▁trav o prost ▁groups ▁ .
▁the ▁effective ness ▁of ▁ar ipi pra zole ▁sand oz ▁in ▁the ▁treatment ▁of ▁schi zo ph r enia ▁and ▁bi po lar ▁i ▁disorder ▁in ▁patients ▁a ged ▁65 ▁years ▁and ▁older ▁has ▁not ▁been ▁established ▁ .
▁well ing ▁of ▁the ▁face ▁ , ▁lips ▁and ▁ thro at
▁co - administration ▁with ▁inhibi tors ▁of ▁organic ▁an ion ▁transport ing ▁poly pe pti de ▁1 b ▁( ▁o at p 1 b ▁) ▁ , ▁such ▁as ▁rif ampi cin ▁ , ▁ata zana vir ▁ , ▁dar una vir ▁ , ▁lo pina vir ▁ , ▁sa quina vir ▁ , ▁tip rana vir ▁ , ▁co bici stat ▁or ▁ciclo spor in ▁ .
▁the ▁other ▁ingredients ▁are ▁: ▁so dium ▁chlor ide ▁ , ▁po tas s ium ▁chlor ide ▁ , ▁po tas s ium ▁di hydro gen ▁ phos pha te ▁ , ▁di so dium ▁ phos pha te ▁di hydrat e ▁ , ▁magnesium ▁chlor ide ▁he xa hydrat e ▁ , ▁calci um ▁chlor ide ▁di hydrat e ▁ , ▁so dium ▁cit rate ▁ , ▁ci tric ▁acid ▁and ▁water ▁for ▁inject ions ▁ .
▁hi zentr a ▁is ▁used ▁in ▁patients ▁whose ▁blood ▁does ▁not ▁contain ▁enough ▁anti bo dies ▁( ▁protein s ▁that ▁help ▁the ▁body ▁to ▁fight ▁infection s ▁and ▁other ▁disease s ▁) ▁ , ▁also ▁known ▁as ▁immun o glob ulin s ▁ .
▁mye los up pression ▁may ▁lead ▁to ▁neutro p enia ▁and ▁an ▁increased ▁risk ▁of ▁infection ▁ .
▁cotton ▁ball ▁or ▁ga uze
▁in ▁the ▁complicat ed ▁community ▁acquire d ▁pneu monia ▁study ▁that ▁compared ▁z info ro ▁with ▁ce ft ria xon e ▁plus ▁van com y cin ▁ , ▁90 ▁% ▁of ▁the ▁patients ▁treated ▁with ▁z info ro ▁were ▁cu red ▁ , ▁compared ▁with ▁100 ▁% ▁of ▁those ▁receiving ▁ce ft ria xon e ▁plus ▁van com y cin ▁ .
▁p - gp ▁substrat es ▁: ▁lo mita pide ▁inhibi ts ▁p - gp ▁in ▁vi tro ▁ , ▁and ▁may ▁increase ▁the ▁ab sor p tion ▁of ▁p - gp ▁substrat es ▁ .
▁inject ▁only ▁the ▁dose ▁your ▁doctor ▁has ▁told ▁you ▁ .
▁tel ▁: ▁+ ▁33 ▁1 ▁47 ▁73 ▁64 ▁58
▁this ▁bio psy ▁will ▁then ▁be ▁used ▁to ▁make ▁holo c lar ▁ .
▁inner ▁carton ▁box ▁contain ing ▁56 ▁( ▁14 ▁sac hets ▁of ▁4 ▁) ▁am po ules
▁hyper sensitiv ity ▁to ▁the ▁active ▁substance s ▁or ▁to ▁any ▁of ▁the ▁ex cip ient s ▁listed ▁in ▁section ▁6.1 ▁ , ▁or ▁history ▁of ▁a ▁serious ▁hyper sensitiv ity ▁reaction ▁ , ▁including ▁ana phy la ctic ▁reaction ▁ , ▁ana phy la ctic ▁shock ▁ , ▁and ▁ang io ede ma ▁ , ▁to ▁any ▁di pe pti dy l ▁pep tida se -4 ▁( ▁d pp -4 ▁) ▁inhibi tor ▁or ▁to ▁any ▁so dium - glu co se ▁co - transport er ▁2 ▁( ▁sg lt 2 ▁) ▁inhibi tor ▁( ▁see ▁section s ▁4.4 ▁ , ▁4. 8 ▁and ▁6.1 ▁) ▁ .
▁if ▁you ▁are ▁over ▁70 ▁years ▁old ▁or ▁have ▁problems ▁with ▁your ▁ki dne ys ▁it ▁may ▁take ▁longer ▁than ▁30 ▁days ▁to ▁ tolera te ▁the ▁by etta ▁5 ▁micro gram s ▁dose ▁and ▁so ▁your ▁doctor ▁may ▁not ▁increase ▁your ▁dose ▁ .
▁graf t ▁versus ▁host ▁disease b
▁in ▁the ▁event ▁of ▁grade ▁2-4 ▁a cute ▁ toxic ity ▁ , ▁treatment ▁must ▁be ▁dis continu ed ▁immediately ▁ .
▁hyper sensitiv ity ▁reaction ▁observe d ▁for ▁each ▁of ▁these ▁medicinal ▁products ▁( ▁described ▁below ▁) ▁share ▁some ▁common ▁features ▁such ▁as ▁fe ver ▁and ▁/ ▁or ▁ rash ▁with ▁other ▁symptoms ▁indicat ing ▁multi - organ ▁involve ment ▁ .
▁this ▁can ▁be ▁given ▁as ▁75 ▁mg ▁( ▁half ▁a ▁150 ▁mg ▁tablet ▁) ▁twice ▁a ▁day ▁( ▁leaving ▁approximately ▁12 ▁hours ▁between ▁each ▁dose ▁) ▁ , ▁or ▁150 ▁mg ▁( ▁one ▁150 ▁mg ▁tablet ▁) ▁once ▁a ▁day ▁as ▁advise d ▁by ▁your ▁doctor ▁ .
▁in ▁the ▁first ▁study ▁ , ▁66 ▁% ▁of ▁women ▁using ▁sen shi o ▁reported ▁relief ▁from ▁vaginal ▁dry ness ▁( ▁mild ▁or ▁no ▁symptoms ▁) ▁after ▁12 ▁weeks ▁' ▁treatment ▁compared ▁with ▁49 ▁% ▁in ▁the ▁place bo ▁group ▁ .
▁the ▁dose ▁of ▁ava stin ▁needed ▁depend s ▁on ▁your ▁body ▁weight ▁and ▁the ▁kind ▁of ▁cancer ▁to ▁be ▁treated ▁ .
▁how ▁is ▁non a fact ▁used ▁?
▁the ▁european ▁commission ▁gran ted ▁a ▁marketing ▁author isation ▁valid ▁throughout ▁the ▁european ▁union ▁for ▁vi ba tiv ▁on ▁2 ▁september ▁2011 ▁ .
▁is ▁taking ▁aller gy ▁medicine s
▁two ▁of ▁the ▁studies ▁found ▁no ▁difference ▁in ▁risk ▁of ▁neuro psy chia tric ▁hospital isation s ▁between ▁varen ic line ▁users ▁and ▁ nico tine ▁patch ▁users ▁( ▁hazard ▁ratio ▁[ ▁hr ▁] ▁1. 14 ▁; ▁95 ▁% ▁confidence ▁interval ▁[ ▁ci ▁] ▁: ▁0.5 6 -2 . 34 ▁in ▁the ▁first ▁study ▁ , ▁and ▁0 . 76 ▁; ▁95 ▁% ▁ci ▁: ▁ 0.4 0-1 . 46 ▁in ▁the ▁second ▁study ▁) ▁ .
▁se rum ▁concentration s ▁of ▁ver apa mil ▁may ▁be ▁increased ▁by ▁rey ata z ▁/ ▁rito na vir ▁due ▁to ▁cy p 3 a 4 ▁inhibi tion ▁ .
▁v fen d ▁is ▁suppli ed ▁as ▁a ▁white ▁to ▁off - white ▁powder ▁for ▁oral ▁suspens ion ▁providing ▁a ▁white ▁to ▁off - white ▁ , ▁orang e ▁fl avour ed ▁suspens ion ▁when ▁constitu ted ▁with ▁water ▁ .
▁other ▁medicine s ▁and ▁te pad ina
▁every ▁one ▁or ▁two ▁weeks ▁ , ▁the ▁doctor ▁may ▁adjust ▁your ▁dose ▁to ▁find ▁your ▁individual ▁maintenance ▁dose ▁ .
▁you ▁do ▁not ▁receive ▁routine ▁dental ▁care ▁or ▁have ▁not ▁had ▁a ▁dental ▁check - up ▁for ▁a ▁long ▁time ▁;
▁5 ▁g ▁x ▁1 ▁tube
▁the ▁active ▁substance ▁is ▁em trici ta bine ▁ .
▁do ▁not ▁use ▁vi als ▁which ▁are ▁damage d ▁ , ▁or ▁if ▁the ▁solution ▁is ▁not ▁clear ▁or ▁if ▁it ▁contain s ▁any ▁parti cles ▁ .
▁it ▁is ▁un know n ▁whether ▁es lic arba ze pine ▁ac etate ▁is ▁ex cre ted ▁in ▁human ▁milk ▁ .
▁immun os up press ants ▁such ▁as ▁ cyclo spor ine ▁ , ▁si rol imus ▁ , ▁or ▁tac rol imus ▁( ▁medicine s ▁used ▁to ▁prevent ▁organ ▁transplant ▁ reje ction ▁) ▁: ▁when ▁you ▁start ▁or ▁stop ▁taking ▁sus tiva ▁ , ▁your ▁doctor ▁will ▁close ly ▁monitor ▁your ▁plasma ▁levels ▁of ▁the ▁immun os up press ant ▁and ▁may ▁need ▁to ▁adjust ▁its ▁dose ▁ .
▁in ▁the ▁dedicated ▁cardiovascular ▁study ▁and ▁the ▁larger ▁poole d ▁analysis ▁ , ▁dis continu ations ▁due ▁to ▁advers e ▁reaction s ▁related ▁to ▁volume ▁de ple tion ▁and ▁serious ▁advers e ▁reaction s ▁related ▁to ▁volume ▁de ple tion ▁were ▁not ▁increased ▁with ▁can a gli flo zin ▁ .
▁one ▁pack ▁of ▁cel va pan ▁contain s ▁20 ▁multi dos e ▁vi als ▁of ▁5 ▁ml ▁suspens ion ▁for ▁inject ion ▁for ▁10 ▁dos es ▁ .
▁very ▁common ▁side ▁effects ▁( ▁may ▁affect ▁more ▁than ▁1 ▁in ▁10 ▁people ▁) ▁are ▁:
▁this ▁can ▁be ▁taken ▁either ▁as ▁one ▁300 ▁mg ▁tablet ▁twice ▁a ▁day ▁or ▁two ▁300 ▁mg ▁tablets ▁once ▁a ▁day ▁ .
▁rever sible ▁neutro p enia ▁ , ▁ thro mbo cy top enia ▁ , ▁or ▁ana emia ▁developed ▁in ▁a ▁few ▁dog s ▁treated ▁with ▁8 ▁or ▁10 ▁mg ▁/ ▁kg ▁/ ▁day ▁( ▁total ▁olan za pine ▁exposure ▁[ ▁au c ▁] ▁is ▁12- ▁to ▁15- fold ▁greater ▁than ▁that ▁of ▁a ▁man ▁given ▁a ▁12- mg ▁dose ▁) ▁ .
▁the ▁adjust ed ▁mean ▁change ▁in ▁the ▁pain ▁vas ▁after ▁12 ▁weeks ▁of ▁to cili zum ab ▁treatment ▁was ▁a ▁re duction ▁of ▁41 ▁points ▁on ▁a ▁scale ▁of ▁0 ▁- ▁100 ▁compared ▁to ▁a ▁re duction ▁of ▁1 ▁for ▁place bo ▁patients ▁( ▁p ▁< ▁0.0 001 ▁) ▁ .
▁lan tus ▁100 ▁unit s ▁/ ▁ml ▁solution ▁for ▁inject ion ▁insulin ▁g lar gine
▁ therapy ▁with ▁bas al ▁insulin ▁should ▁be ▁dis continu ed ▁prior ▁to ▁initiat ion ▁of ▁xul to phy ▁ .
▁more over ▁ , ▁no ▁major ▁side ▁effects ▁were ▁seen ▁with ▁long ▁term ▁use ▁of ▁novo thir teen ▁ .
▁the ▁collective ▁analysis ▁of ▁pre clin ical ▁and ▁clinic al ▁irrita tion ▁studies ▁for ▁the ▁oro dis per sible ▁tablet ▁indicate ▁that ▁this ▁formula tion ▁in ▁un like ly ▁to ▁pose ▁risk ▁for ▁local ▁irrita tion ▁with ▁clinic al ▁use ▁ .
▁breast - feed ing ▁should ▁be ▁dis continu ed ▁during ▁treatment ▁with ▁signifo r ▁ .
▁this ▁is ▁generally ▁done ▁on ▁a ▁case - by - case ▁basis ▁ .
▁what ▁ex ta via ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁4 73 ▁ml ▁oral ▁solution
▁a ▁question naire ▁to ▁ga ther ▁detailed ▁ad r ▁report ▁documentation ▁ .
▁securi tain er ▁label ▁and ▁carton ▁label
▁via ▁del ▁commercio ▁25 ▁/ ▁27 ▁63 100 ▁mari no ▁del ▁tron to ▁( ▁ap ▁) ▁ital y
▁a ▁lower ▁pe ar l ▁index ▁represent s ▁a ▁lower ▁chance ▁of ▁getting ▁pregnant ▁ .
▁evo ta z ▁is ▁expected ▁to ▁increase ▁ri lp ivi rine ▁plasma ▁concentration s ▁ .
▁dog s ▁should ▁not ▁be ▁used ▁for ▁breed ing ▁while ▁under ▁treatment ▁ .
▁content s ▁of ▁the ▁pack ▁and ▁other ▁information ▁what ▁firma gon ▁contain s
▁as th enia ▁fatigue ▁oed ema ▁py re xia 10
▁i trac ona zole ▁ , ▁vor ico na zole ▁ , ▁posa con a zole ▁( ▁anti fung als ▁) ▁ , ▁corti co steroid s ▁( ▁such ▁as ▁de xa met has one ▁)
▁multi pack ▁contain ing ▁8 ▁( ▁2 ▁pack s ▁of ▁4 ▁) ▁vi als ▁ .
▁risk ▁factors ▁that ▁may ▁pred is pose ▁this ▁patient ▁population ▁to ▁increased ▁mortal ity ▁include ▁age ▁> ▁65 ▁years ▁ , ▁dys pha gia ▁ , ▁sed ation ▁ , ▁mal nutri tion ▁and ▁de hydrat ion ▁ , ▁pulmonar y ▁conditions ▁( ▁e . g . ▁ , ▁pneu monia ▁ , ▁with ▁or ▁without ▁aspira tion ▁) ▁ , ▁or ▁con com i tant ▁use ▁of ▁ben zo dia zep ines ▁ .
▁step - by - step ▁instructions ▁for ▁use ▁and ▁handling ▁ , ▁recon stitu tion ▁ , ▁and ▁administration
▁if ▁you ▁have ▁a ▁fit ▁( ▁se iz ure ▁) ▁ , ▁you ▁should ▁stop ▁taking ▁my s imba ▁and ▁consult ▁your ▁doctor ▁immediately ▁ .
▁pre - dos ing ▁with ▁di phen hy dra mine ▁di minis hed ▁these ▁effects ▁ , ▁suggest ing ▁that ▁his tamine ▁may ▁play ▁a ▁role ▁in ▁this ▁process ▁ .
▁take ▁the ▁medicine ▁package ▁and ▁this ▁le a flet ▁with ▁you ▁ .
▁content s ▁of ▁the ▁pack ▁and ▁other ▁information ▁what ▁sil gard ▁contain s
▁if ▁ , ▁based ▁on ▁clinic al ▁need ▁ , ▁a ▁decision ▁to ▁treat ▁is ▁never the less ▁taken ▁ , ▁the ▁patient ▁should ▁be ▁carefully ▁monitor ed ▁for ▁the ▁appearance ▁of ▁suicida l ▁symptoms ▁( ▁see ▁section ▁5.1 ▁) ▁ .
▁if ▁you ▁experience ▁any ▁of ▁the ▁following ▁serious ▁side ▁effects ▁ , ▁stop ▁taking ▁the ▁medicine ▁and ▁contact ▁your ▁doctor ▁immediately ▁: ▁-
▁keto con a zole ▁cm in ▁↑ ▁ 868 ▁% ▁keto con a zole ▁c max ▁↑ ▁111 ▁%
▁in ▁the ▁week ▁96 ▁ef fica cy ▁analysis ▁ , ▁the ▁vir ologic ▁response ▁rate ▁[ ▁confirm ed ▁unde tec table ▁viral ▁load ▁( ▁< ▁50 ▁hi v -1 ▁ rna ▁copie s ▁/ ▁ml ▁) ▁] ▁was ▁evaluat ed ▁in ▁patients ▁receiving ▁ri lp ivi rine ▁25 ▁mg ▁once ▁daily ▁in ▁addition ▁to ▁a ▁br ▁versus ▁patients ▁receiving ▁efa vir enz ▁600 ▁mg ▁once ▁daily ▁in ▁addition ▁to ▁a ▁br ▁ .
▁hold ▁for ▁10 ▁seconds ▁to ▁make ▁sure ▁you ▁get ▁the ▁full ▁dose ▁ .
▁patients ▁were ▁divide d ▁into ▁three ▁body - weight ▁groups ▁and ▁dos ed ▁with ▁bo sent an ▁at ▁approximately ▁2 ▁mg ▁/ ▁kg ▁twice ▁daily ▁for ▁12 ▁weeks ▁ .
▁> ▁2.5 ▁cm ▁to ▁5 ▁cm
▁for ▁intra ven ous ▁use ▁after ▁recon stitu tion ▁read ▁the ▁package ▁le a flet ▁before ▁use ▁ .
▁it ▁can ▁increase ▁the ▁risk ▁of ▁getting ▁serious ▁side ▁effects ▁ .
▁of ▁the ▁12 ▁cases ▁of ▁cyst oid ▁ma cular ▁oed ema ▁ , ▁5 ▁were ▁reported ▁as ▁recover ed ▁and ▁7 ▁as ▁ongoing ▁at ▁end ▁of ▁study ▁ .
▁ tyl valo sin ▁has ▁activity ▁against ▁path ogen ic ▁organism s ▁isola ted ▁from ▁a ▁range ▁of ▁animal ▁species - main ly ▁gram - posi tive ▁organism s ▁and ▁my co plasma ▁but ▁also ▁some ▁gram - nega tive ▁organism s ▁ , ▁including ▁laws onia ▁intra cel lular is ▁ .
▁table ▁1 ▁- ▁change ▁in ▁fe v 1 ▁from ▁base line ▁over ▁26 ▁weeks ▁in ▁the ▁mitt ▁and ▁adult ▁population s
▁2001 4 ▁nerv iano ▁( ▁mi ▁) ▁ital y
▁other ▁information ▁about ▁sono vu e
▁dangerous ly ▁excessive ▁in take ▁of ▁water ▁ , ▁life ▁threat en ing ▁complica tions ▁of ▁un control led ▁diabetes
▁if ▁fo am ing ▁occur s ▁ , ▁allow ▁the ▁solution ▁to ▁sett le ▁in ▁the ▁vi al ▁until ▁fo am ing ▁sub side s ▁( ▁approximately ▁5 ▁minutes ▁) ▁and ▁the ▁solution ▁is ▁clear ▁ .
▁para mount ▁: ▁ka plan ▁mei er ▁plot ▁of ▁progression - free ▁survival ▁( ▁p fs ▁) ▁and ▁overall ▁survival ▁( ▁os ▁) ▁for ▁continua tion ▁alim ta ▁maintenance ▁versus ▁place bo ▁in ▁patients ▁with ▁n sc lc ▁other ▁than ▁predomina nt ly ▁s quam ous ▁cell ▁his t ology ▁( ▁measure d ▁from ▁random isation ▁)
▁the ▁final ▁dose ▁must ▁be ▁given ▁within ▁one ▁month ▁after ▁the ▁last ▁exposure ▁to ▁mos qui to es ▁ .
▁values ▁for ▁test ▁and ▁reference ▁are ▁mean ▁( ▁% ▁co e ffi cient ▁of ▁variation ▁) ▁ .
▁box ▁of ▁50 ▁l yo phil isa te ▁vi als ▁and ▁50 ▁solve nt ▁vi als ▁ .
▁at ▁12 ▁weeks ▁( ▁primary ▁end point ▁) ▁ , ▁to vano r ▁bre ezh a ler ▁increased ▁tro ugh ▁fe v 1 ▁by ▁72 ▁ml ▁in ▁patients ▁with ▁the ▁lo west ▁degree ▁of ▁rever si bility ▁( ▁< ▁5 ▁% ▁) ▁and ▁by ▁113 ▁ml ▁in ▁those ▁patients ▁with ▁a ▁higher ▁degree ▁of ▁rever si bility ▁at ▁base line ▁( ▁ ≥ ▁5 ▁% ▁) ▁compared ▁to ▁place bo ▁( ▁both ▁p ▁< ▁0.0 5 ▁) ▁ .
▁bude son ide ▁/ ▁form ote rol ▁teva ▁ pharma ▁b . v . is ▁indicate d ▁in ▁adults ▁18 ▁years ▁of ▁age ▁and ▁older ▁only ▁ .
▁cr amp s ▁and ▁muscle ▁pain s ▁skin ▁ rash ▁or ▁' ▁hi ves ▁' ▁anywhere ▁on ▁the ▁body
▁because ▁roti go tine ▁enter s ▁your ▁blood stream ▁through ▁your ▁skin ▁ , ▁food ▁or ▁drink ▁does ▁not ▁affect ▁the ▁way ▁this ▁medicine ▁works ▁ .
▁mer ck ▁sharp ▁& ▁do h me ▁cy pru s ▁limited
▁the ▁ch mp ▁therefore ▁decided ▁that ▁in ly ta ▁' s ▁benefits ▁are ▁greater ▁than ▁its ▁risk s ▁and ▁recommended ▁that ▁it ▁be ▁given ▁marketing ▁author isation ▁ .
▁read ▁the ▁package ▁le a flet ▁carefully
▁the ▁educational ▁pack ▁must ▁be ▁available ▁for ▁distribution ▁prior ▁to ▁the ▁launch ▁of ▁the ▁new ▁indica tion ▁( ▁treatment ▁of ▁prolifera ting ▁infantil e ▁ha em angi oma ▁) ▁in ▁the ▁member ▁state ▁ .
▁in ▁treatment - na ï ve ▁patients ▁ , ▁the ▁clinic al ▁study ▁data ▁on ▁use ▁of ▁ra lte grav ir ▁are ▁limited ▁to ▁use ▁in ▁combination ▁with ▁two ▁nucleo ti de ▁rever se ▁tran script ase ▁inhibi tors ▁( ▁nr tis ▁) ▁( ▁em trici ta bine ▁and ▁te no fo vir ▁di so prox il ▁fumar ate ▁) ▁ .
▁susceptible ▁person s ▁may ▁suffer ▁bron cho con stri ction ▁in ▁the ▁event ▁of ▁an ▁in hal ed ▁over dos e ▁ .
▁on ▁the ▁basis ▁of ▁phase ▁i i ▁and ▁phase ▁i ii ▁clinic al ▁trial ▁data ▁ , ▁a ▁population ▁exposure - respons e ▁relationship ▁was ▁established ▁between ▁average ▁plasma ▁concentration ▁of ▁certo liz um ab ▁pe gol ▁during ▁a ▁dos ing ▁interval ▁( ▁ca v g ▁) ▁and ▁ef fica cy ▁( ▁ac r ▁20 ▁responder ▁definition ▁) ▁ .
▁during ▁the ▁re fill ▁procedure ▁it ▁is ▁important ▁to ▁fill ▁out ▁the ▁re fill ▁work she et ▁and ▁to ▁calcula te ▁re fill ▁accu ra cy ▁to ▁evaluat e ▁system ▁function ▁ .
▁if ▁you ▁notice ▁any ▁of ▁these ▁symptoms ▁se ek ▁medical ▁advice ▁immediately ▁; ▁a ▁combination ▁of ▁fe ver ▁ , ▁fast er ▁breath ing ▁ , ▁sweat ing ▁ , ▁muscle ▁sti ff ness ▁and ▁ drow si ness ▁or ▁sleep ines s ▁( ▁the ▁fre que ncy ▁of ▁this ▁side ▁effect ▁cannot ▁be ▁estima ted ▁from ▁the ▁available ▁data ▁) ▁ .
▁for ▁the ▁dos age ▁or ▁recommended ▁dose ▁modification s ▁of ▁con com i tant ly ▁used ▁che mo therapeut ic ▁agents ▁ , ▁refer ▁to ▁the ▁product ▁information ▁for ▁these ▁medicinal ▁products ▁ .
▁the ▁presence ▁of ▁neo plast ic ▁changes ▁ , ▁other ▁than ▁osteo sar com as ▁ , ▁was ▁also ▁reported ▁in ▁the ▁longer ▁term ▁( ▁12 ▁to ▁15 ▁months ▁) ▁rat ▁ toxic ity ▁studies ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁table ▁6 ▁: ▁5 ▁years ▁persist ence ▁data ▁in ▁to dd ler s ▁a ged ▁12 -23 ▁months ▁at ▁vaccin ation ▁( ▁study ▁men ac wy - tt -03 2 ▁)
▁the ▁rate ▁and ▁extent ▁of ▁ab sor p tion ▁of ▁ta dala fil ▁are ▁not ▁influence d ▁by ▁food ▁ , ▁thu s ▁cialis ▁may ▁be ▁taken ▁with ▁or ▁without ▁food ▁ .
▁in ▁such ▁cases ▁ , ▁the ▁side ▁effects ▁may ▁be ▁more ▁intense ▁) ▁ .
▁under ▁conditions ▁of ▁greater ▁than ▁2 ▁% ▁system ic ▁le ak age ▁( ▁observe d ▁in ▁13 ▁of ▁51 ▁patients ▁) ▁maximum ▁system ic ▁concentration s ▁of ▁taso ner min ▁were ▁still ▁at ▁least ▁ten ▁times ▁lower ▁than ▁in ▁the ▁per fusion ▁circuit ▁ .
▁keep ▁out ▁of ▁reach ▁and ▁sight ▁of ▁children ▁ .
▁pack ▁size ▁of ▁one ▁pre - fill ed ▁sy ringe ▁ , ▁in ▁either ▁a ▁bli ster ed ▁or ▁non - bli ster ed ▁packaging ▁ .
▁what ▁benefit ▁has ▁nu loj ix ▁shown ▁during ▁the ▁studies ▁?
▁tell ▁your ▁doctor ▁or ▁ pharma ci st ▁if ▁you ▁are ▁taking ▁any ▁of ▁these ▁ .
▁it ▁is ▁recommended ▁that ▁pa e dia tric ▁patients ▁ , ▁if ▁possible ▁ , ▁be ▁brought ▁up ▁to ▁date ▁with ▁all ▁immun isation s ▁in ▁agreement ▁with ▁current ▁immun isation ▁guidelines ▁prior ▁to ▁initiat ing ▁hum ira ▁ therapy ▁ .
▁le flu nom ide ▁med ac ▁is ▁contra indica ted ▁in ▁patients ▁with ▁severe ▁hypo prote ina emia ▁or ▁im pair ment ▁of ▁ liver ▁function ▁( ▁see ▁section ▁4.3 ▁) ▁ .
▁further more ▁ , ▁an ▁immediate - ▁release ▁oral ▁suspens ion ▁dos age ▁form ▁is ▁available ▁for ▁all ▁age ▁groups ▁for ▁a ▁twice ▁daily ▁administration ▁( ▁please ▁refer ▁to ▁the ▁respective ▁summary ▁of ▁product ▁character istic s ▁) ▁ .
▁ask ▁your ▁doctor ▁or ▁ pharma ci st ▁for ▁advice ▁before ▁taking ▁any ▁medicine ▁ .
▁sive x tro ▁200 ▁mg ▁powder ▁for ▁concentrat e ▁ ted izol id ▁ phos pha te
▁the ▁adjudica ted ▁major ▁ble ed ing ▁and ▁cr n m ▁ble ed ing ▁at ▁any ▁anatomi cal ▁site ▁were ▁generally ▁lower ▁in ▁the ▁a pix aban ▁group ▁as ▁compared ▁to ▁the ▁en ox apa rin ▁/ ▁war far in ▁group ▁ .
▁there ▁are ▁no ▁data ▁on ▁dal bava ncin ▁as ▁an ▁inhibi tor ▁of ▁cy p 2 c 8 ▁ .
▁ lon surf ▁caused ▁an ▁increase ▁in ▁the ▁incide nce ▁of ▁gastro inte stin al ▁ toxic ities ▁including ▁na use a ▁ , ▁vom i ting ▁and ▁di ar r ho e a ▁ .
▁pa zo pan ib ▁has ▁not ▁been ▁studie d ▁in ▁patients ▁who ▁have ▁had ▁an ▁event ▁within ▁the ▁previous ▁6 ▁months ▁ .
▁mix ing ▁the ▁powder ▁and ▁water ▁to ▁make ▁up ▁your ▁medicine
▁trans larna ▁1,000 ▁mg ▁granul es ▁for ▁oral ▁suspens ion
▁ huma log ▁bas al ▁should ▁only ▁be ▁given ▁by ▁sub cuta ne ous ▁inject ion ▁ .
▁mus culos kelet al ▁che st ▁pain ▁* ▁ , ▁ar thri tis ▁ , ▁bone ▁pain ▁ , ▁joint ▁swe lling ▁ , ▁mus culos kelet al ▁pain
▁in ▁cycle s ▁3 ▁and ▁beyond ▁ , ▁emp licit i ▁is ▁ad minister ed ▁once ▁every ▁2 ▁weeks ▁on ▁days ▁1 ▁and ▁15 ▁ .
▁vand etan ib ▁should ▁not ▁be ▁given ▁to ▁patients ▁who ▁have ▁a ▁history ▁of ▁ tors ades ▁de ▁point es ▁unless ▁all ▁risk ▁factors ▁that ▁contribute d ▁to ▁ tors ades ▁have ▁been ▁correct ed ▁ .
▁once ▁opened ▁ , ▁use ▁by ▁ ................ ▁{ ▁leave ▁space ▁for ▁the ▁date ▁to ▁be ▁insert ed ▁} ▁ .
▁1 ▁bottle ▁of ▁10 ▁dos es ▁( ▁20 ▁ml ▁) ▁1 ▁bottle ▁of ▁50 ▁dos es ▁( ▁100 ▁ml ▁)
▁in ▁an ▁add - on ▁to ▁gli me piri de ▁study ▁ , ▁at ▁weeks ▁24 ▁and ▁48 ▁ , ▁minor ▁episode s ▁of ▁hypo gly ca emia ▁were ▁reported ▁more ▁frequently ▁in ▁the ▁group ▁treated ▁with ▁da pag lif lozi n ▁10 ▁mg ▁plus ▁gli me piri de ▁( ▁6. 0 ▁% ▁and ▁ 7.9 ▁% ▁ , ▁respective ly ▁) ▁than ▁in ▁the ▁place bo ▁plus ▁gli me piri de ▁group ▁( ▁2.1 ▁% ▁and ▁2.1 ▁% ▁ , ▁respective ly ▁) ▁ .
▁other ▁products ▁contain ing ▁zo le dro nic ▁acid ▁as ▁an ▁active ▁substance ▁are ▁available ▁for ▁on c ology ▁indica tions ▁ .
▁re fact o ▁af ▁500 ▁iu ▁powder ▁and ▁solve nt ▁for ▁solution ▁for ▁inject ion ▁in ▁pre - fill ed ▁sy ringe
▁this ▁means ▁prefer ably ▁6 ▁hours ▁( ▁for ▁medicine s ▁taken ▁twice ▁daily ▁) ▁or ▁12 ▁hours ▁( ▁for ▁medicine s ▁taken ▁once ▁daily ▁) ▁apart ▁from ▁gi ot rif ▁:
▁suppli ed ▁in ▁a ▁single - use ▁vi al ▁designed ▁to ▁deliver ▁4.0 ▁ml ▁of ▁concentrat e ▁for ▁dilu tion ▁into ▁500 ▁ml ▁of ▁ir rig ation ▁solution ▁for ▁o cular ▁use ▁ .
▁your ▁doctor ▁has ▁determine d ▁the ▁correct ▁dose ▁of ▁this ▁medicine ▁based ▁on ▁how ▁much ▁you ▁or ▁the ▁child ▁you ▁are ▁car ing ▁for ▁we igh s ▁ .
▁flu ▁or ▁' ▁flu - like ▁' ▁symptoms
▁as ▁e chino co cco sis ▁is ▁a ▁not ifi able ▁disease ▁to ▁the ▁world ▁organisation ▁for ▁animal ▁health ▁( ▁o ie ▁) ▁ , ▁specific ▁guidelines ▁on ▁the ▁treatment ▁and ▁follow - up ▁ , ▁and ▁on ▁the ▁safe guard ▁of ▁person s ▁ , ▁need ▁to ▁be ▁obtain ed ▁from ▁the ▁relevant ▁ competent ▁authority ▁ .
▁hep atos ple nic ▁t - cell ▁lymph oma ▁has ▁been ▁reported ▁in ▁patients ▁with ▁infla mma tory ▁bo wel ▁disease ▁* ▁treated ▁with ▁aza thi op rine ▁( ▁the ▁pro drug ▁to ▁6- mer cap to puri ne ▁) ▁or ▁6- mer cap to puri ne ▁ , ▁either ▁with ▁or ▁without ▁con com i tant ▁treatment ▁with ▁anti - t n f ▁al pha ▁anti body ▁ .
▁the ▁positive ▁predict ive ▁value ▁of ▁strong ▁fluor esc ence ▁was ▁higher ▁( ▁10 0.0 ▁% ▁; ▁90 ▁% ▁ci ▁: ▁9 1.1 ▁% ▁ -10 0.0 ▁% ▁) ▁than ▁of ▁we ak ▁fluor esc ence ▁( ▁8 3.3 ▁% ▁; ▁90 ▁% ▁ci ▁: ▁6 8.1 ▁% ▁ -9 3.2 ▁% ▁) ▁ .
▁the ▁sy ring es ▁should ▁be ▁of ▁small ▁enough ▁volume ▁that ▁the ▁pre scribe d ▁dose ▁can ▁be ▁withdraw n ▁from ▁the ▁vi al ▁with ▁reasonable ▁accu ra cy ▁ .
▁that ▁vi read ▁should ▁only ▁be ▁used ▁in ▁patients ▁with ▁im pair ed ▁renal ▁function ▁if ▁the ▁potential ▁benefits ▁of ▁treatment ▁are ▁considered ▁to ▁out we igh ▁the ▁potential ▁risk s
▁muscle ▁spas ms ▁ , ▁muscle ▁we ak ness
▁is en tress ▁is ▁used ▁in ▁combination ▁with ▁other ▁anti - hi v ▁medicine s ▁to ▁treat ▁adults ▁and ▁children ▁from ▁the ▁age ▁of ▁4 ▁weeks ▁who ▁are ▁infect ed ▁with ▁human ▁immun o de fici en cy ▁virus ▁( ▁hi v -1 ▁) ▁ , ▁a ▁virus ▁that ▁causes ▁acquire d ▁immun e ▁de fici en cy ▁syndrome ▁( ▁aid s ▁) ▁ .
▁as ▁expected ▁ , ▁all ▁animals ▁developed ▁anti bo dies ▁to ▁the ▁a av ▁protein ▁ shell ▁ .
▁therefore ▁ , ▁ha e modi al ysis ▁is ▁of ▁little ▁clinic al ▁benefit ▁in ▁remo ving ▁a log lip tin ▁in ▁over dos e ▁ .
▁vel phor o ▁works ▁by ▁ binding ▁ phos phor us ▁from ▁food ▁in ▁your ▁digestiv e ▁tract ▁( ▁stomach ▁and ▁inte stin es ▁) ▁ .
▁ therapy ▁should ▁be ▁rein iti ated ▁at ▁approximately ▁25 ▁% ▁lower ▁than ▁the ▁previous ▁dose ▁after ▁ha emo glob in ▁levels ▁fall ▁to ▁12 ▁g ▁/ ▁dl ▁( ▁7.5 ▁mm ol ▁/ ▁l ▁) ▁or ▁below ▁ .
▁what ▁is ▁versi can ▁plus ▁dh ppi ▁?
▁single ▁and ▁multiple ▁5 ▁and ▁15- minut e ▁in fusion s ▁of ▁2 ▁ , ▁4 ▁ , ▁8 ▁and ▁16 ▁mg ▁zo le dro nic ▁acid ▁in ▁64 ▁patients ▁yi eld ed ▁the ▁following ▁ pharma cok ine tic ▁data ▁ , ▁which ▁were ▁found ▁to ▁be ▁dose ▁independent ▁ .
▁very ▁common ▁: ▁na use a ▁ , ▁vom i ting ▁and ▁di ar r ho e a ▁( ▁all ▁of ▁which ▁may ▁be ▁severe ▁) ▁ , ▁which ▁may ▁lead ▁to ▁de hydrat ion ▁( ▁see ▁section s ▁4.2 ▁and ▁4.4 ▁)
▁eu ▁/ ▁1 ▁/ ▁01 ▁/ ▁185 ▁/ ▁04 9 ▁1 ▁pack ▁eu ▁/ ▁1 ▁/ ▁01 ▁/ ▁185 ▁/ ▁06 1 ▁4 ▁pack
▁efa vir enz ▁induc ed ▁fo e tal ▁resor p tions ▁in ▁rat s ▁ .
▁in ▁study ▁sc - ii i ▁ , ▁a bata cept ▁sc ▁was ▁evaluat ed ▁in ▁combination ▁with ▁met ho tre xa te ▁ , ▁or ▁as ▁a bata cept ▁mono therapy ▁ , ▁and ▁compared ▁to ▁m t x ▁mono therapy ▁in ▁in duction ▁of ▁re mission ▁following ▁12 ▁months ▁of ▁treatment ▁ , ▁and ▁the ▁possible ▁maintenance ▁of ▁drug - free ▁re mission ▁after ▁complete ▁drug ▁withdraw al ▁ , ▁in ▁adult ▁m t x - na ive ▁patients ▁with ▁highly ▁active ▁early ▁rhe um ato id ▁ar thri tis ▁( ▁mean ▁das 28 - c rp ▁of ▁5. 4 ▁; ▁mean ▁symptom ▁du ration ▁less ▁than ▁ 6.7 ▁months ▁) ▁with ▁poor ▁prognos tic ▁factors ▁for ▁rapid ly ▁progressive ▁disease ▁( ▁e . g . ▁anti - ▁cit rul lina ted ▁protein ▁anti bo dies ▁[ ▁ac pa ▁+ ▁] ▁ , ▁as ▁measure d ▁by ▁anti - cc p 2 ▁as say ▁ , ▁and ▁/ ▁or ▁ rf ▁+ ▁ , ▁base line ▁joint ▁eros ions ▁) ▁ .
▁in ▁a ▁two - genera tion ▁reproduc tive ▁study ▁on ▁pre - and ▁post na tal ▁development ▁os pem ife ne ▁induc ed ▁an ▁increased ▁post - im plant ation ▁loss ▁ , ▁an ▁increased ▁number ▁of ▁dead ▁pup s ▁at ▁birth ▁as ▁well ▁as ▁an ▁increased ▁incide nce ▁of ▁post na tal ▁loss ▁of ▁pup s ▁in ▁the ▁f 1 ▁generation ▁ .
▁11. 6 ▁% ▁of ▁the ▁patients ▁had ▁marginal ▁zone ▁lymph oma ▁( ▁m z l ▁) ▁and ▁7.1 ▁% ▁had ▁small ▁lymph o cy tic ▁lymph oma ▁( ▁s ll ▁) ▁ .
▁the ▁active ▁substance ▁in ▁cim zia ▁ , ▁certo liz um ab ▁pe gol ▁ , ▁is ▁an ▁immun os up press ant ▁medicine ▁ , ▁a ▁medicine ▁that ▁reduce s ▁the ▁activity ▁of ▁the ▁immun e ▁system ▁( ▁the ▁body ▁' s ▁natural ▁de f ences ▁) ▁ .
▁the ▁usual ▁dose ▁of ▁du lo xe tine ▁zen tiva ▁is ▁60 ▁mg ▁once ▁a ▁day ▁ , ▁but ▁your ▁doctor ▁will ▁pre scribe ▁the ▁dose ▁that ▁is ▁right ▁for ▁you ▁ .
▁table ▁2 ▁: ▁responder ▁analysis ▁at ▁6 ▁months
▁if ▁clinic ally ▁indicate d ▁ , ▁ph leb oto my ▁may ▁be ▁perform ed ▁ .
▁patients ▁who ▁are ▁using ▁any ▁form ▁of ▁organic ▁nit rate ▁or ▁ni tric ▁oxid e ▁donor s ▁( ▁such ▁as ▁am yl ▁nit rite ▁) ▁( ▁see ▁section ▁4.5 ▁) ▁ .
▁co - administration ▁of ▁bri mica ▁genu air ▁with ▁other ▁anti cho liner gi c ▁and ▁/ ▁or ▁long - ac ting ▁β 2- ad r energi c ▁ago nist ▁contain ing ▁medicinal ▁products ▁has ▁not ▁been ▁studie d ▁and ▁is ▁not ▁recommended ▁ .
▁you ▁must ▁stop ▁taking ▁these ▁medicine s ▁for ▁at ▁least ▁14 ▁days ▁before ▁starting ▁my s imba ▁( ▁see ▁" ▁do ▁not ▁take ▁my s imba ▁" ▁) ▁ .
▁inject ion ▁site ▁infection ▁ , ▁lower ▁respirator y ▁tract ▁infection
▁both ▁studies ▁demonstrat ed ▁the ▁ability ▁of ▁ta sime lte on ▁to ▁entra in ▁the ▁master ▁body ▁c lock ▁in ▁patients ▁with ▁non -24 ▁and ▁reset ▁demonstrat ed ▁that ▁continued ▁daily ▁dos ing ▁of ▁ta sime lte on ▁is ▁necessary ▁to ▁maintain ▁entra in ment ▁ .
▁the ▁safety ▁and ▁ef fica cy ▁of ▁doce ta xel ▁in ▁na so pha ryn ge al ▁car cino ma ▁in ▁children ▁a ged ▁1 ▁month ▁to ▁less ▁than ▁18 ▁years ▁have ▁not ▁yet ▁been ▁established ▁ .
▁each ▁hard ▁capsule ▁contain s ▁15 ▁mg ▁of ▁stavu dine ▁ .
▁method ▁and ▁route ▁of ▁administration
▁bi no crit ▁ 8,000 ▁iu ▁/ ▁ 0.8 ▁ml ▁solution ▁for ▁inject ion ▁in ▁a ▁pre - fill ed ▁sy ringe ▁each ▁sy ringe ▁contain s ▁ 0.8 ▁ml ▁of ▁solution ▁for ▁inject ion ▁ .
▁s cc ▁in ▁mg it ▁® ▁n ▁/ ▁n ▁( ▁% ▁)
▁allergi c ▁reaction s ▁have ▁been ▁reported ▁( ▁fre que ncy ▁not ▁known ▁) ▁in ▁patients ▁taking ▁pag lita z ▁ .
▁this ▁means ▁that ▁you ▁have ▁too ▁few ▁red ▁blood ▁cell s ▁and ▁your ▁ha emo glob in ▁level ▁is ▁too ▁low ▁( ▁your ▁body ▁' s ▁tissu es ▁might ▁not ▁receive ▁enough ▁oxygen ▁) ▁ .
▁to ler ability ▁of ▁the ▁maximum ▁dose ▁of ▁20 ▁mg ▁may ▁be ▁lower ▁in ▁el der ly ▁patients ▁( ▁ ≥ ▁65 ▁years ▁old ▁) ▁( ▁see ▁section s ▁4.2 ▁and ▁4. 8 ▁) ▁ .
▁you ▁must ▁not ▁breast - feed ▁if ▁you ▁are ▁taking ▁cap e cita bine ▁sun ▁ .
▁after ▁12 ▁weeks ▁or ▁at ▁the ▁time ▁of ▁escape ▁ , ▁due ▁to ▁disease ▁worse ning ▁ , ▁patients ▁were ▁treated ▁in ▁the ▁open ▁label ▁phase ▁at ▁weight ▁appropriate ▁dos ing ▁ .
▁ex ace rb ation ▁rate ▁per ▁year
▁accident al ▁in gestion ▁of ▁the ▁entire ▁content s ▁of ▁a ▁bottle ▁of ▁op atan ol ▁would ▁deliver ▁a ▁maximum ▁system ic ▁exposure ▁of ▁5 ▁mg ▁olo pata dine ▁ .
▁women ▁of ▁child be aring ▁potential ▁who ▁are ▁not ▁using ▁reliable ▁methods ▁of ▁contra ception ▁( ▁see ▁section s ▁4.4 ▁ , ▁4.5 ▁and ▁ 4.6 ▁)
▁approximately ▁10-20 ▁% ▁is ▁ex cre ted ▁in ▁urin e ▁ .
▁in ▁addition ▁ , ▁the ▁post - marketing ▁reports ▁with ▁on ca spar ▁that ▁include ▁spontane ous ▁reports ▁as ▁well ▁as ▁serious ▁advers e ▁events ▁from ▁clinic al ▁studies ▁ .
▁therefore ▁this ▁medicine ▁is ▁not ▁recommended ▁in ▁this ▁age ▁group ▁ .
▁when ▁considering ▁the ▁use ▁of ▁si tag lip tin ▁in ▁combination ▁with ▁another ▁anti - dia be tic ▁medicinal ▁product ▁ , ▁its ▁conditions ▁for ▁use ▁in ▁patients ▁with ▁renal ▁im pair ment ▁should ▁be ▁check ed ▁ .
▁physician s ▁should ▁consider ▁pre - tre at ment ▁( ▁e . g . ▁ , ▁with ▁anti hi stamine ▁ , ▁hydro cor tis one ▁and ▁/ ▁or ▁para ce ta mol ▁) ▁prior ▁to ▁the ▁next ▁in fusion ▁for ▁patients ▁with ▁a ▁history ▁of ▁mild ▁to ▁moderat e ▁ir r ▁to ▁ved oli zum ab ▁ , ▁in ▁order ▁to ▁min imize ▁their ▁risk s ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁co - administration ▁with ▁keto con a zole ▁( ▁400 ▁mg ▁) ▁in ▁healthy ▁volunteer s ▁increased ▁mean ▁vil ante rol ▁au c ▁( ▁0 - t ▁) ▁and ▁c max ▁ , ▁65 ▁% ▁and ▁22 ▁% ▁respective ly ▁ .
▁for ▁patients ▁being ▁withdraw n ▁from ▁it ▁op iate s ▁ , ▁the ▁it ▁op iate ▁in fusion ▁dose ▁should ▁be ▁gradual ly ▁tape red ▁over ▁a ▁few ▁weeks ▁and ▁replace d ▁with ▁a ▁ pharma c ological ly ▁equivalent ▁dose ▁of ▁oral ▁op iate s ▁ .
▁never ▁store ▁your ▁pen ▁with ▁the ▁need le ▁attached ▁ .
▁ inflammation ▁leading ▁to ▁dys function ▁or ▁ob struct ion ▁in ▁bile ▁secret ion ▁( ▁cho le static ▁hepatitis ▁) ▁specific ▁changes ▁in ▁the ▁electro card i ogram ▁( ▁q t ▁prolong ation ▁)
▁do ▁not ▁use ▁solutions ▁that ▁are ▁cloud y ▁or ▁have ▁deposit s ▁ .
▁in ▁case ▁of ▁skin ▁exposure ▁ , ▁ne xo brid ▁must ▁be ▁rin sed ▁off ▁with ▁water ▁ .
▁there ▁are ▁no ▁data ▁on ▁the ▁use ▁of ▁garda sil ▁9 ▁in ▁individuals ▁with ▁im pair ed ▁immun e ▁responsive ness ▁ .
▁the ▁recommended ▁starting ▁dose ▁is ▁a ▁1- mg ▁tablet ▁taken ▁3 ▁times ▁a ▁day ▁for ▁2 ▁weeks ▁ .
▁this ▁is ▁a ▁summary ▁of ▁the ▁european ▁public ▁assessment ▁report ▁( ▁e par ▁) ▁for ▁var gate f ▁ .
▁non - ga stro inte stin al ▁fi stu la ▁( ▁including ▁tra che al ▁ , ▁pneu mo media sti num ▁ , ▁tra che o - o es op hage al ▁) ▁ , ▁pulmonar y ▁e mbol ism ▁ , ▁respirator y ▁tract ▁ha e mor r hage ▁( ▁including ▁pulmonar y ▁ , ▁bron chi al ▁ , ▁tra che al ▁) ▁ , ▁pneu monia ▁aspira tion
▁in ▁patients ▁with ▁mild - to - moder ate ▁renal ▁im pair ment ▁( ▁30 -70 ▁ml ▁/ ▁min ▁creati nine ▁clear ance ▁) ▁ , ▁stron tium ▁clear ance ▁decrease s ▁as ▁creati nine ▁clear ance ▁decrease s ▁( ▁approximately ▁30 ▁% ▁decrease ▁over ▁the ▁creati nine ▁clear ance ▁range ▁30 ▁to ▁70 ▁ml ▁/ ▁min ▁) ▁and ▁there by ▁induc es ▁an ▁increase ▁in ▁stron tium ▁plasma ▁levels ▁ .
▁the ▁media n ▁recovery ▁of ▁the ▁ad minister ed ▁radio active ▁dose ▁was ▁approximately ▁82 ▁% ▁in ▁the ▁fa e ces ▁ , ▁9 ▁% ▁in ▁ex hal ed ▁air ▁and ▁1 ▁% ▁in ▁urin e ▁ .
▁leve ti race tam ▁act avis ▁250 ▁mg ▁film - co ated ▁tablets
▁in ▁babi es ▁born ▁very ▁prematur ely ▁( ▁at ▁or ▁before ▁28 ▁weeks ▁of ▁ge station ▁) ▁longer ▁gap s ▁than ▁normal ▁between ▁breath s ▁may ▁occur ▁for ▁2-3 ▁days ▁after ▁vaccin ation ▁ .
▁bri vi act ▁solution ▁for ▁inject ion ▁/ ▁in fusion ▁can ▁be ▁ad minister ed ▁as ▁a ▁bol us ▁inject ion ▁or ▁as ▁an ▁in fusion ▁:
▁how ▁to ▁take ▁clo pido gre l ▁apo tex
▁what ▁izba ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁expert ▁advice ▁should ▁first ▁be ▁so ught ▁ .
▁please ▁read ▁section ▁3 ▁of ▁this ▁package ▁le a flet ▁very ▁carefully ▁ .
▁for ▁total ▁hip ▁b md ▁ , ▁8 2.3 ▁% ▁of ▁patients ▁receiving ▁3 ▁mg ▁inject ion ▁every ▁3 ▁months ▁were ▁responder s ▁at ▁one ▁year ▁ , ▁compared ▁with ▁7 5.1 ▁% ▁of ▁patients ▁receiving ▁2.5 ▁mg ▁daily ▁oral ly ▁( ▁p ▁= ▁0.0 2 ▁) ▁ .
▁minimum ▁particular s ▁to ▁appear ▁on ▁sac hets
▁the ▁active ▁substance ▁in ▁xi ap ex ▁is ▁collage na se ▁clo stri dium ▁his tol yti cum ▁ , ▁and ▁this ▁collage na se ▁is ▁produced ▁using ▁the ▁micro organ ism ▁clo stri dium ▁his tol yti cum ▁ .
▁the ▁maximum ▁recommended ▁dose ▁for ▁these ▁patients ▁is ▁40 ▁mg ▁every ▁weeks ▁ .
▁xo terna ▁bre ezh a ler ▁- ▁tio tropi um
▁the ▁full ▁e par ▁for ▁vel a ctis ▁can ▁be ▁found ▁on ▁the ▁agency ▁' s ▁website ▁: ▁ema . europa . eu ▁/ ▁find ▁medicine ▁/ ▁veterinar y ▁medicine s ▁/ ▁european ▁public ▁assessment ▁reports ▁ .
▁in ▁rabbi ts ▁and ▁mon key s ▁no ▁advers e ▁effects ▁were ▁observe d ▁ .
▁serious ▁life - th rea te ning ▁infection s ▁including ▁mening itis ▁ , ▁en do card itis ▁ , ▁tubercul osis ▁and ▁a typ ical ▁my coba cter ial ▁infection ▁ .
▁if ▁not ▁used ▁immediately ▁ , ▁in - use ▁storage ▁times ▁and ▁conditions ▁prior ▁to ▁use ▁are ▁the ▁responsibility ▁of ▁the ▁user ▁and ▁would ▁normal ly ▁not ▁be ▁longer ▁than ▁24 ▁hours ▁at ▁2 ▁c ▁- ▁8 ▁c ▁ , ▁unless ▁dilu tion ▁has ▁taken ▁place ▁in ▁control led ▁and ▁valida ted ▁a se ptic ▁conditions ▁ .
▁after ▁single ▁dose ▁administration ▁in ▁the ▁dose ▁range ▁of ▁75 ▁to ▁600 ▁mg ▁ , ▁a ▁2- fold ▁increase ▁in ▁dose ▁results ▁in ▁a ▁~ ▁2.3 ▁and ▁2.6 - fold ▁increase ▁in ▁au c ▁and ▁c max ▁ , ▁respective ly ▁ .
▁see ▁section ▁5.1 ▁for ▁further ▁information ▁ .
▁talk ▁to ▁your ▁doctor ▁or ▁nurse ▁before ▁using ▁a bra xan e
▁always ▁use ▁one ▁of ▁the ▁oral ▁sy ring es ▁provided ▁to ▁take ▁the ▁medicine ▁ .
▁anxiety ▁symptoms ▁ , ▁confusion ▁and ▁dis orientation ▁ , ▁depression ▁ , ▁mood ▁changes ▁ , ▁night mare ▁ , ▁hal lucina tion ▁ , ▁mental ▁disorder s
▁cardiac ▁arrest ▁ , ▁my o card ial ▁in far ction ▁ , ▁complete ▁av ▁block ▁ , ▁bra dy car dia ▁ , ▁at rial ▁flutt er ▁ , ▁new - ons et ▁ , ▁worse ning ▁or ▁re curr ence ▁of ▁at rial ▁fi bril lation
▁la mi vu dine ▁exhibi ts ▁linear ▁ pharma cok ine tics ▁over ▁the ▁ therapeut ic ▁dose ▁range ▁and ▁display s ▁limited ▁plasma ▁protein ▁ binding ▁in ▁vi tro ▁( ▁< ▁36 ▁% ▁) ▁ .
▁do ▁not ▁use ▁this ▁medicine ▁if ▁the ▁pack ▁is ▁damage d ▁or ▁shows ▁sign s ▁of ▁tam per ing ▁ .
▁dark ▁urin e ▁ , ▁urin ary ▁in con tinen ce
▁what ▁bond ron at ▁looks ▁like ▁and ▁content s ▁of ▁the ▁pack
▁more ▁than ▁60 ▁% ▁of ▁all ▁patients ▁were ▁ca uca sian ▁and ▁25 ▁% ▁of ▁all ▁patients ▁were ▁asian ▁ .
▁the ▁co - administration ▁of ▁desco vy ▁is ▁not ▁recommended ▁with ▁certain ▁antico n vul s ants ▁( ▁e . g . ▁ , ▁carb amaz e pine ▁ , ▁o x car ba ze pine ▁ , ▁ phen oba rbi tal ▁and ▁ phen y to in ▁) ▁ , ▁anti my coba cter ial s ▁( ▁e . g . ▁ , ▁rif ampi cin ▁ , ▁rif abu tin ▁ , ▁rif a pen tine ▁) ▁ , ▁bo ce pre vir ▁ , ▁tela pre vir ▁ , ▁st . ▁joh n ▁' s ▁ wort ▁and ▁hi v ▁prote ase ▁inhibi tors ▁( ▁pis ▁) ▁other ▁than ▁ata zana vir ▁ , ▁lo pina vir ▁and ▁dar una vir ▁( ▁see ▁section ▁4.5 ▁) ▁ .
▁rito na vir ▁is ▁a ▁ potent ▁cy p 3 a ▁inhibi tor ▁which ▁inhibi ts ▁the ▁metabolism ▁of ▁lo pina vir ▁and ▁therefore ▁ , ▁increase s ▁plasma ▁levels ▁of ▁lo pina vir ▁ .
▁ innova x - ilt ▁ , ▁suspens ion ▁and ▁solve nt ▁for ▁suspens ion ▁for ▁inject ion ▁for ▁chicken s
▁un control led ▁open - label ▁studies ▁suggest ▁sustain ed ▁long - term ▁ef fica cy ▁ , ▁although ▁no ▁control led ▁study ▁has ▁been ▁conduct ed ▁for ▁longer ▁than ▁three ▁months
▁geno toxic ity ▁studies ▁confirm ed ▁the ▁potential ▁for ▁cla sto ge nic ▁effects ▁in ▁mamma lian ▁cell s ▁in ▁vi tro ▁and ▁in ▁vivo ▁ .
▁in fusion ▁site ▁er y thema ▁ , ▁in fusion ▁site ▁pain ▁ , ▁in fusion ▁site ▁pru ritu s
▁the ▁most ▁frequent ▁advers e ▁reaction s ▁were ▁main ly ▁gastro inte stin al ▁related ▁( ▁na use a ▁which ▁was ▁the ▁most ▁frequent ▁reaction ▁and ▁associated ▁with ▁the ▁initiat ion ▁of ▁treatment ▁and ▁decrease d ▁over ▁time ▁ , ▁and ▁di ar r ho e a ▁) ▁ .
▁therefore ▁ , ▁the ▁use ▁of ▁ir besar tan ▁hydro ch lor o thi azi de ▁zen tiva ▁is ▁not ▁recommended ▁ .
▁advers e ▁reaction s ▁observe d ▁only ▁during ▁post - marketing ▁are ▁marked ▁( ▁* ▁) ▁ .
▁treatment ▁should ▁be ▁pre scribe d ▁and ▁super vis ed ▁by ▁specialist ▁physician s ▁experienced ▁in ▁the ▁management ▁of ▁immun os up press ive ▁ therapy ▁and ▁of ▁renal ▁transplant ▁patients ▁ .
▁if ▁you ▁notice ▁any ▁slow ▁down ▁in ▁the ▁growth ▁or ▁unexpected ▁puber ty ▁development ▁of ▁your ▁child ▁ , ▁please ▁contact ▁your ▁doctor ▁ .
▁each ▁single - use ▁sy ringe ▁contain s ▁either ▁75 ▁milli gram s ▁( ▁75 ▁milli gram s ▁per ▁ml ▁) ▁or ▁150 ▁milli gram s ▁( ▁150 ▁milli gram s ▁per ▁ml ▁) ▁of ▁ali ro cum ab ▁ .
▁eye ▁problems ▁including ▁damage ▁to ▁the ▁retin a ▁ , ▁ob struct ion ▁of ▁the ▁retin al ▁arter y ▁ , ▁ inflammation ▁of ▁the ▁op tic ▁nerv e ▁ , ▁swe lling ▁of ▁the ▁eye ▁and ▁cotton ▁wo ol ▁spot s ▁( ▁white ▁deposit s ▁on ▁the ▁retin a ▁) ▁ ,
▁human ▁data ▁are ▁la cking ▁ .
▁the ▁geometri c ▁mean ▁cm in ▁for ▁in dina vir ▁( ▁0.3 3 ▁mg ▁/ ▁l ▁) ▁when ▁given ▁with ▁rito na vir ▁and ▁efa vir enz ▁was ▁higher ▁than ▁the ▁mean ▁historical ▁cm in ▁( ▁0.1 5 ▁mg ▁/ ▁l ▁) ▁when ▁in dina vir ▁was ▁given ▁alone ▁at ▁800 ▁mg ▁q 8 h ▁ .
▁this ▁medicinal ▁product ▁contain s ▁2. 34 ▁mm ol ▁( ▁or ▁54 ▁mg ▁) ▁so dium ▁per ▁vi al ▁ .
▁che st ▁pain ▁ , ▁flu shing ▁ , ▁palp it ations ▁( ▁pou nding ▁heart ▁beat ▁) ▁ , ▁rapid ▁heart ▁rate ▁ ,
▁this ▁medicine ▁contain s ▁less ▁than ▁1 ▁mm ol ▁so dium ▁( ▁23 ▁mg ▁) ▁per ▁dose ▁ , ▁i . e . ▁essential ly ▁' ▁so dium - free ▁' ▁ .
▁when ▁it ▁is ▁appropriate ▁to ▁tit rate ▁down ▁to ▁a ▁lower ▁strength ▁than ▁is ▁available ▁for ▁bude son ide ▁/ ▁form ote rol ▁teva ▁ , ▁a ▁change ▁to ▁an ▁alternative ▁fixed - dos e ▁combination ▁of ▁bude son ide ▁and ▁form ote rol ▁fumar ate ▁contain ing ▁a ▁lower ▁dose ▁of ▁the ▁in hal ed ▁corti co steroid ▁is ▁required ▁ .
▁when ▁you ▁start ▁a ▁new ▁pack ▁ , ▁use ▁the ▁new ▁see bri ▁bre ezh a ler ▁in hal er ▁that ▁is ▁suppli ed ▁in ▁the ▁pack ▁ .
▁it ▁is ▁available ▁as ▁tablets ▁( ▁75 ▁mg ▁) ▁ .
▁to ▁prime ▁the ▁pump ▁ , ▁fully ▁de press ▁the ▁pump ▁mechanism ▁repeat ed ly ▁until ▁gel ▁is ▁observe d ▁ , ▁then ▁de press ▁the ▁pump ▁one ▁more ▁time ▁ , ▁and ▁disc ard ▁this ▁portion ▁of ▁the ▁medicinal ▁product ▁to ▁assure ▁precise ▁dose ▁delivery ▁ .
▁re fill ▁the ▁container ▁with ▁an ▁additional ▁volume ▁( ▁minimum ▁of ▁120 ▁ml ▁) ▁of ▁water ▁or ▁orang e ▁juice ▁ , ▁stir ▁vigor ously ▁ , ▁and ▁drink ▁at ▁once ▁ .
▁do ▁not ▁use ▁if ▁the ▁content ▁appears ▁otherwise ▁ .
▁patient ▁a ges ▁range d ▁from ▁42 ▁to ▁94 ▁years ▁with ▁a ▁mean ▁of ▁65 ▁years ▁ .
▁the ▁most ▁common ly ▁reported ▁advers e ▁reaction s ▁were ▁in fusion ▁associated ▁reaction s ▁ , ▁which ▁occur red ▁in ▁13. 7 ▁% ▁of ▁adult ▁patients ▁treated ▁with ▁rep la gal ▁in ▁clinic al ▁trial s ▁ .
▁the ▁prompt ▁remo val ▁of ▁fa e ces ▁( ▁within ▁12 ▁hours ▁) ▁reduce s ▁the ▁risk ▁of ▁transmission ▁of ▁infection ▁ .
▁with ▁the ▁use ▁of ▁thy rogen ▁ , ▁the ▁t sh ▁stimul ation ▁necessary ▁for ▁radio io dine ▁up take ▁and ▁thy ro glob ulin ▁release ▁is ▁achieve d ▁while ▁patients ▁are ▁maintain ed ▁eu thy roid ▁on ▁th st ▁ , ▁thu s ▁avoid ing ▁the ▁morbi d ity ▁associated ▁with ▁hypo thy roid ism ▁ .
▁the ▁marketing ▁author isation ▁holder ▁( ▁mah ▁) ▁shall ▁ensure ▁that ▁all ▁physician s ▁who ▁are ▁expected ▁to ▁pre scribe ▁/ ▁use ▁rep so ▁are ▁provided ▁with ▁a ▁physician ▁educational ▁pack ▁contain ing ▁the ▁following ▁:
▁the ▁det ection ▁of ▁anti body ▁formation ▁is ▁dependent ▁on ▁the ▁ sensitiv ity ▁and ▁specific ity ▁of ▁the ▁as say ▁ .
▁one ▁maximum ▁single ▁dose ▁of ▁mate ver ▁concentrat e ▁contain s ▁2. 49 ▁mm ol ▁( ▁or ▁57 . 21 mg ▁) ▁of ▁so dium ▁( ▁ 0.8 ▁mm ol ▁( ▁or ▁19 ▁mg ▁) ▁of ▁so dium ▁per ▁vi al ▁) ▁ .
▁fun gal ▁infection s ▁such ▁as ▁th rush ▁ ,
▁advers e ▁reaction s ▁occur ring ▁more ▁frequently ▁( ▁ ≥ ▁3 ▁% ▁) ▁in ▁tar ce va - tre ated ▁patients ▁than ▁in ▁the ▁place bo ▁group ▁in ▁the ▁pivo tal ▁study ▁br . 21 ▁ , ▁and ▁in ▁at ▁least ▁10 ▁% ▁of ▁patients ▁in ▁the ▁tar ce va ▁group ▁ , ▁are ▁summa ris ed ▁by ▁national ▁cancer ▁institut e - com mon ▁ toxic ity ▁criteri a ▁( ▁ nci - ct c ▁) ▁grade ▁in ▁table ▁1 ▁ .
▁the ▁solution ▁should ▁be ▁inspect ed ▁visual ly ▁prior ▁to ▁use ▁ .
▁the ▁combine d ▁administration ▁of ▁ciclo spor in ▁and ▁tac rol imus ▁should ▁be ▁avoid ed ▁and ▁care ▁should ▁be ▁taken ▁when ▁ad minister ing ▁tac rol imus ▁to ▁patients ▁who ▁have ▁previously ▁received ▁ciclo spor in ▁( ▁see ▁section s ▁4.2 ▁and ▁4.5 ▁) ▁ .
▁this ▁may ▁lead ▁to ▁lower ▁ , ▁potential ly ▁sub therapeut ic ▁plasma ▁concentration s ▁of ▁de x tro met hor phan ▁and ▁decrease d ▁ef fica cy ▁of ▁nu ede xta ▁ .
▁suspens ion ▁: ▁70 ▁ml ▁( ▁10,000 ▁dos es ▁) ▁;
▁date ▁of ▁latest ▁rene wal ▁: ▁9 ▁september ▁2014 ▁ .
▁population ▁ pharma cok ine tic ▁analysis ▁of ▁sa prop ter in ▁including ▁patients ▁from ▁birth ▁to ▁49 ▁years ▁of ▁age ▁showed ▁that ▁body ▁weight ▁is ▁the ▁only ▁co varia te ▁substantial ly ▁affect ing ▁clear ance ▁or ▁volume ▁of ▁distribution ▁ .
▁the ▁safety ▁and ▁ef fica cy ▁of ▁af a mela not ide ▁in ▁children ▁and ▁adolescents ▁a ged ▁0 ▁to ▁17 ▁years ▁have ▁not ▁yet ▁been ▁established ▁ .
▁the ▁recommended ▁dose ▁of ▁ram uci rum ab ▁is ▁8 ▁mg ▁/ ▁kg ▁on ▁days ▁1 ▁and ▁15 ▁of ▁a ▁28 ▁day ▁cycle ▁ , ▁prior ▁to ▁pac lita xel ▁in fusion ▁ .
▁effects ▁in ▁non - clin ical ▁studies ▁were ▁observe d ▁only ▁at ▁exposure s ▁considered ▁ sufficient ly ▁in ▁excess ▁of ▁the ▁maximum ▁human ▁exposure ▁indicat ing ▁little ▁relevan ce ▁to ▁clinic al ▁use ▁ .
▁try ▁to ▁reset ▁it ▁by ▁following ▁the ▁instructions ▁under ▁' ▁prepar ing ▁the ▁na sal ▁spray ▁for ▁use ▁' ▁ .
▁the ▁recommended ▁dose ▁is ▁20 ▁mg ▁three ▁times ▁a ▁day ▁( ▁tid ▁) ▁ .
▁barrier ▁contra ception ▁should ▁always ▁be ▁used ▁in ▁combination ▁with ▁other ▁methods ▁of ▁contra ception ▁( ▁for ▁example ▁ , ▁oral ▁or ▁other ▁hormonal ▁contra cep tives ▁ , ▁see ▁section ▁4.5 ▁) ▁while ▁on ▁ therapy ▁with ▁a trip la ▁ .
▁as ▁the ▁veterinar y ▁medicinal ▁product ▁may ▁cause ▁moderat e ▁eye ▁irrita tion ▁ , ▁avoid ▁contact ▁with ▁eyes ▁ .
▁properly ▁dispose ▁of ▁vi als ▁contain ing ▁remain ing ▁water ▁and ▁il aris ▁solution ▁( ▁if ▁any ▁) ▁as ▁direct ed ▁by ▁your ▁health care ▁provider ▁or ▁ pharma ci st ▁ .
▁xen ical ▁only ▁works ▁in ▁the ▁presence ▁of ▁dieta ry ▁fat ▁ .
▁the ▁tablets ▁are ▁available ▁in ▁bli ster ▁pack s ▁of ▁7 ▁ , ▁10 ▁ , ▁28 ▁ , ▁30 ▁ , ▁100 ▁and ▁112 ▁tablets ▁and ▁in ▁perfor ated ▁bli ster ▁pack s ▁contain ing ▁7 ▁x ▁1 ▁ , ▁10 ▁x ▁1 ▁ , ▁28 ▁x ▁1 ▁ , ▁30 ▁x ▁1 ▁ , ▁100 ▁x ▁1 ▁and ▁112 ▁x ▁1 ▁tablets ▁ .
▁results ▁from ▁a ▁clinic al ▁study ▁demonstrat ed ▁no ▁clinic ally ▁significant ▁ pk ▁interaction ▁between ▁vis mode gib ▁and ▁i trac ona zole ▁( ▁a ▁strong ▁p - gly co prote in ▁inhibi tor ▁) ▁in ▁healthy ▁volunteer s ▁ .
▁dog s ▁less ▁than ▁5 ▁kg ▁dog s ▁5 ▁to ▁10 ▁kg ▁dog s ▁10 ▁to ▁20 ▁kg ▁dog s ▁20 ▁to ▁40 ▁kg ▁dog s ▁40 ▁to ▁60 ▁kg
▁re bi f ▁ 8.8 ▁micro gram s ▁solution ▁for ▁inject ion ▁in ▁pre - fill ed ▁pen ▁inter fer on ▁beta -1 a
▁take ▁a erius ▁only ▁as ▁it ▁is ▁pre scribe d ▁for ▁you ▁ .
▁insulin ▁human ▁win thro p ▁in fus at ▁has ▁been ▁developed ▁for ▁use ▁in ▁hoe ch st ▁in fuso r ▁and ▁h - tron ▁ .
▁cd 4 ▁cell ▁count ▁mean ▁change ▁from ▁base line ▁( ▁x ▁106 ▁/ ▁l ▁) ▁b
▁oral ▁ex ogen ous ▁est radio l ▁is ▁ex tensi ve ly ▁metabol ized ▁ .
▁this ▁is ▁increased ▁to ▁one ▁tablet ▁once ▁a ▁day ▁( ▁1 x ▁10 ▁mg ▁) ▁in ▁the ▁second ▁week ▁and ▁to ▁1 ▁and ▁a ▁half ▁tablets ▁once ▁a ▁day ▁( ▁1 x ▁15 ▁mg ▁) ▁in ▁the ▁third ▁week ▁ .
▁if ▁serious ▁ble ed ing ▁occur s ▁that ▁is ▁not ▁controlla ble ▁with ▁pressure ▁ , ▁the ▁integr ilin ▁in fusion ▁should ▁be ▁stopped ▁immediately ▁and ▁any ▁un fraction ated ▁hep arin ▁that ▁is ▁given ▁con com i tant ly ▁ .
▁the ▁ pharma cok ine tics ▁of ▁ever ol imus ▁have ▁not ▁been ▁studie d ▁in ▁patients ▁young er ▁than ▁1 ▁year ▁of ▁age ▁ .
▁women ▁of ▁child be aring ▁potential ▁/ ▁contra ception ▁in ▁male ▁and ▁female s
▁if ▁a ▁dose ▁is ▁missed ▁and ▁a ▁monthly ▁interval ▁between ▁dos ing ▁is ▁exceed ed ▁then ▁immediate ▁administration ▁of ▁the ▁veterinar y ▁medicinal ▁product ▁and ▁resum p tion ▁of ▁monthly ▁dos ing ▁will ▁minimi se ▁the ▁opportunity ▁for ▁the ▁development ▁of ▁adult ▁heart worm s ▁ .
▁for ▁a ▁further ▁supply ▁ , ▁a ▁new ▁per scription ▁is ▁required ▁ .
▁she lf ▁life ▁of ▁the ▁veterinar y ▁medicinal ▁product ▁as ▁package d ▁for ▁sale ▁: ▁1 ▁year ▁ .
▁do ▁not ▁use ▁after ▁the ▁exp i ry ▁date ▁on ▁the ▁pack ▁ .
▁the ▁full ▁e par ▁for ▁cubi cin ▁can ▁be ▁found ▁on ▁the ▁agency ▁' s ▁website ▁: ▁ema . europa . eu ▁/ ▁find ▁medicine ▁/ ▁human ▁medicine s ▁/ ▁european ▁public ▁assessment ▁reports ▁ .
▁store ▁and ▁use ▁liquid ▁nit rogen ▁only ▁in ▁a ▁dry ▁and ▁well - ventil ated ▁place ▁ .
▁why ▁has ▁bo vili s ▁b tv 8 ▁been ▁approved ▁?
▁in ▁some ▁instance s ▁ , ▁the ▁reaction ▁re oc curr ed ▁when ▁tys abri ▁was ▁rein tro duce d ▁ .
▁i asi bon ▁contain s ▁less ▁than ▁1 ▁mm ol ▁so dium ▁( ▁23 ▁mg ▁) ▁per ▁dose ▁ , ▁i . e . ▁essential ly ▁" ▁so dium - free ▁ . ▁"
▁sign s ▁and ▁symptoms ▁of ▁a ▁severe ▁allergi c ▁reaction ▁could ▁include ▁:
▁patient ▁information ▁book let ▁/ ▁patient ▁alert ▁card
▁the ▁following ▁war nings ▁and ▁precau tions ▁related ▁to ▁topic al ▁op h thal mic ▁use ▁of ▁ phen yle ph rine ▁and ▁keto ro lac ▁should ▁be ▁considered ▁with ▁the ▁use ▁of ▁om id ria ▁:
▁in ▁patients ▁with ▁hetero zy go us ▁familia l ▁hyper ch olesterol emia ▁( ▁hef h ▁) ▁on ▁high ▁dose ▁stati n ▁ , ▁the ▁system ic ▁exposure ▁of ▁e volo cum ab ▁was ▁slightly ▁lower ▁than ▁in ▁subject s ▁on ▁low - to - moder ate ▁dose ▁stati n ▁( ▁the ▁ratio ▁of ▁au c last ▁0 . 74 ▁[ ▁90 ▁% ▁ci ▁0.2 9 ▁; ▁1.9 ▁] ▁) ▁ .
▁when ▁applied ▁top ically ▁ , ▁system ic ▁over dos e ▁with ▁imi qui mod ▁cream ▁is ▁un like ly ▁due ▁to ▁minimal ▁per cuta ne ous ▁ab sor p tion ▁ .
▁cau tion ▁should ▁be ▁exercise d ▁before ▁starting ▁treatment ▁and ▁close ▁sur ve illa nce ▁should ▁be ▁perform ed ▁throughout ▁the ▁treatment ▁period ▁in ▁all ▁patients ▁ , ▁especially ▁if ▁he pati c ▁injury ▁risk ▁factors ▁or ▁con com i tant ▁medicinal ▁products ▁associated ▁with ▁risk ▁of ▁he pati c ▁injury ▁are ▁present ▁ .
▁the ▁ef fica cy ▁and ▁safety ▁of ▁em pag lif lozi n ▁was ▁evaluat ed ▁in ▁a ▁double - blind ▁ , ▁place bo ▁control led ▁study ▁of ▁12 ▁weeks ▁du ration ▁in ▁patients ▁with ▁type ▁2 ▁diabetes ▁and ▁high ▁blood ▁pressure ▁on ▁different ▁anti dia be tic ▁and ▁up ▁to ▁2 ▁anti hy per tensi ve ▁ therapie s ▁ .
▁the ▁tablets ▁should ▁be ▁swa llow ed ▁with ▁some ▁water ▁or ▁other ▁non - al co ho lic ▁drink ▁ .
▁once ▁the ▁vi al ▁has ▁been ▁opened ▁ , ▁the ▁product ▁must ▁be ▁used ▁straight ▁away ▁ .
▁the ▁withdraw al ▁period ▁is ▁the ▁time ▁allowed ▁after ▁administration ▁of ▁the ▁medicine ▁and ▁before ▁the ▁animal ▁can ▁be ▁sla ught er ed ▁and ▁the ▁me at ▁used ▁for ▁human ▁consum p tion ▁ .
▁how ▁to ▁take ▁ex viera
▁ liver ▁disease ▁: ▁the ▁safety ▁and ▁ef fica cy ▁of ▁sa quina vir ▁/ ▁rito na vir ▁has ▁not ▁been ▁established ▁in ▁patients ▁with ▁significant ▁under ly ing ▁ liver ▁disorder s ▁ , ▁therefore ▁sa quina vir ▁/ ▁rito na vir ▁should ▁be ▁used ▁ca uti ously ▁in ▁this ▁patient ▁population ▁ .
▁→ ▁don ▁' t ▁drive ▁or ▁use ▁machines ▁if ▁you ▁' re ▁feeling ▁un well ▁ .
▁in ▁some ▁patients ▁with ▁advanced ▁hi v ▁infection ▁( ▁aid s ▁) ▁and ▁a ▁history ▁of ▁opportun istic ▁infection ▁ , ▁sign s ▁and ▁symptoms ▁of ▁ inflammation ▁from ▁previous ▁infection s ▁may ▁occur ▁soon ▁after ▁anti - hi v ▁treatment ▁is ▁started ▁ .
▁all ▁patients ▁had ▁potential ▁contribu ting ▁factors ▁for ▁the ▁development ▁of ▁m ds ▁/ ▁am l ▁; ▁the ▁majority ▁of ▁cases ▁were ▁in ▁g br ca ▁mutation ▁car rier s ▁and ▁some ▁of ▁the ▁patients ▁had ▁a ▁history ▁of ▁previous ▁cancer ▁or ▁of ▁bone ▁mar row ▁dys plas ia ▁ .
▁approximately ▁70 ▁% ▁of ▁the ▁oral ly ▁ad minister ed ▁stavu dine ▁dose ▁was ▁ex cre ted ▁as ▁an ▁un change d ▁drug ▁in ▁urin e ▁ .
▁however ▁ , ▁data ▁demonstrat ing ▁the ▁complete ▁rever si bility ▁of ▁clinic al ▁effects ▁( ▁reduce d ▁testi cular ▁size ▁ , ▁reduce d ▁e ja c ulation ▁volume ▁ , ▁reduce d ▁sperm ▁count ▁and ▁reduce d ▁libido ▁) ▁including ▁fertil ity ▁after ▁6 ▁months ▁ , ▁or ▁repeat ed ▁implant ation ▁ , ▁are ▁limited ▁ .
▁the ▁degree ▁and ▁fre que ncy ▁of ▁hyper gly ca emia ▁observe d ▁in ▁the ▁two ▁pivo tal ▁studies ▁in ▁a cro mega ly ▁patients ▁were ▁higher ▁with ▁signifo r ▁intra mus cular ▁use ▁than ▁with ▁active ▁control ▁( ▁oc tre oti de ▁intra mus cular ▁use ▁or ▁lan re oti de ▁deep ▁sub cuta ne ous ▁inject ion ▁) ▁ .
▁you ▁will ▁be ▁told ▁when ▁your ▁child ▁should ▁come ▁back ▁for ▁the ▁next ▁inject ion
▁table ▁7 ▁: ▁ef fica cy ▁outcome s ▁( ▁pa e dia tric ▁patients ▁6 ▁years ▁to ▁less ▁than ▁18 ▁years ▁of ▁age ▁) ▁at ▁week ▁48 ▁( ▁study ▁ai 42 4- 020 ▁)
▁the ▁distribution ▁volume ▁of ▁fonda par in ux ▁is ▁limited ▁( ▁7 -11 ▁litre s ▁) ▁ .
▁he xa cima ▁or ▁an ▁appropriate ▁combination ▁of ▁other ▁vaccin es ▁can ▁be ▁used ▁for ▁the ▁boost er ▁dose ▁ .
▁a ▁daily ▁pain ▁journal ▁to ▁record ▁daily ▁pain ▁levels ▁ , ▁providing ▁patients ▁and ▁physician s ▁with ▁a ▁follow - up ▁tool ▁for ▁daily ▁symptoms ▁and ▁treatment ▁ef fica cy ▁ .
▁almost ▁ 7,000 ▁patients ▁received ▁glu stin ▁in ▁all ▁of ▁the ▁studies ▁combine d ▁ .
▁the ▁recommended ▁dose ▁of ▁zin bry ta ▁is ▁150 ▁mg ▁inject ed ▁sub cuta ne ously ▁once ▁a ▁month ▁ .
▁when ▁po ul vac ▁e . ▁ coli ▁is ▁given ▁to ▁a ▁chicken ▁or ▁tur key ▁ , ▁the ▁animal ▁' s ▁immun e ▁system ▁recog nis es ▁the ▁parts ▁of ▁the ▁bacteri um ▁contain ed ▁in ▁the ▁vaccin e ▁as ▁' ▁foreign ▁' ▁and ▁makes ▁anti bo dies ▁against ▁it ▁ .
▁common ▁side ▁effects ▁( ▁may ▁affect ▁up ▁to ▁1 ▁in ▁10 ▁people ▁) ▁are ▁:
▁co - administration ▁of ▁vi read ▁and ▁di dano sine ▁is ▁not ▁recommended ▁as ▁this ▁may ▁result ▁in ▁an ▁increased ▁risk ▁of ▁advers e ▁reaction s ▁( ▁see ▁section ▁4.5 ▁) ▁ .
▁this ▁treatment ▁combination ▁has ▁not ▁demonstrat ed ▁increased ▁clinic al ▁benefit ▁ .
▁ph eno thi az ines ▁ , ▁but y ro phen one ▁or ▁clo za pine ▁( ▁used ▁to ▁treat ▁mental ▁illness ▁) ▁ .
▁sexual ▁dys function ▁ , ▁decrease d ▁libido ▁ .
▁do ▁not ▁shake ▁the ▁pen ▁hard ▁ .
▁content s ▁of ▁the ▁pack ▁and ▁other ▁information ▁what ▁ab se a med ▁contain s
▁patients ▁should ▁be ▁instru cted ▁to ▁se ek ▁medical ▁advice ▁if ▁sign s ▁/ ▁symptoms ▁suggest ive ▁of ▁a ▁tubercul osis ▁infection ▁( ▁e . g . ▁ , ▁persist ent ▁co ugh ▁ , ▁was ting ▁/ ▁weight ▁loss ▁ , ▁low ▁grade ▁fe ver ▁ , ▁list less ness ▁) ▁occur ▁during ▁or ▁after ▁ therapy ▁with ▁hum ira ▁ .
▁she lf - life ▁after ▁first ▁opening ▁the ▁container ▁: ▁6 ▁months ▁ .
▁manufacturing ▁author isation ▁holder ▁responsible ▁for ▁bat ch ▁release
▁each ▁tablet ▁contain s ▁15 ▁mg ▁pi og lita zone ▁( ▁as ▁hydro ch lor ide ▁) ▁ .
▁however ▁ , ▁con com i tant ▁administration ▁of ▁500 ▁mg ▁of ▁asa ▁twice ▁a ▁day ▁for ▁one ▁day ▁did ▁not ▁significantly ▁increase ▁the ▁prolong ation ▁of ▁ble ed ing ▁time ▁induc ed ▁by ▁clo pido gre l ▁in take ▁ .
▁this ▁le a flet ▁was ▁last ▁revi sed ▁in
▁swa llow ▁the ▁capsule s ▁whole ▁ , ▁prefer ably ▁with ▁water ▁ .
▁hold ▁the ▁vi al ▁adapter ▁in ▁its ▁protect ive ▁cap ▁and ▁place ▁it ▁ square ly ▁over ▁the ▁top ▁of ▁the ▁vi al ▁ .
▁mean ▁number ▁of ▁re lapse s ▁within ▁the ▁past ▁3 ▁years
▁hep s era ▁with ▁food ▁and ▁drink
▁the ▁advantage s ▁of ▁treatment ▁should ▁be ▁we ighed ▁against ▁the ▁possible ▁risk ▁for ▁the ▁fo etus ▁in ▁every ▁individual ▁case ▁ .
▁dis continu ation ▁of ▁nec itum um ab ▁in ▁patients ▁who ▁experience ▁a ▁v te ▁or ▁a te ▁should ▁be ▁considered ▁after ▁a ▁thorough ▁benefit ▁risk ▁assessment ▁for ▁the ▁individual ▁patient ▁ .
▁in ▁lipo sar com a ▁the ▁ef fica cy ▁of ▁e ribu lin ▁is ▁support ed ▁by ▁the ▁pivo tal ▁phase ▁3 ▁sar com a ▁study ▁( ▁study ▁30 9 ▁) ▁ .
▁increased ▁weight ▁ , ▁decrease d ▁appetit e ▁ , ▁increased ▁appetit e
▁you ▁or ▁your ▁partner ▁must ▁use ▁an ▁effective ▁method ▁of ▁contra ception ▁during ▁treatment ▁ .
▁chronic ▁infection ▁of ▁the ▁nos e ▁ , ▁fun gal ▁infection s ▁ , ▁various ▁infection s ▁( ▁of ▁the ▁nos e ▁and ▁ thro at ▁ , ▁ki dne y ▁or ▁blad der ▁) ▁ , ▁steril e ▁ inflammation ▁of ▁the ▁layer s ▁li ning ▁the ▁brain ▁ , ▁serious ▁allergi c ▁reaction s ▁ , ▁disorder ▁of ▁the ▁thy roid ▁ , ▁excessive ▁response ▁to ▁stimul i ▁ , ▁memory ▁im pair ment ▁ , ▁difficult y ▁in ▁speaking ▁ , ▁unusual ▁taste ▁in ▁the ▁mouth ▁ , ▁im pair ed ▁balance ▁ , ▁in volu ntar y ▁trem bling ▁ , ▁eye ▁pain ▁or ▁swe lling ▁ , ▁verti go ▁ , ▁fluid ▁in ▁middle ▁ear ▁ , ▁per i pher al ▁cold ness ▁ , ▁ve in ▁ inflammation ▁ , ▁ear ▁and ▁ thro at ▁swe lling ▁ , ▁abdominal ▁dis tension ▁ , ▁rapid ▁swe lling ▁of ▁the ▁skin ▁ , ▁a cute ▁ inflammation ▁of ▁the ▁skin ▁ , ▁cold ▁sweat ▁ , ▁increased ▁reaction ▁of ▁the ▁skin ▁to ▁sun light ▁ , ▁excessive ▁sweat ing ▁also ▁during ▁sleep ▁ , ▁muscle ▁t witch ing ▁ , ▁excess ▁of ▁se rum ▁protein ▁in ▁the ▁urin e ▁ , ▁che st ▁tight ness ▁ , ▁feeling ▁hot ▁ , ▁bur ning ▁sensation ▁ , ▁swe lling ▁ , ▁increased ▁rate ▁of ▁breath ing ▁ , ▁changes ▁to ▁blood ▁test ▁results ▁ .
▁follow ▁close ly ▁the ▁instructions ▁for ▁dos age ▁ , ▁monitoring ▁( ▁blood ▁and ▁urin e ▁tests ▁) ▁ , ▁die t ▁and ▁physical ▁activity ▁( ▁physical ▁work ▁and ▁exercise ▁) ▁as ▁discuss ed ▁with ▁your ▁doctor ▁ .
▁ke tek ▁should ▁not ▁be ▁used ▁during ▁and ▁2 ▁weeks ▁after ▁treatment ▁with ▁cy p 3 a 4 ▁induc ers ▁( ▁such ▁as ▁rif ampi cin ▁ , ▁ phen y to in ▁ , ▁carb amaz e pine ▁ , ▁ phen oba rbi tal ▁ , ▁st ▁joh n ▁' s ▁ wort ▁) ▁ .
▁patients ▁could ▁continue ▁cri zo tin ib ▁treatment ▁beyond ▁the ▁time ▁of ▁response ▁evaluation ▁criteri a ▁in ▁solid ▁tu mo urs ▁( ▁reci st ▁) ▁- de fin ed ▁disease ▁progression ▁at ▁the ▁discret ion ▁of ▁the ▁investiga tor ▁if ▁the ▁patient ▁was ▁still ▁experi en cing ▁clinic al ▁benefit ▁ .
▁cas po fung in ▁accord ▁should ▁be ▁used ▁with ▁cau tion ▁in ▁children ▁below ▁12 ▁months ▁of ▁age ▁ , ▁because ▁it ▁has ▁not ▁been ▁studie d ▁ sufficient ly ▁in ▁this ▁age ▁group ▁ .
▁application ▁site ▁pain ▁ , ▁application ▁site ▁er y thema
▁in ▁addition ▁ , ▁decrease d ▁number ▁of ▁implant ation ▁sites ▁per ▁litt er ▁and ▁a ▁prolong ation ▁of ▁ge station ▁were ▁seen ▁when ▁pup s ▁were ▁mat ed ▁after ▁reach ing ▁matur ity ▁ .
▁therefore ▁ , ▁the ▁ch mp ▁decided ▁that ▁fy com pa ▁' s ▁benefits ▁are ▁greater ▁than ▁its ▁risk s ▁and ▁recommended ▁that ▁it ▁be ▁given ▁marketing ▁author isation ▁ .
▁store ▁in ▁a ▁refrigera tor ▁( ▁2 ▁ ̊ ▁c ▁- ▁8 ▁ ̊ ▁c ▁) ▁ .
▁in ▁summary ▁ , ▁the ▁combination ▁of ▁er lo tin ib ▁with ▁proto n ▁pump ▁inhibi tors ▁should ▁be ▁avoid ed ▁ .
▁mi card is ▁must ▁not ▁be ▁used ▁in ▁women ▁who ▁are ▁more ▁than ▁three ▁months ▁pregnant ▁ .
▁in ▁cat s ▁ , ▁no ▁ pharma c ological ▁effects ▁on ▁respira tion ▁and ▁cardiovascular ▁function ▁were ▁observe d ▁up ▁to ▁a ▁cum ul ative ▁intra ven ous ▁dose ▁of ▁10 ▁mg ▁/ ▁kg ▁ .
▁what ▁ema dine ▁looks ▁like ▁and ▁the ▁content s ▁of ▁the ▁pack
▁in vega ▁should ▁be ▁used ▁with ▁cau tion ▁in ▁el der ly ▁patients ▁with ▁dem entia ▁with ▁risk ▁factors ▁for ▁stroke ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁exposure ▁to ▁dar una vir ▁was ▁higher ▁in ▁hi v -1 ▁infect ed ▁patients ▁than ▁in ▁healthy ▁subject s ▁ .
▁patients ▁should ▁be ▁evaluat ed ▁for ▁tubercul osis ▁and ▁test ed ▁for ▁laten t ▁infection ▁prior ▁to ▁initiat ing ▁bela ta cept ▁ .
▁clinic al ▁data ▁suggest ▁that ▁no ▁change ▁in ▁starting ▁dose ▁is ▁required ▁in ▁patients ▁with ▁mild ▁renal ▁im pair ment ▁ .
▁least ▁24 ▁to ▁48 ▁hours ▁before ▁the ▁che mo therapy ▁and ▁radio therapy ▁start s ▁ .
▁tras tuz um ab ▁em tan sine ▁has ▁not ▁been ▁studie d ▁in ▁patients ▁with ▁se rum ▁trans ami nas es ▁> ▁2.5 ▁ul n ▁or ▁total ▁bilir u bin ▁> ▁1.5 ▁ul n ▁prior ▁to ▁initiat ion ▁of ▁treatment ▁ .
▁what ▁you ▁need ▁to ▁know ▁before ▁you ▁take ▁sil den a fil ▁teva ▁do ▁not ▁take ▁sil den a fil ▁teva
▁this ▁should ▁take ▁about ▁5 ▁seconds ▁ .
▁immun e ▁response ▁in ▁patients ▁with ▁end ogen ous ▁or ▁i at rogen ic ▁immun os up pression ▁may ▁be ▁in sufficient ▁ .
▁some ▁patients ▁may ▁develop ▁anti bo dies ▁( ▁made ▁by ▁your ▁body ▁to ▁fight ▁a ▁foreign ▁protein ▁) ▁to ▁induc tos ▁ .
▁1 ▁fre que ncy ▁category ▁deri ved ▁from ▁laborator y ▁values ▁collect ed ▁as ▁part ▁of ▁routine ▁laborator y ▁monitoring ▁in ▁clinic al ▁trial s
▁am lo di pine ▁/ ▁val sar tan ▁my lan ▁10 ▁mg ▁/ ▁160 ▁mg ▁film - co ated ▁tablets ▁each ▁tablet ▁contain s ▁10 ▁mg ▁am lo di pine ▁and ▁160 ▁mg ▁val sar tan ▁ .
▁what ▁you ▁need ▁to ▁know ▁before ▁you ▁use ▁doce ta xel ▁accord
▁some ▁patients ▁with ▁more ▁extend ed ▁dos ing ▁interval s ▁( ▁greater ▁than ▁once ▁week ly ▁) ▁of ▁e po etin ▁may ▁not ▁maintain ▁adequat e ▁ha emo glob in ▁levels ▁( ▁see ▁section ▁5.1 ▁) ▁and ▁may ▁require ▁an ▁increase ▁in ▁e po etin ▁dose ▁ .
▁in ▁control led ▁clinic al ▁trial s ▁ , ▁23. 8 ▁% ▁of ▁patients ▁treated ▁with ▁proven ge ▁required ▁op io ids ▁( ▁a ▁single ▁dose ▁of ▁pe thi dine ▁) ▁on ▁the ▁day ▁of ▁in fusion ▁for ▁in fusion ▁reaction s ▁( ▁see ▁section s ▁4.4 ▁and ▁4. 8 ▁) ▁ .
▁if ▁you ▁are ▁un able ▁to ▁take ▁daily ▁calci um ▁supplement s ▁ .
▁adults ▁a ged ▁50 ▁years ▁and ▁older
▁pseudo mona s ▁a eru gin osa ▁is ▁a ▁very ▁common ▁bacteri um ▁that ▁infect s ▁nearly ▁all ▁cyst ic ▁fibro sis ▁patients ▁at ▁some ▁time ▁during ▁their ▁lives ▁ .
▁each ▁capsule ▁of ▁du lo xe tine ▁li lly ▁contain s ▁pelle ts ▁of ▁du lo xe tine ▁hydro ch lor ide ▁with ▁a ▁cover ing ▁to ▁protect ▁them ▁from ▁stomach ▁acid ▁ .
▁sign s ▁may ▁include ▁che st ▁pain ▁or ▁he avi ness ▁in ▁the ▁che st ▁ , ▁sud den ▁nu mb ▁or ▁we ak ▁feeling ▁in ▁the ▁face ▁ , ▁arms ▁ , ▁or ▁leg s ▁ .
▁resol or ▁can ▁be ▁taken ▁with ▁or ▁without ▁food ▁and ▁drink s ▁ , ▁at ▁any ▁time ▁of ▁the ▁day ▁ .
▁no ▁advers e ▁effects ▁on ▁female ▁reproduc tion ▁and ▁post - na tal ▁development ▁in ▁rat s ▁were ▁seen ▁at ▁system ic ▁exposure s ▁up ▁to ▁2 , 300 ▁times ▁human ▁exposure s ▁at ▁the ▁maximum ▁recommended ▁intra the cal ▁dose ▁ .
▁however ▁ , ▁the ▁study ▁had ▁to ▁be ▁stopped ▁early ▁because ▁of ▁side ▁effects ▁( ▁ki dne y ▁and ▁lung ▁problems ▁) ▁ .
▁the ▁first ▁dose ▁of ▁your ▁treatment ▁is ▁given ▁over ▁90 ▁minutes ▁and ▁you ▁will ▁be ▁observe d ▁by ▁a ▁health ▁professional ▁while ▁it ▁is ▁being ▁given ▁in ▁case ▁you ▁have ▁any ▁side ▁effects ▁ .
▁common ▁sign s ▁of ▁an ▁allergi c ▁reaction ▁include ▁skin ▁ rash ▁and ▁hi ves ▁( ▁these ▁may ▁affect ▁up ▁to ▁1 ▁in ▁100 ▁people ▁) ▁ .
▁an ▁over view ▁for ▁all ▁spontane ous ▁advers e ▁reaction s ▁by ▁soc ▁ , ▁high ▁level ▁term ▁( ▁hl t ▁) ▁and ▁prefer red ▁term ▁( ▁pt ▁) ▁ , ▁strat ified ▁according ▁to ▁type ▁of ▁report ▁( ▁med ically ▁confirm ed ▁or ▁non - med ically ▁confirm ed ▁) ▁and ▁including ▁the ▁number ▁of ▁fatal ▁reports ▁ , ▁for ▁the ▁period ▁covered ▁by ▁the ▁report ▁and ▁cum ul ative ly ▁ .
▁each ▁ml ▁contain s ▁: ▁melo xi cam ▁1.5 ▁mg
▁s wir l ▁gent ly ▁before ▁use ▁ .
▁ara - c ▁: ▁cy tos ine ▁arab ino side ▁; ▁c p ▁: ▁ cyclo phos pha mi de ▁; ▁de x ▁: ▁de xa met has one ▁; ▁m t x ▁: ▁met ho tre xa te ▁; ▁6- ▁mp ▁: ▁6- mer cap to puri ne ▁v m 26 ▁: ▁te ni po side ▁; ▁v cr ▁: ▁vin cris tine ▁; ▁i da ▁: ▁i dar ubi cine ▁; ▁i . v . ▁: ▁intra ven ous
▁< ▁1 ▁/ ▁1,000 ▁) ▁; ▁and ▁very ▁rare ▁( ▁< ▁1 ▁/ ▁10,000 ▁) ▁ , ▁not ▁known ▁( ▁cannot ▁be ▁estima ted ▁from ▁the ▁available ▁data ▁) ▁ .
▁remove ▁the ▁need le ▁ , ▁gent ly ▁s wir l ▁the ▁vi al ▁to ▁mix ▁the ▁content s ▁ , ▁and ▁then ▁let ▁it ▁stand ▁at ▁room ▁temperature ▁for ▁at ▁least ▁15 ▁minutes ▁ .
▁if ▁you ▁are ▁allergi c ▁to ▁temo por fin ▁or ▁any ▁of ▁the ▁other ▁ingredients ▁of ▁this ▁medicine ▁( ▁listed ▁in ▁section ▁6 ▁) ▁ ,
▁the ▁training ▁materials ▁for ▁surge ons ▁will ▁include ▁information ▁on ▁how ▁to ▁collect ▁the ▁carti lage ▁bio psy ▁from ▁patients ▁ , ▁perform ▁the ▁operation ▁and ▁follow ▁patients ▁up ▁ .
▁it ▁must ▁not ▁be ▁used ▁inter change ably ▁with ▁other ▁formula tions ▁of ▁do xor ubi cin ▁hydro ch lor ide ▁ .
▁other ▁information ▁about ▁sci nti mun
▁ef fica cy ▁results ▁for ▁ge mini ▁i i ▁at ▁week ▁52
▁patients ▁with ▁a ▁history ▁of ▁severe ▁ rash ▁associated ▁with ▁tha li domi de ▁treatment ▁should ▁not ▁receive ▁le nali domi de ▁ .
▁va scul itis ▁( ▁predomina tel ▁y ▁cu tane ous ▁) ▁ , ▁leuk o cy to c last ▁ ic ▁va scul itis
▁so dium ▁star ch ▁gly cola te ▁( ▁type ▁a ▁) ▁magnesium ▁stea rate
▁in ▁female ▁rat s ▁given ▁ex en ati de ▁for ▁2 ▁years ▁ , ▁an ▁increased ▁incide nce ▁of ▁benign ▁thy roid ▁c - cell ▁ade noma s ▁was ▁observe d ▁at ▁the ▁highest ▁dose ▁ , ▁250 ▁m c g ▁/ ▁kg ▁/ ▁day ▁ , ▁a ▁dose ▁that ▁produced ▁an ▁ex en ati de ▁plasma ▁exposure ▁130 - fold ▁the ▁human ▁clinic al ▁exposure ▁ .
▁if ▁you ▁notice ▁any ▁of ▁these ▁symptoms ▁please ▁inform ▁your ▁doctor ▁ .
▁use ▁need les ▁only ▁once ▁ .
▁uc b ▁ pharma ▁s . a . ▁allé e ▁de ▁la ▁recherche ▁60 ▁ , ▁b -10 70 ▁brus sels ▁ , ▁belgi um ▁ .
▁please ▁check ▁with ▁your ▁doctor ▁and ▁follow ▁the ▁recommended ▁du ration ▁of ▁treatment ▁ .
▁tel mis ar tan ▁teva ▁ pharma ▁80 ▁mg ▁tablets
▁very ▁common ▁: ▁weight ▁gain 13 ▁ , ▁eleva ted ▁tri gly ceri de ▁levels ▁14 ▁ , ▁increased ▁appetit e ▁ .
▁each ▁dose ▁contain s ▁10 ▁micro gram s ▁ex en ati de ▁ .
▁these ▁changes ▁all ▁rever sed ▁after ▁dis continu ation ▁of ▁treatment ▁ .
▁an ▁increase ▁in ▁heart ▁rate ▁was ▁observe d ▁in ▁rat s ▁ , ▁rabbi ts ▁ , ▁dog s ▁and ▁mon key s ▁ .
▁the ▁risk s ▁and ▁benefits ▁of ▁im lyg ic ▁should ▁be ▁considered ▁before ▁continu ing ▁treatment ▁if ▁persist ent ▁infection ▁or ▁de lay ed ▁hea ling ▁develop s ▁ .
▁she lf - life ▁after ▁first ▁opening ▁of ▁the ▁container ▁: ▁4 ▁weeks ▁ .
▁visit ▁5 ▁- ▁blood ▁cell ▁collection ▁( ▁leuk ap here sis ▁) ▁visit ▁6 ▁- ▁proven ge ▁in fusion
▁at ▁treatment ▁initiat ion ▁with ▁feb ux osta t ▁fl are ▁pro phy la xis ▁for ▁at ▁least ▁6 ▁months ▁with ▁an ▁n said ▁or ▁col chi cine ▁is ▁recommended ▁( ▁see ▁section ▁4.2 ▁) ▁ .
▁ra lo xi fen e ▁is ▁indicate d ▁for ▁the ▁treatment ▁and ▁pre vention ▁of ▁osteo por osis ▁in ▁post meno paus al ▁women ▁ .
▁cro h n ▁' s ▁disease ▁ , ▁ul cer ative ▁col itis ▁ , ▁and ▁worse ning ▁of ▁depression ▁have ▁been ▁associated ▁with ▁co c ▁use ▁ .
▁in ▁long - term ▁clinic al ▁studies ▁with ▁roti go tine ▁ , ▁the ▁majority ▁of ▁ augmentation ▁episode s ▁were ▁seen ▁in ▁the ▁first ▁and ▁second ▁years ▁of ▁treatment ▁ .
▁ne lara bine ▁is ▁for ▁intra ven ous ▁use ▁only ▁and ▁must ▁only ▁be ▁ad minister ed ▁under ▁the ▁super vision ▁of ▁a ▁physician ▁experienced ▁in ▁the ▁use ▁of ▁cy to toxic ▁agents ▁ .
▁clean ▁and ▁dis infect ▁the ▁skin ▁where ▁the ▁inject ion ▁is ▁to ▁be ▁made ▁with ▁a ▁clean sing ▁s wab ▁ .
▁20 ▁mg ▁: ▁white ▁to ▁almost ▁white ▁ , ▁round ▁tablets
▁however ▁ , ▁you ▁and ▁your ▁doctor ▁may ▁decide ▁that ▁you ▁may ▁inject ▁ste lara ▁yourself ▁ .
▁media n ▁time ▁to ▁tum our
▁if ▁you ▁receive ▁more ▁ty ga cil ▁than ▁you ▁should
▁if ▁you ▁get ▁any ▁side ▁effects ▁talk ▁to ▁your ▁doctor ▁ , ▁ pharma ci st ▁or ▁nurse ▁ .
▁limited ▁data ▁from ▁clinic al ▁trial s ▁suggest ▁that ▁d ka ▁occur s ▁with ▁common ▁fre que ncy ▁when ▁patients ▁with ▁type ▁1 ▁diabetes ▁are ▁treated ▁with ▁sg lt 2 ▁inhibi tors ▁ .
▁re duction ▁of ▁to cili zum ab ▁dose ▁due ▁to ▁laborator y ▁ab normal ities ▁has ▁not ▁been ▁studie d ▁in ▁s jia ▁patients ▁ .
▁use ▁a ▁new ▁package ▁instead ▁ .
▁use ▁of ▁optim ark ▁is ▁not ▁recommended ▁in ▁children ▁less ▁than ▁2 ▁years ▁of ▁age ▁because ▁the ▁safety ▁ , ▁ef fica cy ▁ , ▁and ▁impact ▁of ▁ immat ure ▁ki dne y ▁function ▁have ▁not ▁been ▁studie d ▁in ▁this ▁age ▁group ▁ .
▁this ▁will ▁be ▁monitor ed ▁by ▁blood ▁sample s ▁and ▁if ▁required ▁the ▁dose ▁of ▁in hal ed ▁ni tric ▁oxid e ▁must ▁be ▁reduce d ▁ .
▁the ▁medicine ▁can ▁only ▁be ▁obtain ed ▁with ▁a ▁pre scription ▁and ▁treatment ▁should ▁be ▁started ▁and ▁super vis ed ▁by ▁a ▁doctor ▁experienced ▁in ▁treat ing ▁cancer ▁and ▁blood ▁disorder s ▁ .
▁4 ▁chemin ▁du ▁cal quet ▁ , ▁3 1000 ▁to ul ouse ▁ , ▁franc e
▁for ▁in fusion s ▁ , ▁fil gra s tim ▁should ▁be ▁dilu ted ▁in ▁20 ▁ml ▁of ▁50 ▁mg ▁/ ▁ml ▁( ▁5 ▁% ▁) ▁gluco se ▁solution ▁for ▁in fusion ▁( ▁see ▁section ▁ 6.6 ▁) ▁ .
▁a bra xan e ▁is ▁suppli ed ▁as ▁a ▁steril e ▁l yo phi lised ▁powder ▁for ▁recon stitu tion ▁before ▁use ▁ .
▁common ▁( ▁these ▁may ▁occur ▁with ▁up ▁to ▁1 ▁in ▁10 ▁dos es ▁of ▁the ▁vaccin e ▁) ▁:
▁what ▁is ▁the ▁risk ▁associated ▁with ▁versi can ▁plus ▁pi ▁?
▁ago mela tine ▁failed ▁to ▁differenti ate ▁from ▁place bo ▁in ▁two ▁trial s ▁where ▁the ▁active ▁control ▁ , ▁paro xe tine ▁or ▁flu o xe tine ▁ , ▁showed ▁as say ▁ sensitiv ity ▁ .
▁the ▁safety ▁and ▁ef fica cy ▁of ▁ne ul asta ▁have ▁not ▁been ▁evaluat ed ▁in ▁patients ▁receiving ▁che mo therapy ▁associated ▁with ▁de lay ed ▁mye los up pression ▁e . g . ▁ , ▁nit roso ure as ▁ .
▁each ▁tablet ▁contain s ▁5 ▁/ ▁10 ▁/ ▁15 ▁/ ▁20 ▁mg ▁of me man tine ▁hydro ch lor ide ▁equivalent ▁to ▁4. 15 ▁/ ▁8. 31 ▁/ ▁12. 46 ▁/ ▁16. 62 ▁mg ▁me man tine ▁ .
▁ liver pool ▁l 24 ▁9 j w ▁unit ed ▁king dom
▁un com mon ▁( ▁ ≥ ▁1 ▁/ ▁1000 ▁to
▁ toxic ▁death s ▁occur red ▁in ▁1 ▁patient ▁in ▁the ▁at ▁arm ▁( ▁con ges tive ▁heart ▁failure ▁) ▁and ▁in ▁4 ▁patients ▁in ▁the ▁ac ▁arm ▁( ▁1 ▁due ▁to ▁se ptic ▁shock ▁and ▁3 ▁due ▁to ▁con ges tive ▁heart ▁failure ▁) ▁ .
▁therefore ▁ , ▁the ▁ch mp ▁' s ▁view ▁was ▁that ▁ , ▁as ▁for ▁abil ify ▁ , ▁the ▁benefit ▁out we igh s ▁the ▁identified ▁risk ▁ .
▁the ▁european ▁commission ▁gran ted ▁a ▁marketing ▁author isation ▁valid ▁throughout ▁the ▁european ▁union ▁ , ▁for ▁pana cur ▁aqua sol ▁on ▁09 ▁/ ▁12 ▁/ ▁2011 ▁ .
▁h ba 1 c ▁( ▁% ▁) ▁at ▁week ▁24 1
▁treatment ▁of ▁adults ▁and ▁children ▁with ▁certain ▁kind s ▁of ▁blood ▁cancer ▁( ▁such ▁as ▁mye loma ▁or ▁chronic ▁lymph o cy tic ▁leuk a emia ▁) ▁which ▁lead ▁to ▁severe ly ▁low ▁immun o glob ulin ▁levels ▁in ▁the ▁blood ▁and ▁cause ▁re current ▁infection s ▁ .
▁the ▁non - tera to ge nic ▁dose ▁in ▁rat s ▁was ▁4.4 ▁times ▁ , ▁on ▁an ▁au c ▁basis ▁ , ▁the ▁maximum ▁dose ▁for ▁seconda ry ▁hp t ▁ .
▁read ▁all ▁of ▁this ▁le a flet ▁carefully ▁ , ▁including ▁the ▁instructions ▁for ▁use ▁of ▁insulin ▁human ▁win thro p ▁com b ▁15 ▁solo star ▁ , ▁pre - fill ed ▁pen ▁ , ▁before ▁you ▁start ▁using ▁this ▁medicine ▁because ▁it ▁contain s ▁important ▁information ▁for ▁you ▁ .
▁odds ▁ratio ▁( ▁or ▁) ▁( ▁95 ▁% ▁ci ▁)
▁to cer an ib ▁select ive ly ▁inhibi ts ▁the ▁ty ros ine ▁kina se ▁activity ▁of ▁several ▁members ▁of ▁the ▁split ▁kina se ▁receptor ▁ty ros ine ▁kina se ▁( ▁ rt k ▁) ▁family ▁some ▁of ▁which ▁are ▁implica ted ▁in ▁tum our ▁growth ▁ , ▁path ologic ▁ang io gene sis ▁ , ▁and ▁meta static ▁progression ▁of ▁cancer ▁ .
▁kar ve a ▁300 ▁mg ▁film - co ated ▁tablets ▁are ▁suppli ed ▁in ▁bli ster ▁pack s ▁of ▁14 ▁ , ▁28 ▁ , ▁30 ▁ , ▁56 ▁ , ▁84 ▁ , ▁90 ▁or ▁98 ▁film - ▁co ated ▁tablets ▁ .
▁if ▁such ▁effects ▁occur ▁ , ▁a ▁was hout ▁( ▁see ▁below ▁) ▁to ▁reduce ▁plasma ▁levels ▁of ▁a 77 17 26 ▁should ▁be ▁considered ▁ .
▁at ▁24 ▁weeks ▁ , ▁16 ▁of ▁23 ▁( ▁69 ▁% ▁) ▁adolescents ▁( ▁12 ▁to ▁17 ▁years ▁of ▁age ▁) ▁treated ▁with ▁dolu te grav ir ▁once ▁daily ▁( ▁35 ▁mg ▁n ▁= ▁4 ▁; ▁50 ▁mg ▁n ▁= ▁19 ▁) ▁plus ▁obr ▁achieve d ▁viral ▁load ▁less ▁than ▁50 ▁copie s ▁/ ▁ml ▁ .
▁tra cle er ▁with ▁food ▁and ▁drink
▁even ▁more ▁rare ly ▁ , ▁ liver ▁tu mo urs ▁which ▁are ▁cancer ▁have ▁been ▁found ▁ .
▁brin zola mi de ▁was ▁ter ato ge nic ▁in ▁rat s ▁ , ▁but ▁not ▁rabbi ts ▁ , ▁following ▁system ic ▁administration ▁ .
▁the ▁full ▁e par ▁and ▁risk ▁management ▁plan ▁summary ▁for ▁vi mizi m ▁can ▁be ▁found ▁on ▁the ▁agency ▁' s ▁website ▁: ▁ema . europa . eu ▁/ ▁find ▁medicine ▁/ ▁human ▁medicine s ▁/ ▁european ▁public ▁assessment ▁reports ▁ .
▁the ▁active ▁substance ▁in ▁ne xa var ▁ , ▁so raf en ib ▁ , ▁is ▁a ▁protein ▁kina se ▁inhibi tor ▁ .
▁192 ▁patients ▁were ▁treated ▁ .
▁tel mis ar tan ▁is ▁large ly ▁ bound ▁to ▁plasma ▁protein ▁( ▁> ▁9 9.5 ▁% ▁) ▁ , ▁main ly ▁album in ▁and ▁al pha -1 ▁acid ▁gly co prote in ▁ .
▁patients ▁were ▁random ised ▁to ▁either ▁ac la sta ▁5 ▁mg ▁single ▁in fusion ▁or ▁to ▁oral ▁ris ed rona te ▁5 ▁mg ▁daily ▁for ▁one ▁year ▁ .
▁tac rol imus ▁au ct ▁↑ ▁221 ▁%
▁parti al ▁or ▁total ▁loss ▁of ▁vision
▁circulation ▁problems ▁such ▁as ▁low ▁or ▁high ▁blood ▁pressure ▁ ,
▁if ▁you ▁have ▁severe ▁ liver ▁problems ▁( ▁child ▁pu gh ▁c ▁) ▁ , ▁do ▁not ▁take ▁a dem pas ▁ .
▁can ▁be ▁used ▁during ▁pre gna ncy ▁and ▁lac tation ▁in ▁co ws
▁note ▁: ▁do ▁not ▁use ▁any ▁areas ▁in ▁which ▁you ▁feel ▁ lump s ▁ , ▁firm ▁kn ots ▁ , ▁or ▁pain ▁; ▁talk ▁to ▁your ▁doctor ▁or ▁health care ▁professional ▁about ▁anything ▁you ▁find ▁ .
▁ca 2 250 25 ▁: ▁this ▁random ised ▁study ▁in ▁patients ▁with ▁meta static ▁colore c tal ▁cancer ▁who ▁had ▁received ▁prior ▁o xa li plat in - ▁ , ▁i rino te can - ▁and ▁fluor op y rimi dine - based ▁treatment ▁for ▁meta static ▁disease ▁compared ▁the ▁addition ▁of ▁ce tu xim ab ▁as ▁a ▁single ▁agent ▁to ▁best ▁support ive ▁care ▁( ▁b sc ▁) ▁( ▁28 7 ▁patients ▁) ▁with ▁best ▁support ive ▁care ▁( ▁ 285 ▁patients ▁) ▁ .
▁your ▁doctor ▁can ▁perform ▁a ▁blood ▁test ▁to ▁assess ▁the ▁risk ▁of ▁ble ed ing ▁ .
▁kin ▁ rash ▁( ▁hi ves ▁) ▁or ▁red ness
▁do ▁not ▁place ▁a ▁dra in ▁directly ▁in ▁the ▁implant ▁site ▁ .
▁your ▁doctor ▁will ▁take ▁special ▁care ▁and ▁monitor ▁your ▁small ▁bo wel ▁function ▁and ▁monitor ▁for ▁sign s ▁and ▁symptoms ▁indicat ing ▁problems ▁with ▁your ▁gall blad der ▁ , ▁bile ▁ duct s ▁and ▁pan cre as ▁ .
▁if ▁you ▁cannot ▁ tolera te ▁the ▁recommended ▁dose ▁of ▁300 ▁mg ▁per ▁day ▁because ▁of ▁side ▁effects ▁( ▁see ▁section ▁4 ▁) ▁your ▁doctor ▁may ▁reduce ▁your ▁recommended ▁daily ▁dose ▁of ▁var gate f ▁to ▁200 ▁mg ▁per ▁day ▁( ▁two ▁capsule s ▁of ▁100 ▁mg ▁) ▁ .
▁it ▁is ▁recommended ▁to ▁also ▁monitor ▁se rum ▁al pha - fe to prote in ▁concentration s ▁ .
▁ fold ▁the ▁skin ▁light ly ▁and ▁insert ▁the ▁inject ion ▁need le ▁completely ▁at ▁a ▁45 ▁° ▁to ▁90 ▁° ▁angle ▁using ▁a ▁dar t - like ▁motion ▁ .
▁however ▁ , ▁the ▁data ▁concern ing ▁immun isation ▁were ▁in sufficient ▁to ▁conclude ▁on ▁an ▁adequat e ▁immun e ▁response ▁to ▁these ▁vaccin es ▁following ▁administration ▁of ▁tal tz ▁ .
▁sen shi o ▁has ▁no ▁known ▁or ▁negli gi ble ▁influence ▁on ▁the ▁ability ▁to ▁drive ▁and ▁use ▁machines ▁ .
▁in ▁a ▁single - dos e ▁study ▁in ▁healthy ▁volunteer s ▁and ▁subject s ▁with ▁end ▁stage ▁renal ▁disease ▁ , ▁the ▁reti ga bine ▁au c ▁was ▁increased ▁by ▁approximately ▁100 ▁% ▁in ▁the ▁subject s ▁with ▁end ▁stage ▁renal ▁disease ▁relative ▁to ▁healthy ▁volunteer s ▁ .
▁personal ▁history ▁of ▁my o pathy ▁and ▁/ ▁or ▁r hab dom yol ysis ▁with ▁stati ns ▁and ▁/ ▁or ▁fibra tes ▁or ▁confirm ed ▁creati ne ▁ phos pho kina se ▁( ▁ ck ▁) ▁eleva tion ▁above ▁5 ▁times ▁the ▁ul n ▁under ▁previous ▁stati n ▁treatment ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁anti de press ants ▁with ▁ser oto ner gi c ▁effect ▁can ▁lower ▁the ▁se iz ure ▁thre s hold ▁ .
▁statement ▁of ▁active ▁substance ▁( ▁s ▁)
▁general ▁support ive ▁care ▁of ▁the ▁patient ▁is ▁indicate d ▁including ▁monitoring ▁of ▁vital ▁sign s ▁and ▁observation ▁of ▁the ▁clinic al ▁status ▁of ▁the ▁patient ▁ .
▁so dium ▁hydro xi de ▁( ▁for ▁ph ▁adjust ment ▁) ▁hydro ch lor ic ▁acid ▁( ▁for ▁ph ▁adjust ment ▁)
▁the ▁majority ▁of ▁side ▁effects ▁are ▁mild ▁and ▁trans ient ▁ .
▁remove ▁one ▁box ▁contain ing ▁ , ▁one ▁sy ringe ▁ , ▁one ▁vi al ▁adapter ▁ , ▁one ▁vi al ▁ , ▁two ▁alcohol ▁pad s ▁and ▁one ▁need le ▁from ▁the ▁carton ▁ .
▁co - administration ▁of ▁100 ▁mg ▁a log lip tin ▁once ▁daily ▁and ▁1,000 ▁mg ▁met form in ▁hydro ch lor ide ▁twice ▁daily ▁for ▁6 ▁days ▁in ▁healthy ▁subject s ▁had ▁no ▁clinic ally ▁relevant ▁effects ▁on ▁the ▁ pharma cok ine tics ▁of ▁a log lip tin ▁or ▁met form in ▁ .
▁however ▁ , ▁cau tion ▁should ▁be ▁exercise d ▁when ▁olan za pine ▁is ▁pre scribe d ▁with ▁medicine s ▁known ▁to ▁increase ▁q t c ▁interval ▁ , ▁especially ▁in ▁the ▁el der ly ▁ , ▁in ▁patients ▁with ▁con geni tal ▁long ▁q t ▁syndrome ▁ , ▁con ges tive ▁heart ▁failure ▁ , ▁heart ▁hyper trop hy ▁ , ▁hypo kala emia ▁or ▁hypo magn esa emia ▁ .
▁e vol tra ▁treatment ▁should ▁be ▁started ▁and ▁super vis ed ▁by ▁a ▁doctor ▁who ▁has ▁experience ▁in ▁the ▁management ▁of ▁patients ▁with ▁a cute ▁leuk a emia s ▁ .
▁what ▁la mi vu dine ▁teva ▁ pharma ▁b . v . ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁do ▁not ▁tha w ▁in ▁hot ▁or ▁ ice ▁cold ▁water ▁ .
▁however ▁ , ▁this ▁was ▁not ▁observe d ▁for ▁les ions ▁in ▁the ▁pan cre as ▁ , ▁ki dne y ▁ , ▁ova ry ▁or ▁prostat e ▁g land ▁ .
▁in ▁p ku ▁ , ▁it ▁works ▁by ▁en han cing ▁the ▁activity ▁of ▁the ▁defect ive ▁enzym e ▁ , ▁while ▁in ▁bh 4 ▁de fici en cy ▁it ▁replace s ▁the ▁missing ▁co factor ▁ .
▁cy to toxic ▁ , ▁special ▁handling ▁instructions ▁( ▁see ▁package ▁le a flet ▁) ▁ .
▁the ▁medicinal ▁product ▁should ▁be ▁dilu ted ▁and ▁used ▁immediately ▁ .
▁do ▁not ▁put ▁the ▁cover ▁back ▁on ▁used ▁need les ▁ .
▁for ▁this ▁product ▁the ▁effective ▁dose ▁result ing ▁from ▁an ▁inject ed ▁activity ▁of ▁2 ▁ 590 ▁mb q ▁is ▁7 96 ▁ms v ▁ .
▁the ▁in ▁vi tro ▁results ▁showed ▁that ▁cy p 3 a 4 ▁was ▁the ▁major ▁human ▁p 450 ▁enzym e ▁cata lys ing ▁the ▁bio transform ation ▁of ▁imati ni b ▁ .
▁if ▁you ▁have ▁recently ▁had ▁any ▁surgery ▁ , ▁especially ▁if ▁this ▁might ▁affect ▁how ▁you ▁absorb ▁food ▁or ▁medicine s ▁from ▁your ▁stomach ▁or ▁gut ▁if ▁you ▁are ▁planning ▁to ▁have ▁any ▁surgery - ▁your ▁doctor ▁may ▁ask ▁you ▁to ▁stop ▁taking ▁im bru vica ▁for ▁a ▁short ▁time ▁ .
▁sign s ▁of ▁an ▁allergi c ▁reaction ▁may ▁include ▁it chy ▁skin ▁ rash ▁ , ▁short ness ▁of ▁breath ▁and ▁swe lling ▁of ▁the ▁face ▁or ▁ton gue . ▁if ▁you ▁have ▁a ▁severe ▁infection ▁with ▁a ▁high ▁temperature ▁( ▁over ▁38 ▁° ▁c ▁) ▁ .
▁required ▁amount ▁of ▁concentrat e - solve nt ▁mix ture
▁modest ▁prolong ation ▁of ▁the ▁pr ▁interval ▁was ▁also ▁not ed ▁in ▁subject s ▁receiving ▁lo pina vir ▁/ ▁rito na vir ▁in ▁the ▁same ▁study ▁on ▁day ▁3 ▁ .
▁for ▁storage ▁conditions ▁of ▁the ▁recon stitu ted ▁medicinal ▁product ▁see ▁section ▁6.3 ▁ .
▁each ▁pre - fill ed ▁sy ringe ▁contain s ▁60 ▁mg ▁of ▁de nos um ab ▁in ▁1 ▁ml ▁of ▁solution ▁( ▁60 ▁mg ▁/ ▁ml ▁) ▁ .
▁continued ▁ therapy ▁should ▁be ▁carefully ▁considered ▁in ▁a ▁subject ▁not ▁respond ing ▁by ▁week ▁12 ▁ .
▁in ▁case ▁of ▁persist ent ▁lymph ade no pathy ▁ , ▁the ▁a eti ology ▁of ▁the ▁lymph ade no pathy ▁should ▁be ▁investiga ted ▁ .
▁the ▁primary ▁measure ▁of ▁ef fica cy ▁( ▁as as ▁20 ▁) ▁was ▁a ▁ ≥ ▁20 ▁% ▁improvement ▁in ▁at ▁least ▁3 ▁of ▁the ▁4 ▁assessment ▁in ▁an ky los ing ▁ spon dy liti s ▁( ▁as as ▁) ▁domain s ▁( ▁patient ▁global ▁assessment s ▁ , ▁back ▁pain ▁ , ▁bas fi ▁ , ▁and ▁ inflammation ▁) ▁and ▁ absence ▁of ▁deteriora tion ▁in ▁the ▁remain ing ▁domain ▁ .
▁ta fin lar ▁50 ▁mg ▁and ▁75 ▁mg ▁hard ▁capsule s ▁are ▁available ▁in ▁pack s ▁contain ing ▁28 ▁or ▁120 ▁capsule s ▁ .
▁in ▁vi tro ▁studies ▁have ▁demonstrat ed ▁that ▁clo fara bine ▁inhibi ts ▁cell ▁growth ▁in ▁and ▁is ▁cy to toxic ▁to ▁a ▁variety ▁of ▁rapid ly ▁prolifera ting ▁ha e mat ological ▁and ▁solid ▁tum our ▁cell ▁lines ▁ .
▁z y delig ▁is ▁a ▁cancer ▁medicine ▁that ▁contain s ▁the ▁active ▁substance ▁i del alis ib ▁ .
▁if ▁you ▁are ▁a ▁diabet ic ▁or ▁have ▁an ▁illness ▁known ▁as ▁' ▁diabet ic ▁retin o pathy ▁' ▁( ▁problems ▁with ▁the ▁blood ▁ves sels ▁in ▁the ▁eye ▁caused ▁by ▁diabetes ▁)
▁do ▁not ▁touch ▁the ▁inject ion ▁button ▁yet ▁ .
▁1 g ▁gel ▁contain s ▁: ▁100 ▁mg ▁extract ▁( ▁as ▁dry ▁extract ▁ , ▁ref in ed ▁) ▁from ▁bir ch ▁bar k ▁from ▁betul a ▁pen dula ▁ro th ▁ , ▁betul a ▁pub es cens ▁e hr h . ▁as ▁well ▁as ▁hybrid s ▁of ▁both ▁species ▁( ▁equivalent ▁to ▁0.5 - 1.0 ▁g ▁bir ch ▁bar k ▁) ▁ , ▁correspond ing ▁to ▁72 - 88 ▁mg ▁betul in ▁ .
▁si f rol ▁0.0 88 ▁mg ▁tablets ▁are ▁white ▁ , ▁of ▁round ▁shape ▁ , ▁flat ▁ , ▁and ▁without ▁scor ing ▁ .
▁as ▁with ▁any ▁vaccin e ▁rare ▁ , ▁occasion al ▁hyper sensitiv ity ▁reaction s ▁( ▁i . e . ▁ana phy la xis ▁ , ▁ang io ede ma ▁ , ▁dys p no e a ▁ , ▁circula tory ▁shock ▁ , ▁col lapse ▁) ▁may ▁occur ▁ .
▁in ▁clinic al ▁trial s ▁with ▁sanc uso ▁ , ▁there ▁were ▁no ▁treatment - related ▁effects ▁on ▁heart ▁rate ▁or ▁blood ▁pressure ▁ .
▁tres iba ▁is ▁given ▁as ▁an ▁inject ion ▁under ▁the ▁skin ▁( ▁sub cuta ne ous ▁inject ion ▁) ▁ .
▁it ▁is ▁not ▁known ▁if ▁a den uri c ▁may ▁har m ▁your ▁un born ▁child ▁ .
▁pre gabal in ▁p fiz er ▁with ▁food ▁ , ▁drink ▁and ▁alcohol
▁patients ▁with ▁sick le ▁cell ▁ana emia
▁the ▁need ▁to ▁provide ▁comprehensive ▁advice ▁and ▁counsel ling ▁to ▁patients ▁ .
▁cy mbal ta ▁should ▁be ▁used ▁in ▁pre gna ncy ▁only ▁if ▁the ▁potential ▁benefit ▁justifi es ▁the ▁potential ▁risk ▁to ▁the ▁fo etus ▁ .
▁media n ▁change ▁in ▁u fc ▁( ▁% ▁from ▁base line ▁)
▁heli xa te ▁ne x gen ▁2000 ▁iu ▁contain s ▁the ▁active ▁substance ▁human ▁reco mbin ant ▁coa g ulation ▁factor ▁vii i ▁( ▁octo co g ▁alfa ▁) ▁ .
▁if ▁de hydrat ion ▁or ▁renal ▁dys function ▁become s ▁evident ▁ , ▁appropriate ▁action ▁must ▁be ▁taken ▁which ▁may ▁include ▁the ▁need ▁to ▁interrupt ▁or ▁reduce ▁dos es ▁of ▁to lv ap tan ▁and ▁/ ▁or ▁di ure tics ▁and ▁increased ▁fluid ▁in take ▁ .
▁percentage ▁of ▁patients ▁who ▁achieve d ▁m ci db
▁de fera sir ox ▁induc ed ▁similar ▁response s ▁in ▁ir on - over load ed ▁patients ▁with ▁other ▁ana emia s ▁ .
▁people ▁donat ing ▁their ▁own ▁blood ▁before ▁surgery
▁un com mon ▁: ▁other ▁inject ion ▁site ▁reaction
▁p vc ▁bli sters ▁with ▁aluminium ▁foi l ▁back ing ▁in ▁a ▁pack ▁contain ing ▁28 ▁x ▁1 ▁mg ▁film - co ated ▁tablets ▁in ▁seconda ry ▁heat ▁seal ed ▁card ▁packaging ▁ .
▁it ▁could ▁take ▁several ▁weeks ▁to ▁find ▁the ▁dose ▁that ▁is ▁right ▁for ▁you ▁ .
▁routine ▁op h thal m ologic ▁monitoring ▁of ▁patients ▁is ▁recommended ▁ .
▁extreme ▁care ▁should ▁be ▁taken ▁in ▁the ▁use ▁of ▁eco nor ▁in ▁pig s ▁of ▁the ▁dan ish ▁and ▁s wed ish ▁land race ▁breed s ▁ , ▁and ▁their ▁cross bre ed s ▁there of ▁ , ▁especially ▁in ▁young er ▁pig s ▁ .
▁if ▁you ▁or ▁your ▁child ▁experiences ▁a ▁severe ▁in fusion ▁reaction ▁like ▁this ▁ , ▁se ek ▁immediate ▁medical ▁attention ▁ .
▁prompt ▁dis continu ation ▁of ▁inter fer on ▁al pha ▁administration ▁and ▁treatment ▁with ▁corti co steroid s ▁appear ▁to ▁be ▁associated ▁with ▁resolution ▁of ▁pulmonar y ▁advers e ▁events ▁ .
▁the ▁val sar tan ▁contain ed ▁within ▁ne par vis ▁is ▁more ▁bio ava il able ▁than ▁the ▁val sar tan ▁in ▁other ▁market ed ▁tablet ▁formula tions ▁( ▁see ▁section ▁5.2 ▁) ▁ .
▁if ▁you ▁experience ▁worse ning ▁abdominal ▁pain ▁you ▁should ▁inform ▁your ▁doctor ▁ .
▁there ▁have ▁been ▁cases ▁of ▁patients ▁dis continu ing ▁jak avi ▁who ▁sustain ed ▁more ▁severe ▁events ▁ , ▁particularly ▁in ▁the ▁presence ▁of ▁a cute ▁inter current ▁illness ▁ .
▁bude son ide ▁/ ▁form ote rol ▁teva ▁ pharma ▁b . v . ▁320 ▁micro gram s ▁/ ▁9 ▁micro gram s ▁in hal ation ▁powder ▁ .
▁disorder s ▁associated ▁with ▁visual ▁disturb ances ▁ , ▁including ▁r ped ▁and ▁r vo ▁ , ▁have ▁been ▁observe d ▁with ▁tram etin ib ▁ .
▁as ▁for ▁all ▁pre term ▁infants ▁ , ▁those ▁treated ▁with ▁ca ffe ine ▁cit rate ▁should ▁be ▁carefully ▁monitor ed ▁for ▁the ▁development ▁of ▁nec rot ising ▁en tero coli tis ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁if ▁accident al ▁skin ▁exposure ▁occur s ▁ , ▁was h ▁the ▁skin ▁immediately ▁with ▁so ap ▁and ▁water ▁ .
▁ad minister ▁one ▁dose ▁of ▁1 ▁ml ▁sub cuta ne ously ▁according ▁to ▁the ▁following ▁vaccin ation ▁scheme ▁:
▁each ▁bottle ▁contain s ▁a ▁si lica ▁gel ▁de sic cant ▁( ▁dry ing ▁agent ▁) ▁that ▁must ▁be ▁kept ▁in ▁the ▁bottle ▁to ▁help ▁protect ▁your ▁tablets ▁ .
▁the ▁immun ogen i city ▁of ▁men ve o ▁in ▁children ▁2 ▁to ▁23 ▁months ▁of ▁age ▁was ▁evaluat ed ▁in ▁several ▁studies ▁ .
▁pre scribe rs ▁should ▁draw ▁the ▁attention ▁of ▁pa e dia tric ▁patients ▁and ▁their ▁parent ▁/ ▁care rs ▁to ▁the ▁advice ▁in ▁the ▁packaging ▁le a flet ▁on ▁prevent ing ▁heat ▁stroke ▁and ▁over he ating ▁in ▁children ▁as ▁provided ▁ .
▁som a vert ▁10 ▁mg ▁powder ▁and ▁solve nt ▁for ▁solution ▁for ▁inject ion ▁one ▁vi al ▁contain s ▁10 ▁mg ▁of ▁pe g vis om ant ▁ .
▁o 1 ▁manis a ▁ , ▁a 22 ▁i raq ▁and ▁a 24 ▁cruz eiro
▁temo zo lom ide ▁sand oz ▁may ▁cause ▁permanent ▁infer t ility ▁ .
▁din utu xim ab ▁react s ▁specifically ▁with ▁the ▁gan glio side ▁g d 2 ▁ , ▁which ▁is ▁highly ▁express ed ▁on ▁the ▁surface ▁of ▁neuro blas toma ▁cell s ▁and ▁minimal ly ▁express ed ▁on ▁the ▁surface ▁of ▁normal ▁human ▁neuron s ▁ , ▁per i pher al ▁pain ▁fibre s ▁ , ▁and ▁skin ▁melan o cy tes ▁ .
▁pa zo pan ib ▁should ▁be ▁ad minister ed ▁at ▁least ▁1 ▁hour ▁before ▁or ▁2 ▁hours ▁after ▁administration ▁of ▁short - ac ting ▁anta cid s ▁ .
▁duo pla vin ▁75 ▁mg ▁/ ▁75 ▁mg ▁film - co ated ▁tablets ▁( ▁tablets ▁) ▁are ▁ oval ▁ , ▁slightly ▁bi con ve x ▁ , ▁yellow ▁ , ▁en grave d ▁on ▁one ▁side ▁with ▁' ▁c 75 ▁' ▁and ▁' ▁a 75 ' on ▁the ▁other ▁side ▁ .
▁this ▁is ▁because ▁for ▁this ▁medicine ▁to ▁be ▁as ▁effective ▁as ▁possible ▁ , ▁it ▁is ▁important ▁to ▁follow ▁the ▁dos ing ▁schedule ▁ .
▁vor tio xe tine ▁was ▁statistic ally ▁significantly ▁better ▁than ▁ago mela tine ▁as ▁measure d ▁by ▁improvement ▁in ▁the ▁mad rs ▁total ▁score ▁and ▁support ed ▁by ▁the ▁clinic al ▁relevan ce ▁as ▁demonstrat ed ▁by ▁the ▁proportion s ▁of ▁responder s ▁and ▁remit ters ▁and ▁improvement ▁in ▁the ▁c gi - i ▁ .
▁combination ▁with ▁calci um ▁channel ▁block ers
▁the ▁maximum ▁dose ▁is ▁8 ▁mg ▁per ▁day ▁ .
▁cyst a gon ▁treatment ▁should ▁be ▁started ▁by ▁a ▁doctor ▁who ▁has ▁experience ▁in ▁the ▁treatment ▁of ▁cyst inos is ▁ .
▁the ▁appropriate ▁dose ▁of ▁t m z ▁should ▁be ▁inf used ▁intra ven ously ▁using ▁a ▁pump ▁over ▁a ▁period ▁of ▁90 ▁minutes ▁ .
▁the ▁most ▁common ▁advers e ▁reaction s ▁occur ring ▁in ▁ ≥ ▁3 ▁% ▁of ▁patients ▁treated ▁with ▁z info ro ▁were ▁di ar r ho e a ▁ , ▁head ache ▁ , ▁na use a ▁ , ▁and ▁pru ritu s ▁ , ▁and ▁were ▁generally ▁mild ▁or ▁moderat e ▁in ▁sever ity ▁ .
▁please ▁refer ▁to ▁the ▁summary ▁of ▁product ▁character istic s ▁for ▁mel phal an ▁for ▁details ▁regarding ▁incomp at abili ties ▁with ▁mel phal an ▁ .
▁teva ▁ pharma ▁b . v . ▁ , ▁s wens weg ▁5 ▁ , ▁20 31 ga ▁haar lem ▁ , ▁the ▁ne ther lands
▁i xia ro ▁should ▁be ▁given ▁only ▁to ▁adults ▁ , ▁adolescents ▁ , ▁children ▁and ▁infants ▁a ged ▁2 ▁months ▁and ▁older ▁travel ling ▁to ▁countries ▁ , ▁where ▁je ▁is ▁ende mic ▁or ▁who ▁are ▁at ▁risk ▁through ▁work ▁ .
▁it ▁activa tes ▁the ▁enzym e ▁gua ny late ▁cy cla se ▁ , ▁result ing ▁in ▁an ▁increased ▁level ▁of ▁ cycli c ▁gua no sine ▁mono phos pha te ▁( ▁c g mp ▁) ▁in ▁the ▁corpus ▁cave rnos um ▁ .
▁of ▁the ▁ 783 ▁patients ▁initial ly ▁random ised ▁to ▁active ▁treatment ▁in ▁ra - i ▁ , ▁50 8 ▁completed ▁52 ▁weeks ▁of ▁place bo - ▁control led ▁treatment ▁and ▁enter ed ▁the ▁open - label ▁extension ▁study ▁ .
▁in ▁patients ▁with ▁no ▁detect able ▁eg fr ▁protein ▁expression ▁ , ▁no ▁improvement ▁in ▁overall ▁survival ▁( ▁hazard ▁ratio ▁[ ▁hr ▁] ▁= ▁1.5 2 ▁[ ▁0 . 74 ▁ , ▁3. 12 ▁] ▁) ▁or ▁progression ▁free ▁survival ▁( ▁hazard ▁ratio ▁[ ▁hr ▁] ▁= ▁1. 33 ▁[ ▁0 . 65 ▁ , ▁2. 70 ▁] ▁was ▁observe d ▁ .
▁z onis ami de ▁my lan ▁100 ▁mg ▁hard ▁capsule s
▁this ▁is ▁intended ▁to ▁aid ▁in ▁the ▁protection ▁of ▁health care ▁professionals ▁ , ▁patients ▁who ▁self - in ject ▁doctor - pre scribe d ▁medicine s ▁ , ▁and ▁individuals ▁who ▁assist ▁self - in ject ing ▁patients ▁from ▁accident al ▁need le stick ▁injuries ▁ .
▁you ▁will ▁be ▁instru cted ▁by ▁the ▁child ▁' s ▁doctor ▁or ▁his ▁/ ▁her ▁assistant ▁on ▁the ▁technique ▁of ▁giving ▁an ▁inject ion ▁and ▁on ▁the ▁amount ▁to ▁be ▁given ▁to ▁the ▁child ▁ .
▁it ▁is ▁recommended ▁to ▁monitor ▁blood ▁pressure ▁and ▁to ▁treat ▁hyper tension ▁in ▁accordance ▁with ▁standard ▁medical ▁practice ▁ .
▁for ▁patients ▁requiri ng ▁additional ▁symptom a tic ▁relief ▁ , ▁the ▁dose ▁may ▁be ▁increased ▁every ▁4 -7 ▁days ▁to ▁a ▁maximum ▁of ▁0.5 4 ▁mg ▁of ▁base ▁( ▁0 . 75 ▁mg ▁of ▁salt ▁) ▁per ▁day ▁( ▁as ▁shown ▁in ▁the ▁table ▁below ▁) ▁ .
▁a ▁risk ▁management ▁plan ▁has ▁been ▁developed ▁to ▁ensure ▁that ▁zo le dro nic ▁acid ▁teva ▁is ▁used ▁as ▁safe ly ▁as ▁possible ▁ .
▁i ker vis ▁should ▁not ▁be ▁used ▁if ▁you ▁are ▁pregnant ▁ .
▁exceed ▁a ▁daily ▁dose ▁of ▁10 ▁mg ▁when
▁by ▁att ach ing ▁to ▁p d g fr α ▁on ▁sar com a ▁cell s ▁ , ▁ lar tru vo ▁is ▁expected ▁to ▁block ▁its ▁activity ▁ , ▁there by ▁slow ing ▁down ▁the ▁growth ▁of ▁the ▁cancer ▁ .
▁ri xu bis ▁500 ▁iu ▁powder ▁and ▁solve nt ▁for ▁solution ▁for ▁inject ion ▁non ac og ▁gamma ▁( ▁reco mbin ant ▁human ▁coa g ulation ▁factor ▁ ix ▁)
▁consistent ▁with ▁the ▁above ▁results ▁ , ▁in ▁a ▁meta - analys is ▁including ▁6 ▁studies ▁of ▁3 35 ▁clo pido gre l - tre ated ▁subject s ▁at ▁stea dy ▁state ▁ , ▁it ▁was ▁shown ▁that ▁active ▁metabol ite ▁exposure ▁was ▁decrease d ▁by ▁28 ▁% ▁for ▁intermedi ate ▁metabol iser s ▁ , ▁and ▁72 ▁% ▁for ▁poor ▁metabol iser s ▁while ▁plate let ▁ aggregat ion ▁inhibi tion ▁( ▁5 ▁μ m ▁ad p ▁) ▁was ▁decrease d ▁with ▁difference s ▁in ▁i pa ▁of ▁ 5.9 ▁% ▁and ▁21. 4 ▁% ▁ , ▁respective ly ▁ , ▁when ▁compared ▁to ▁ex tensi ve ▁metabol iser s ▁ .
▁schi zo ph r enia ▁is ▁a ▁mental ▁illness ▁that ▁has ▁a ▁number ▁of ▁symptoms ▁ , ▁including ▁dis organi sed ▁thinking ▁and ▁speech ▁ , ▁hal lucina tions ▁( ▁hearing ▁or ▁seeing ▁things ▁that ▁are ▁not ▁there ▁) ▁ , ▁su spicio us ness ▁and ▁delu sions ▁( ▁mistake n ▁belief s ▁) ▁ .
▁the ▁european ▁medicine s ▁agency ▁has ▁wa i ved ▁the ▁obliga tion ▁to ▁submit ▁the ▁results ▁of ▁studies ▁with ▁ul ti bro ▁bre ezh a ler ▁in ▁all ▁sub set s ▁of ▁the ▁pa e dia tric ▁population ▁in ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁( ▁cop d ▁) ▁( ▁see ▁section ▁4.2 ▁for ▁information ▁on ▁pa e dia tric ▁use ▁) ▁ .
▁in ▁a ▁place bo - control led ▁study ▁of ▁rev atio ▁as ▁an ▁ad jun ct ▁to ▁intra ven ous ▁e po prost en ol ▁in ▁pulmonar y ▁arterial ▁hyper tension ▁ , ▁a ▁total ▁of ▁134 ▁patients ▁were ▁treated ▁with ▁rev atio ▁( ▁in ▁a ▁fixed ▁tit ration ▁starting ▁from ▁20 ▁mg ▁ , ▁to ▁40 ▁mg ▁and ▁then ▁80 ▁mg ▁ , ▁three ▁times ▁a ▁day ▁as ▁to ler ated ▁) ▁and ▁e po prost en ol ▁ , ▁and
▁recon stitu ted ▁vaccin e ▁: ▁pink ▁/ ▁red ▁ , ▁or ▁yellow ish ▁colour ▁with ▁s light ▁op al esc ence ▁ .
▁there ▁will ▁be ▁a ▁rub ber ▁stopper ▁under ne ath ▁- ▁keep ▁this ▁in ▁the ▁vi al ▁ .
▁when ▁you ▁will ▁first ▁start ▁taking ▁leve ti race tam ▁teva ▁ , ▁your ▁doctor ▁will ▁pre scribe ▁you ▁a ▁lower ▁dose ▁( ▁500 ▁mg ▁each ▁day ▁) ▁during ▁2 ▁weeks ▁before ▁giving ▁you ▁the ▁lo west ▁general ▁dose ▁of ▁1,000 ▁mg ▁ .
▁in ▁patients ▁in adequa tely ▁control led ▁on ▁sul phon y lu rea ▁alone ▁or ▁in ▁combination ▁with ▁met form in ▁ , ▁the ▁re duction ▁was ▁3.5 ▁mm h g ▁with ▁xul to phy ▁and ▁3.2 ▁mm h g ▁with ▁place bo ▁ .
▁this ▁dose ▁must ▁not ▁exceed ▁300 ▁mg ▁twice ▁a ▁day ▁ .
▁this ▁educational ▁pack ▁is ▁ai med ▁at ▁strength en ing ▁awareness ▁of ▁important ▁identified ▁risk s ▁of ▁blad der ▁cancer ▁and ▁heart ▁failure ▁and ▁the ▁overall ▁recommendations ▁intended ▁to ▁optim ise ▁the ▁benefit - risk ▁margin ▁at ▁the ▁patient ▁level ▁ .
▁a ▁further ▁study ▁looked ▁at ▁the ▁effects ▁of ▁e po etin ▁alfa ▁he xal ▁given ▁under ▁the ▁skin ▁in ▁4 16 ▁patients ▁with ▁chronic ▁ki dne y ▁failure ▁ .
▁if ▁op tic lik ▁does ▁not ▁function ▁well ▁ , ▁you ▁can ▁draw ▁the ▁insulin ▁from ▁the ▁cart ridge ▁into ▁an ▁inject ion ▁sy ringe ▁ .
▁treatment ▁of ▁symptom a tic ▁ana emia ▁in ▁adult ▁and ▁pa e dia tric ▁chronic ▁renal ▁failure ▁patients
▁what ▁is ▁the ▁risk ▁associated ▁with ▁xo la ir ▁?
▁date ▁of ▁first ▁author isation ▁/ ▁rene wal ▁of ▁the ▁author isation
▁this ▁medicine ▁has ▁been ▁pre scribe d ▁for ▁your ▁child ▁only ▁ .
▁hyper sensitiv ity ▁to ▁any ▁of ▁the ▁active ▁substance s ▁or ▁to ▁any ▁of ▁the ▁ex cip ient s ▁listed ▁in ▁section ▁6.1 ▁ .
▁the ▁media n ▁stea dy - state ▁c max ▁and ▁au c ▁( ▁0 -24 ▁) ▁values ▁after ▁administration ▁of ▁200 ▁mg ▁pa zo pan ib ▁once ▁daily ▁in ▁patients ▁with ▁severe ▁he pati c ▁im pair ment ▁were ▁approximately ▁18 ▁% ▁and ▁15 ▁% ▁ , ▁of ▁the ▁correspond ing ▁media n ▁values ▁after ▁administration ▁of ▁800 ▁mg ▁once ▁daily ▁in ▁patients ▁with ▁normal ▁he pati c ▁function ▁ .
▁immun e ▁media ted ▁ha em oly tic ▁ana emia ▁( ▁anti body - media ted ▁destruction ▁of ▁red ▁blood ▁cell s ▁)
▁ro tation ▁cycle ▁1 ▁: ▁upp er ▁left ▁section ▁of ▁each ▁area ▁ro tation ▁cycle ▁2 ▁: ▁lower ▁right ▁section ▁of ▁each ▁area ▁ro tation ▁cycle ▁3 ▁: ▁middle ▁left ▁section ▁of ▁each ▁area ▁ro tation ▁cycle ▁4 ▁upp er ▁right ▁section ▁of ▁each ▁area ▁ro tation ▁cycle ▁5 ▁: ▁lower ▁left ▁section ▁of ▁each ▁area ▁ro tation ▁cycle ▁6 ▁: ▁middle ▁right ▁section ▁of ▁each ▁area
▁the ▁following ▁unde sir able ▁effects ▁have ▁been ▁reported ▁following ▁the ▁wide spre ad ▁use ▁of ▁the ▁vaccin e ▁ .
▁for ▁children ▁a ged ▁2 ▁years ▁and ▁above ▁and ▁we igh ing ▁less ▁than ▁25 ▁kg ▁the ▁granul es ▁should ▁be ▁used ▁ .
▁in ▁these ▁severe ▁cases ▁con com i tant ▁treatment ▁may ▁be ▁necessary ▁ .
▁am lo di pine ▁ , ▁dil tia zem ▁ , ▁fel odi pine ▁ , ▁ni fed i pine ▁ , ▁nic ardi pine
▁since ▁flu o xe tine ▁share s ▁a ▁similar ▁metabol ic ▁profile ▁with ▁paro xe tine ▁ , ▁i . e . ▁a ▁strong ▁cy p 2 d 6 ▁inhibi tory ▁effect ▁ , ▁a ▁similar ▁lack ▁of ▁interaction ▁would ▁be ▁expected ▁for ▁flu o xe tine ▁ .
▁each ▁hard ▁capsule ▁contain s ▁4 ▁micro gram s ▁of ▁sun set ▁yellow ▁( ▁e 110 ▁) ▁ .
▁all ▁patients ▁should ▁be ▁encourage d ▁to ▁maintain ▁good ▁oral ▁hygien e ▁ , ▁under go ▁routine ▁dental ▁check - ups ▁ , ▁and ▁immediately ▁report ▁any ▁oral ▁symptoms ▁such ▁as ▁dental ▁mobil ity ▁ , ▁pain ▁or ▁swe lling ▁ , ▁or ▁non - hea ling ▁of ▁so res ▁or ▁dis charge ▁during ▁treatment ▁with ▁zo meta ▁ .
▁adults ▁ , ▁adolescents ▁ ≥ ▁16 ▁years ▁of ▁age ▁and ▁el der ly ▁:
▁what ▁you ▁need ▁to ▁know ▁before ▁you ▁take ▁duo pla vin
▁this ▁should ▁lead ▁to ▁a ▁re duction ▁in ▁ liver ▁damage ▁and ▁an ▁improvement ▁in ▁your ▁ liver ▁function ▁ .
▁there ▁is ▁no ▁need ▁for ▁dose ▁adjust ment ▁with ▁any ▁of ▁the ▁a ed s ▁including ▁cy p 3 a 4 ▁induc ers ▁ .
▁if ▁you ▁experience ▁irrita tion ▁( ▁e . g . ▁sting ing ▁bur ning ▁) ▁ , ▁reduce ▁the ▁use ▁of ▁van i qa ▁to ▁once ▁daily ▁until ▁the ▁irrita tion ▁has ▁gone ▁ .
▁need ▁and ▁clinic al ▁importance ▁of ▁advers e ▁drug ▁reaction ▁( ▁ad r ▁) ▁report ing ▁in ▁general ▁ .
▁rem s ima ▁is ▁also ▁used ▁in ▁patients ▁a ged ▁between ▁six ▁and ▁17 ▁years ▁with ▁severe ▁ , ▁active ▁cro h n ▁' s ▁disease ▁or ▁severe ly ▁active ▁ul cer ative ▁col itis ▁ , ▁when ▁they ▁have ▁not ▁responde d ▁to ▁or ▁cannot ▁take ▁other ▁medicine s ▁or ▁treatment s ▁ .
▁store ▁in ▁a ▁refrigera tor ▁( ▁2 ▁c ▁- ▁8 ▁c ▁)
▁remove ▁your ▁kin zal kom b ▁tablet ▁from ▁the ▁bli ster ▁only ▁directly ▁prior ▁to ▁in take ▁ .
▁ana emia ▁( ▁low ▁red ▁blood ▁cell ▁count ▁) ▁ , ▁break down ▁of ▁muscle ▁ , ▁muscle ▁pain ▁or ▁we ak ness ▁which ▁may ▁occur ▁due ▁to ▁damage ▁to ▁the ▁ki dne y ▁tu bule ▁cell s ▁ .
▁poli om ye liti s ▁( ▁poli o ▁ , ▁a ▁disease ▁that ▁affect s ▁the ▁nerv es ▁and ▁can ▁lead ▁to ▁muscle ▁we ak ness ▁or ▁para lys is ▁) ▁; ▁invasi ve ▁disease s ▁( ▁such ▁as ▁mening itis ▁) ▁caused ▁by ▁h . ▁influenza e ▁type ▁b ▁bacteria ▁ .
▁if ▁you ▁or ▁your ▁child ▁forget s ▁to ▁take ▁the ▁second ▁dose ▁of ▁eur arte sim ▁at ▁the ▁right ▁time ▁ , ▁take ▁it ▁as ▁soon ▁as ▁you ▁remember ▁ .
▁what ▁is ▁the ▁el lip ta ▁in hal er ▁?
▁retin al ▁det ach ment ▁ , ▁retin al ▁ha e mor r hage ▁ , ▁vi tre ous ▁ha e mor r hage ▁ , ▁retin al ▁oed ema ▁ .
▁0.2 5 ▁ml ▁boost er ▁dose ▁n ▁= ▁81
▁these ▁are ▁the ▁sign s ▁of ▁low ▁blood ▁sugar ▁:
▁one ▁vi al ▁with ▁6 ▁ml ▁concentrat e ▁for ▁solution ▁for ▁in fusion ▁contain s ▁6 ▁mg ▁iba ndro nic ▁acid ▁( ▁as ▁so dium ▁mono hydrat e ▁) ▁ .
▁patients ▁a ged ▁80 ▁years ▁or ▁above
▁mara vi roc ▁should ▁optimal ly ▁be ▁combine d ▁with ▁other ▁anti ret rovi ral s ▁to ▁which ▁the ▁patient ▁' s ▁virus ▁is ▁sensitive ▁( ▁see ▁section ▁5.1 ▁) ▁ .
▁recon stitu tion ▁and ▁method ▁of ▁administration
▁what ▁are ▁the ▁risk s ▁associated ▁with ▁cy ram za ▁?
▁ion sys ▁should ▁not ▁be ▁applied ▁to ▁a ▁previously ▁used ▁skin ▁site ▁ .
▁definition ▁of ▁women ▁of ▁child be aring ▁potential ▁( ▁wc b p ▁) ▁and ▁actions ▁the ▁pre scribe r ▁should ▁take ▁if ▁child be aring ▁status ▁is ▁un clear
▁this ▁is ▁a ▁summary ▁of ▁the ▁european ▁public ▁assessment ▁report ▁( ▁e par ▁) ▁for ▁au bagi o ▁ .
▁please ▁consult ▁the ▁doctor ▁ , ▁even ▁if ▁these ▁statement s ▁were ▁applicable ▁at ▁any ▁time ▁in ▁the ▁past ▁ .
▁he pati c ▁failure ▁* ▁ , ▁progressive ▁he pati c ▁coma
▁it ▁is ▁important ▁to ▁institut e ▁medication ▁as ▁early ▁as ▁possible ▁in ▁an ▁out break ▁of ▁por cine ▁prolifera tive ▁en tero pathy ▁ .
▁general ▁: ▁in ▁patients ▁whose ▁vas cular ▁tone ▁and ▁renal ▁function ▁depend ▁predomina nt ly ▁on ▁the ▁activity ▁of ▁the ▁re nin - angi oten sin - al do ster one ▁system ▁( ▁e . g . ▁patients ▁with ▁severe ▁con ges tive ▁heart ▁failure ▁or ▁under ly ing ▁renal ▁disease ▁ , ▁including ▁renal ▁arter y ▁sten osis ▁) ▁ , ▁treatment ▁with ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁or ▁ang io ten sin - ii ▁receptor ▁anta gon ists ▁that ▁affect ▁this ▁system ▁has ▁been ▁associated ▁with ▁a cute ▁hypo tension ▁ , ▁az ota emia ▁ , ▁oli guri a ▁ , ▁or ▁rare ly ▁a cute ▁renal ▁failure ▁( ▁see ▁section ▁4.5 ▁) ▁ .
▁do ▁not ▁so ak ▁ , ▁was h ▁or ▁lub rica te ▁the ▁pen ▁as ▁this ▁may ▁damage ▁it ▁ .
▁st ▁segment ▁eleva tion ▁a cute ▁my o card ial ▁in far ction ▁: ▁clo pido gre l ▁should ▁be ▁given ▁as ▁a ▁single ▁daily ▁dose ▁of ▁75 ▁mg ▁initiat ed ▁with ▁a ▁300 - mg ▁load ing ▁dose ▁in ▁combination ▁with ▁asa ▁and ▁with ▁or ▁without ▁ thro mbol y tics ▁ .
▁to uje o ▁contain s ▁insulin ▁called ▁" ▁insulin ▁g lar gine ▁ . ▁"
▁very ▁common ▁: ▁10 ▁( ▁12 ▁)
▁insulin ▁administration ▁via ▁the ▁pump ▁can ▁cause ▁a ▁fat ▁infiltra tion ▁of ▁the ▁ liver ▁at ▁single ▁ , ▁well - de fin ed ▁location s ▁( ▁called ▁focal ▁he pati c ▁stea tos is ▁) ▁ .
▁sign s ▁and ▁symptoms ▁of ▁cardiac ▁dys function ▁such ▁as ▁dys p no e a ▁ , ▁ort hop no e a ▁ , ▁increased ▁co ugh ▁ , ▁pulmonar y ▁oed ema ▁ , ▁s 3 ▁gall op ▁ , ▁or ▁reduce d ▁vent ri cular ▁e je ction ▁ fraction ▁ , ▁have ▁been ▁observe d ▁in ▁patients ▁treated ▁with ▁her cept in ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁read ily ▁available ▁geno ty pic ▁drug ▁resist ance ▁interpretation ▁algorithm s ▁and ▁commercial ly ▁available ▁sus cept i bility ▁tests ▁have ▁established ▁clinic al ▁cut ▁off s ▁for ▁reduce d ▁activity ▁for ▁a baca vir ▁and ▁la mi vu dine ▁as ▁separate ▁drug ▁enti ties ▁that ▁predict ▁sus cept i bility ▁ , ▁parti al ▁sus cept i bility ▁or ▁resist ance ▁based ▁upon ▁either ▁direct ▁measure ment ▁of ▁sus cept i bility ▁or ▁by ▁calcula tion ▁of ▁the ▁hi v -1 ▁resist ance ▁ph eno type ▁from ▁the ▁viral ▁geno type ▁ .
▁at ▁the ▁request ▁of ▁the ▁european ▁medicine s ▁agency
▁the ▁pack ▁size s ▁of ▁5 and ▁10 ▁bottle s ▁are ▁only ▁available ▁in ▁multi pack s ▁contain ing ▁5 ▁or ▁10 ▁bottle s ▁( ▁5 ▁bottle s ▁of ▁100 ▁ml ▁or ▁10 ▁bottle s ▁of ▁100 ▁ml ▁) ▁ .
▁alone ▁or ▁together ▁with ▁the ▁medicine s ▁pe gy la ted ▁lipo som al ▁do xor ubi cin ▁or ▁de xa met has one ▁ , ▁for ▁patients ▁whose ▁disease ▁is ▁worse ning ▁( ▁progressive ▁) ▁after ▁receiving ▁at ▁least ▁one ▁prior ▁treatment ▁and ▁for ▁whom ▁blood ▁stem ▁cell ▁transplant ation ▁was ▁not ▁successful ▁or ▁is ▁un suit able ▁ .
▁card board ▁box ▁for ▁10- dos e ▁vi al
▁the ▁recommended ▁starting ▁dose ▁is ▁200 ▁micro gram s ▁given ▁twice ▁daily ▁ , ▁approximately ▁12 ▁hours ▁apart ▁ .
▁syn flor ix ▁is ▁indicate d ▁for ▁use ▁in ▁children ▁a ged ▁from ▁6 ▁weeks ▁up ▁to ▁5 ▁years ▁ .
▁in ▁cases ▁of ▁oral ▁in toxic ation ▁ , ▁gas tric ▁lava ge ▁and ▁/ ▁or ▁the ▁use ▁of ▁ad sor bent s ▁( ▁such ▁as ▁activa ted ▁char co al ▁) ▁may ▁be ▁helpful ▁if ▁used ▁short ly ▁after ▁in take ▁ .
